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ABSTRACT
Primordial follicles are the essential functional units of the ovary and are formed during
fetal life in humans. Fetal ovary development is a complex process, dependent on
maturation and differentiation of several cell types with differing functions. Flowever,
the factors involved in regulation of this growth and differentiation are not yet well
understood. Ovarian development and organisation is important for normal reproductive
potential. Oocyte competence to support early embryo development is acquired
gradually over the course of oogenesis and folliculogenesis and is completed during
meiotic maturation. This aim of this thesis was to investigate possible roles for growth
factors, namely activin and inhibin, and neurotrophin-4 (NT4) and brain derived
neurotrophic factor (BDNF), in fetal ovary development. The effects of BDNF on
maturation of the bovine oocyte as well as implications for embryo development after
parthenogenetic activation were also investigated.
Activins and inhibins are members of the transforming growth factor (3 (TGF(3)
superfamily. A substantial body of evidence has accrued that activins and inhibins are
regulatory factors in the adult ovary involved in a wide range of functions. Activin is
also expressed in the human gonad at very early stages of development. Expression of
mRNA for the activin (3A and |3B subunits and activin receptors was demonstrated in the
human fetal ovary at 14-21 weeks gestation. Quantitative expression of (3A mRNA
increased two fold across the gestational range examined. Activin subunits and receptors
ALK4, ActRIIA and ActRlIB, were localised by immunohistochemistry. The |3A
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subunit was expressed by oogonia. The |3B subunit and activin receptors were expressed
by both oogonia and somatic cells. Expression of (3A was increased in larger oogonia at
later gestations, but was low in oocytes within newly formed primordial follicles. The
activin-binding protein follistatin was not detected by immunohistochemistry, nor was
the a inhibin subunit. Culture of fetal ovary fragments with activin A increased the
number of oogonia present and oogonial proliferation, as detected by BrdU
incorporation, indicating a role for activin in the autocrine / paracrine regulation of germ
cell proliferation during the period of development leading up to primordial follicle
formation.
Neurotrophins are survival and differentiation factors originally identified in the nervous
system. Expression and localisation ofNT4, BDNF and their common receptors TrkB
and p75 was detected in mid-trimester human fetal ovaries at 14 - 19 weeks gestation,
indicating a possible role in regulation of proliferation or survival of germ cells or their
supportive somatic cells. TrkB signalling appears to be central to the normal formation
of primordial follicles that occurs in the ovary in the few days following birth in the
rodent. The effect of NT4 and BDNF on oogonial survival and proliferation was
investigated using an in vitro tissue culture model. Culture of fetal ovary fragments with
BDNF, NT4, anti-NT4 or both NT4 and anti-NT4 showed no statistical difference
compared to control groups, both in terms of germ cell number and oogonial
proliferation. FTowever culture of fetal ovary fragments with BDNF and anti-NT4
showed a decrease in number of germ cells, and reduced proliferation, supporting a
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theory of differential ligand signalling via Trk B / p75 receptors in the human fetal ovary
prior to primordial follicle formation.
There is also increasing evidence of a role for neurotrophins in adult ovarian
development and function, including oocyte maturation. BDNF is present in human
follicular fluid, and is secreted by cumulus cells in response to cAMP, suggesting that its
production is stimulated by gonadotrophins. RT-PCR and immunohistochemistry
demonstrated that bovine cumulus and oocytes express mRNA and protein for BDNF
and the p75 receptor. Flowever, mRNA for full length and truncated isoforms of the
TrkB receptor are only detected in cumulus, suggesting that oocytes and cumulus differ
in their capacity to respond to neurotrophin signalling. In in vitro maturation
experiments, the proportion of cumulus oocyte complexes maturing to metaphase II was
not altered by BDNF using a serum-free maturation system. However, after maturation,
the proportion of parthenogenetically activated oocytes forming blastocysts was higher
for groups matured with BDNF, an effect that was reversed by maturation in the
presence of a BDNF blocking antibody. Similar effects on progression to Mil and
blastocyst formation were observed using oocytes matured without cumulus. These
results suggest neurotrophins play a role in oocyte maturation by promoting oocyte
cytoplasmic competence to support embryonic development.
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1.1 HUMAN OVARY DEVELOPMENT - INTRODUCTION
Germ cells are not essential for survival of an individual, but are fundamental to the
generation of offspring. As such, they hold the key to life, both in terms of survival of a
species, as well as totipotency. Oocytes also contribute virtually all cytoplasm to the
early embryo. The mechanisms involved in germ cell formation, migration and ovarian
development represent the foundations for adult reproductive function, and whilst
research has helped define developmental events and pathways in fetal ovarian
development and folliculogenesis, much still remains unknown or incompletely
understood. In an era of declining fertility, with increasing demand for Assisted
Reproductive Techniques, it is vital that these normal mechanisms are better understood.
Understanding of developmental and maturational events, and defining the growth
factors essential for normal pathways will hopefully enable an increase in treatment
options for the subfertile, as well as offering new therapeutic techniques to treat
pathological conditions, such as premature ovarian failure.
The following literature review will initially cover the development of the fetal ovary
and then review folliculogenesis, including oocyte maturation. Lastly, two families of
growth factors that are likely to be involved at various stages of ovarian development
will be considered.
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1.2.1 HUMAN GONADAL DEVELOPMENT - INDIFFERENT STAGE
Human gonadal development begins in the 4th embryonic week in parallel with the
formation of the ventral body wall. Undifferentiated primordial germ cells arise from
endoderm lining the yolk sac. Bone morphogenetic protein 4 (BMP4), BMP8b and
components of the Smad signalling pathways produced by extraembryonic ectoderm
(Ying et al., 2000; Tres et al., 2004; Okamura et al., 2005), in association with
endoderm-derived BMP2 (Coucouvanis and Martin, 1999; Ying and Zhao, 2001) are
involved in the specification of primordial germ cells. Studies with double heterozygote
mutant mice have shown BMP2 and BMP4 to have an additive effect on primordial
germ cell generation, whereas the BMP2 and BMP8b do not (Ying et al., 2001; Ying
and Zhao, 2001). Consequently, two signalling pathways have been suggested to be
involved in primordial germ cell development; one for BMP2 and BMP4 and a separate
pathway for BMP8b (Ying et al., 2001; Ying and Zhao, 2001).
Primordial germ cells migrate by amoeboid movement along the dorsal mesentery of the
hindgut to the genital ridges, which lie on the medial aspect of the mesonephric ridge
(Witschi, 1948; Chiquoine, 1954). Factors involved in primordial germ cell migration
remain poorly defined although kit ligand (KL, also known as stem cell factor) and its
receptor c-kit are required for appropriate migration to occur (Manova et al., 1990;
Godin et al., 1991; Loveland and Schlatt, 1997). Adhesion molecules, such as cadherins
and integrins, are also thought to play a role in colonisation of the mesonephric ridge
and in establishing the architecture of the gonad (De Felici et ah, 2005). Failure of
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primordial germ cells to develop or populate the genital ridges results in total failure of
the gonads to develop.
Over the next two weeks the primordial germ cells mitose repeatedly, forming a
population of precursor gametes (Gosden, 1995). Germ cell survival at these early
developmental stages is dependent on locally derived growth factors, including BMP4
(Fujiwara et al., 2001a), and kit ligand (Manova et al., 1990; Godin et al., 1991). At this
point male and female gonads are histologically indistinct, hence are known as
indifferent gonads. In humans, the germ cells are postulated to stimulate the cells of the
coelomic epithelium lining the genital ridge to differentiate into a primitive germinal
epithelium, hence germ cells become embedded and surrounded by somatic cells
(Byskov, 1986).
1.2.2 HUMAN GONADAL DIFFERENTIATION
The Y chromosome is much smaller than the X, and has little deoxyribonucleic acid
(DNA) available for ribonucleic acid (RNA) synthesis. Many genes that control testes
development are, by necessity, located on other chromosomes. However, the Y
chromosome contains a specific single-copy gene, SRY, located in the sex-determining
region. The presence or absence of this gene has a direct effect on gonadal
differentiation (Koopman et al., 1991). Absence or damage to the sequence results in
ovarian development and a phenotypic female (Hawkins et al., 1992). SRY initiates a
cascade of activation of genes "downstream" from the Y chromosome and results in
differentiation of Sertoli cells, a key cell type in the testis that is essential to subsequent
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development. Sertoli cells polarise, aggregate around germ cells and reorganise the
gonad into two compartments: the tubular testis cords, composed of Sertoli cells and
germ cells, and the interstitial space between the cords (Page et al., 1987). Peritubular
myoid cells surround Sertoli cells and co-operate to deposit the basal lamina at the
periphery of tubule structures (Skinner et al., 1985; Tung and Fritz, 1987). Other
interstitial cell types include steroid-secreting Leydig cells, fibroblasts and endothelial
cells that will establish coelomic vasculature. As soon as the testis begins to be
differentiated, it starts to synthesise two substances, testosterone and antimullerian
hormone (AMH). Testosterone is synthesised by Leydig cells and supports
differentiation and growth of Wolffian duct structures (Boehmer et al., 1999). AMFI is a
glycoprotein produced by the fetal Sertoli cells and causes cranial to caudal regression of
Mullerian ducts (Josso, 1972). In the absence of testicular hormones, differentiation
continues in a feminine direction (Jost, 1965). Ovary and testes become histologically
distinct by the 8th embryonic week.
1.2.3 HUMAN FETAL OVARY DEVELOPMENT AND ORGANISATION
Ovarian differentiation occurs approximately two weeks later than testicular
development in humans. The germ cells are termed oogonia and continue to divide
mitotically until they enter meiosis. Cytoplasmic cleavage may be incomplete and result
in daughter cells remaining linked by cytoplasmic bridges (Gondos et al., 1971), which
allows transfer of different substances including growth factors and hormones (Gondos
et al., 1973), gene products (Beatty, 1970) or even organelles (Gosden, 1995). These
syncytia of germ cells are also termed 'nests', and often divide synchronously until
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associations begin to break down at meiosis. Binucleate oogonia may form when
cleavage is incomplete and can potentially give rise to polyploid embryos. Concurrent
with oogonial proliferation, subepithelial mesenchyme invades the gonad, breaking up
the germ cell nests, and forming ovarian stroma.
Three major events take place during the early stages of ovarian differentiation: meiosis
is initiated, oocytes are enclosed in follicles and steroid-producing cells differentiate
once follicles are formed (theca cells) (Byskov, 1986). Once oogonia enter meiosis, they
are termed oocytes and no longer possess stem cell potential. In the human ovary, entry
into meiosis occurs over a wide timescale. It is detectable as early as 11 weeks gestation
(Gondos et al., 1986; Bendsen et al., 2006), and is maximal around 20 weeks (Baker,
1963). DNA is duplicated prior to meiosis and subsequently undergoes genetic
recombination at sites of chiasmata. Meiosis is arrested at this stage (diplotene) of
prophase I, and will not proceed until oocytes have grown to full size in a follicle that
has been stimulated by gonadotrophins (Hilscher, 1991).
The human fetal ovary contains its maximal number of germ cells (approximately 3.5
million per ovary) by mid-gestation. This reflects increase in germ cell number by
mitotic proliferation, which vastly exceeds loss by apoptosis up until this time. Beyond
this point the balance is reversed and there is accelerated loss of large numbers of germ
cells resulting in approximately one third of the maximal number remaining by term
(Baker, 1963) (Figure 1.1).
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Birth
Figure 1.1 Graph showing numbers of germ cells in human ovaries during fetal
development and across adult reproductive life (Baker, 1963).
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A follicle is formed when somatic cells, the pre-granulosa cells, surround an oocyte and
an intact basal lamina encloses this unit (Peters etal., 1978). Follicular formation occurs
from mid-gestation onwards and is believed to be crucial to oocyte survival; if an oocyte
is not enclosed in a follicle, it degenerates (Faddy and Gosden, 1995). The interaction
not only determines oocyte survival by protecting against apoptosis (Fulton et al., 2005)
but also enables bi-directional communication between oocyte and somatic cells. By
virtue of the basal lamina, granulosa and oocyte exist within a microenvironment
without direct contact with other cells. Factors triggering follicular development and
organisation are largely unknown, but germ cells are crucial to formation and
maintenance of follicles in the ovary; in their absence, follicles degenerate into cord-like
structures (Merchant-Larios and Centeno, 1981; McLaren, 1999).
Factor in the germline alpha (FIGLA) is a basic helix-loop-helix transcription factor that
binds zona pellucida promoters (Liang et al., 1997). Figla is expressed in the female
gonad and appears exclusively confined to oogonia / oocytes (Soyal et al., 2000; Bayne
et al., 2004). Although Figla is also expressed at low levels in testis, only female Figla
knockout mice are infertile. Deficiency ofFigla does not affect germ cell migration or
proliferation, and embryonic gonads appear normal. However, oocytes rapidly disappear
after birth and primordial follicles do not form (Soyal et al., 2000). Figla deletion does
not affect transcription of other genes preferentially expressed in the oocyte, including
growth and differentiation factor 9 (GDF9), BMP 15, kit receptor, connexin 43 and
fibroblast growth factor 8 (FGF8), suggesting it may regulate other downstream target
genes critical to follicle formation.
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Low expression of aromatase enzyme mRNA has been observed in first trimester fetal
ovaries (Pakarinen et al., 1990) and the fetal ovary is capable of synthesizing estradiol as
early as the 8th week of fetal age (George and Wilson, 1978), although lacks other
steroidogenic enzymes necessary for de novo synthesis of steroid precursors (Payne and
Jaffe, 1974). Whether this secretion of estradiol plays a physiologic role in the human
sex differentiation is not known, although there is some emerging evidence that it is
required for primordial follicle formation (Billiar et al., 2003; Britt et al., 2004). Thecal
cells are derived from mesenchymal stroma, and are not present until follicular growth
beyond the primordial stage (Gosden, 1995). Precursor thecal cells are recruited during
the transition to primary follicle, but are gonadotrophin and steroid independent and
non-steroidogenic at this stage (Braw-Tal and Roth, 2005).
1.3 FOLLICULOGENESIS
Folliculogenesis requires cell proliferation and cytodifferentiation in order to attain
successively higher levels of cellular organisation. It includes four major developmental
events: 1) primordial follicle recruitment, 2) preantral follicle development, 3) antral
follicle development and 4) follicular selection or atresia, and can be divided into two
phases: 1) the preantral or gonadotrophin-independent phase, which is characterised by
oocyte growth and controlled by locally produced growth factors through autocrine and
paracrine mechanisms, and 2) the antral or gonadotrophin-dependent phase, which is
characterised by the massive increase in the size of the follicle itself. This phase is
regulated by follicle stimulating hormone (FSH) and luteinising hormone (LH), as well
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as by growth factors that stimulate cell proliferation and modulate gonadotropin action
(Erickson and Shimasaki, 2000).
1.4.1 PRIMORDIAL FOLLICLE RECRUITMENT
The human ovary contains about 1 million oocytes at birth. During childhood the ovary
is not a quiescent organ, but contains growing follicles at virtually all stages of
development. Lack of appropriate gonadotrophin support results in atresia, thus oocytes
continue to decline in number, and only about 100,000 will remain by puberty (Baker,
1963). These oocytes are commonly believed to be finite and will continue to decrease
in number until the end of a female's reproductive life, however a recent controversial
publication proposed the concept of germ-line stem cells as a renewable source of
female germ cells, derived from bone marrow and delivered to the ovaries via the blood
stream (Johnson et al., 2005).
Primordial follicles are the fundamental reproductive units of the ovary and give rise to
all dominant follicles. There is continuous recruitment from the pool of primordial
follicles. As many as 20 follicles begin to mature in each wave of recruitment (Gosden,
1995), beginning with the formation of primary follicles, but typically only one will
eventually ovulate. The mechanisms for selection and activation of primordial follicles,
and their entry into the cohort of developing follicles, are not completely understood but
morphometric studies suggest that these follicles initiate growth based upon the order in
which they are formed (Hirshfield, 1991).
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Early follicular growth requires kit ligand, produced by the granulosa cells, and the
presence of c-kit receptor on oocytes (Elvin and Matzuk, 1998; Parrott and Skinner,
1999). Basic fibroblast growth factor (bFGF) is localised to oocytes of primordial and
primary follicles (van Wezel et al., 1995; Nilsson et al., 2001) and is also potent at
inducing primordial follicle development (Nilsson et al., 2001). BMP4 has been shown
to promote the primordial to primary follicle transition, but also appears to be essential
for oocyte survival. When a neutralising antibody to BMP4 was used in organ culture,
all oocytes were lost within 14 days (Nilsson and Skinner, 2003). Other members of the
TGF(3 superfamily have also been demonstrated to play a role in the control of onward
follicular development, including oocyte-specific factors, GDF9 (Dong et al., 1996;
Carabatsos et al., 1998) and BMP15 (also known as GDF9B), (Davis et al., 1991; Braw-
Tal et al., 1993), as well as granulosa-derived BMP7 (Lee et al., 2001b; Lee et al.,
2004). Activin A, its receptors and the binding protein follistatin are expressed at all
follicular stages, indicating a regulatory role of activin A across the entirety of follicular
development (Silva et al., 2004). Another TGFp superfamily member, AMH, has been
found to inhibit, but not completely block, recruitment of primordial follicles (Durlinger
et al., 2002; Visser and Themmen, 2005). In rodents, kit ligand can also promote oocyte
growth (Elvin and Matzuk, 1998).
1.4.2 PREANTRAL FOLLICLE DEVELOPMENT
Most oocyte growth is achieved during the gonadotrophin-independent preantral
follicular stage. This requires complex cytoplasmic organisation and is dependent on the
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production of new gene products and organelles as well as the redistribution and
modification of existing ones (Picton et al., 1998). A primary follicle is defined by the
presence of cuboidal granulosa cells, which are arranged in a single layer around the
oocyte. When more than one layer of granulosa cells surrounds the oocyte, the follicle is
described as secondary, or preantral. During this phase of oocyte growth, a glycoprotein
membrane is secreted, the zona pellucida, which forms a protective coat around the
oocyte. Other events occurring in the preantral follicle during this stage of development
include FSH receptor expression in granulosa cells and recruitment of stromal cells to
form theca interna and externa. Complex autocrine and paracrine interactions exist
between oocytes and their surrounding granulosa cells to ensure growth and
differentiation is co-ordinated (Eppig, 1991; Eppig, 2001; Matzuk et al., 2002).
Granulosa cells are also coupled with each other, and gap junctions are formed between
granulosa and oocyte via processes passing through the developing zona pellucida
(Anderson and Albertini, 1976).
TGFp superfamily members expressed by follicular cells and implicated in this phase of
development include TGF|3, activin (Thomas et al., 2003), GDF9, BMP15 and several
other BMPs (Shimasaki et al., 1999; Elvin et al., 2000; Knight and Glister, 2003).
BMP6 is expressed in oocytes and granulosa cells (Erickson and Shimasaki, 2003;
Souza et al., 2003; Glister et al., 2004) but is derived entirely from oocytes early in
follicular development (McNatty et al., 2005). It enhances proliferation of granulosa
cells, a process required for follicular growth, and prevents premature luteinisation, a
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terminal differentiation event that normally occurs during the periovulatory period. This
theory is supported by findings that BMP6 is present in granulosa cells of preantral and
antral follicles but not detected in the dominant follicle in rats (Erickson and Shimasaki,
2003). Numerous other growth factors have been identified to orchestrate preantral
follicular growth and development, including nerve growth factor (NGF), a member of
the neurotrophin family (Dissen et al., 2001), but will not be considered in further detail
here.
1.4.3 ANTRAL FOLLICLE DEVELOPMENT
Antral (or tertiary) follicular growth and development can be arbitrarily divided into four
stages based on size. In humans, each dominant follicle has a destiny to complete the
transition from small (1-6 mm), to medium (7-11 mm), to large (12-17 mm) to
preovulatory (18-23 mm) follicle. Atretic follicles usually fail to develop beyond the
small to the medium stage (1-10 mm). It is the accumulation of follicular fluid, as well
as cell proliferation, which results in the massive growth of antral follicles. The initial
signals for the development of a follicular antrum are not well understood, but it is
characterised by the appearance of a fluid filled cavity at one pole of the follicle. This
process is termed cavitation and two proteins expressed by the follicle itself are essential
for it to occur, namely granulosa-derived kit ligand (Driancourt et al., 2000) and oocyte
connexin 37 (Simon et al., 1997). If either of these proteins is absent, then no antral
follicles develop and the female is infertile.
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Follicle development beyond the preantral stage is dependent upon gonadotrophins
(Erickson and Danforth, 1995; Kumar etal., 1997) and the final growth of the
preovulatory follicle is critically dependent upon FSH (Zeleznik et al., 1985). FSH
receptors are also vital to normal progression of folliculogenesis. Generation of
knockout mice where all forms of FSH receptor expression are eliminated results in a
genetic model known as the FORKO mouse. Mutants are sterile and do not ovulate
(Danilovich et al., 2000). The FORKO ovary displays only primordial and pre-antral
follicles, with hyperplasia of interstitial tissue in the middle of the ovary (Danilovich et
al., 2000). Follicular growth is also dependent on insulin-like growth factor 1 (IGF-1)
and its receptor (Zhou et al., 1997; Monget and Bondy, 2000), oestradiol synthesis
(Fisher et al., 1998) and the presence of both oestrogen receptor (ER) subtypes, ERa
and ER|3, (Couse et al., 1999a; Couse et al., 1999b; Couse and Korach, 1999; Dupont et
al., 2000) as well as the LH receptor (Lei et al., 2001; Zhang et al., 2001).
FSH binds to its receptor with high affinity. The binding event initiates a conformational
change in the receptor that activates G-proteins and the subsequent cascade of events
results in generation of cyclic adenosine monophosphate (cAMP). Regulatory subunits
of protein kinase A (PKA) bind to cAMP, causing the complex to dissociate and release
two free catalytic subunits. The catalytic subunits phosphorylate serine and threonine
residues of CREB and CREM proteins, which then bind to upstream DNA regulatory
elements known as cAMP response elements (CRE) that act to regulate gene activity.
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This FSH control of gene activity in the granulosa cells is the basis of all processes of
follicle growth and development, including dominance to the preovulatory stage.
It is apparent that co-ordinated differentiation of the oocyte with its surrounding
granulosa cells, and the maintenance of adequate communication between these two cell
types, is critical to ensure correct oocyte meiotic maturation (Klinger and De Felici,
2002). Before antrum formation, oocytes are unable to progress beyond the diplotene
stage of meiosis I and are described as meiotically incompetent (Sorensen and
Wassarman, 1976). This state is attributable to an insufficiency in the regulatory
molecules required to drive meiotic progression (Handel, 1998). However, most oocytes
in antral follicles, by contrast, are meiotically competent and will resume meiosis
spontaneously if removed from the follicle and cultured in supportive medium (Handel,
1998). Meiotic competence is associated with the accumulation of cell cycle regulatory
factors (Chesnel and Eppig, 1995) as well as reorganisation of chromatin and
microtubule configurations (Wickramasinghe et al., 1991). It is important to note
however, that oocytes competent to resume meiosis are not necessarily competent to
undergo complete nuclear maturation or progress to metaphase II (Handel, 1998).
Growth factors such as GDF9, BMP6 and BMP 15, are produced by the oocyte to ensure
on-going co-ordination in follicular development. They act directly in granulosa cells to
inhibit cytodifferentiation, thus maintaining cell proliferation and follicular growth
(Otsuka et al., 2000; Erickson and Shimasaki, 2003; Moore and Shimasaki, 2005).
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Around the time of antrum formation, thecal cells begin to express their differentiated
state. This event involves the expression of a battery of genes, including LH receptors,
insulin receptors, lipoprotein receptors for high density lipoprotein (HDL) and low
density lipoprotein (LDL), steroidogenic acute regulatory (StAR) protein, P450 side
chain cleavage (P450scc), 3(3-hydroxysteroid dehydrogenase (3|3-HSD), and P450
17alpha-hydroxylase (P450cl 7). Expression of these genes enables thecal cells to
produce androstenedione, the androgen substrate required for oestrogen biosynthesis.
LH is the most important effector of thecal cytodifferentiation (Erickson et al., 1985),
but insulin and lipoproteins can act in synergy with LH to amplify this process. A
variety of other regulatory ligands and growth factors have been identified that modulate
mammalian theca androgen production, including insulin and IGF-I (Magoffin and
Erickson, 1988; Li et al., 2001; Mendez et al., 2005), lipoprotein (Dyer and Curtiss,
1988; Magoffin and Erickson, 1988; Zerbinatti et al., 2001), and various members of the
TGF(3 superfamily: activin, inhibin, BMP4, 6 and 7 and GDF9 (Hillier et al., 1991a;
Hillier et al., 1991b; Knight and Glister, 2003; Glister et al., 2005). Except for insulin,
the significance of these regulatory molecules is unclear. Insulin receptors with protein
tyrosine kinase activity are expressed in human theca cells and their signal transduction
pathways have been demonstrated to stimulate androstenedione production. Insulin can
increase androstenedione production by itself, as well as synergize with LH to further
increase androgen biosynthesis. Observations in rodents indicate that LDL and HDL
also stimulate steroidogenesis by human thecal cells (Dyer and Curtiss, 1988; Zerbinatti
and Dyer, 1999), and they too can cooperate with LH to cause further increases in
32
androgen production. Whether increased androgen production by LDL and/or HDL has
any physiological meaning is not clear. Nonetheless, it is noteworthy that HDL is the
most potent stimulator of theca androgen production known so far. Finally, activin and
inhibin can inhibit and stimulate, respectively, androgen production by human thecal
cells in vitro (Hillier et al., 1991a; Hillier et al., 1991b). Recent studies have found that
GDF9 and BMP4 interact with cultured human theca cells to inhibit androgen
biosynthesis (Hickey et al., 2005).
The enlarging follicular antrum eventually divides the population of granulosa cells into
two main groups: cumulus cells, which are associated with the oocyte, and mural
granulosa cells, which line the follicular wall. With advancing follicular development
these populations can be distinguished in molecular as well as morphological terms.
Cumulus cells express few, if any LH receptors, whereas mural granulosa cells express
these receptors, and a gradient of expression is seen with highest expression observed in
cells closest to the basal lamina (Amsterdam et al., 1975). Aromatase is expressed in
mural granulosa of antral and periovulatory follicles, but is absent from cumulus (Inkster
and Brodie, 1991).
1.4.4 FOLLICLE SELECTION AND ATRESIA
Establishing a dominant ovarian follicle capable of ovulating a fertilisable oocyte is
undisputed as a fundamental process in female fertility, although the precise mechanism
of follicular selection and dominance remains to be fully elucidated. FSH plays an
obligatory role in the mechanisms of selection and dominant follicle development and
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the overall process is governed by pituitary gonadotrophins, although their effects are
almost certainly mediated in conjunction with locally synthesised growth factors. LH is
not essential for selection, but is important in regulating dominant follicle formation
through its capacity to stimulate the expression of the aromatase substrate,
androstendione.
Dominant follicle selection initially appears to depend on differential FSH sensitivity
amongst the growing cohort of antral follicles. Activin may contribute to this selection
process by affecting the sensitivity of follicles to FSH (Ginther et al., 2002). Conversely,
AMH has been shown to decrease the sensitivity of follicles for FSH-dependent
selection for dominance (Visser and Themmen, 2005). FSH induces expression of
pregnancy-associated plasma protein-A (PAPP-A), which may be a very early marker of
dominant follicle selection (Hourvitz et al., 2000). PAPP-A is a protease and decreases
the availability of insulin-like growth factor binding globulin-4 and -5 (IGFBP-4 and -5)
(Lawrence et al., 1999). Its presence results in an increase in intrafollicular IGF, a
growth factor that synergises with FSH to increase oestradiol production (Fortune et al.,
2004).
FSH actions are thought to be well defined but recent studies have identified a novel
cAMP signalling pathway, where FSH stimulates phosphorylation of kinases that are
downstream targets of the IGF-1 / phosphatidylinositol 3'-kinase (PI3 kinase) / PDK1
pathway (Gonzalez-Robayna et al., 2000; Richards, 2001). This impacts differentiation
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events by activation of transcription factors and also confers the potential of FSH to
maintain cell survival pathways (Brunet et al., 2001).
As the dominant follicle grows, FSH causes the granulosa cells to acquire the potential
to produce large amounts of oestradiol. Induction of expression of P450 aromatase
(P450arom; the CYP19 gene) in granulosa cells is causal to the acquisition of the
oestrogen potential of the follicle (Findlay et al., 2001; Toda et al., 2001) and enables
oestradiol synthesis utilising androstenedione supplied by thecal cells. Within the
follicle, oestrogen acts in an autocrine and paracrine manner to enhance FSH action on
granulosa cells. The resultant augmented aromatase P450 expression and oestradiol
production is mediated by the oocyte itself (Otsuka et al., 2005). Oestradiol also exerts a
paracrine action on theca cells to up-regulate LH-induced secretion of androgen, an
essential requirement for further oestradiol production by the pre-ovulatory follicle.
Production of inhibin, like oestradiol, increases in selected dominant follicles in an FSH-
and IGF-dependent manner (Gutierrez et al., 1997; Fujiwara et al., 2001b; Spicer et al.,
2002). P450 aromatase activity also increases progressively, reaching very high levels in
the granulosa cells of the preovulatory follicle. From primary follicle stage onwards,
granulosa cells express 17|3-hydroxysteroid dehydrogenase (1 7(j-HSD), but co-
expression of both P450arom and 17|3-HSD enables granulosa cells to become highly






















Figure 1.2 Schematic diagram of the 'two cell, two gonadotrophin' model of regulation
of oestrogen synthesis.
Luteinising hormone receptors are located on theca cells during all stages of the
menstrual cycle. The CYP17 gene encoding 17-hydroxylase/C17-20-lyase activity is
crucial to androgen synthesis, and is expressed exclusively in thecal cells. LH
principally stimulates androstenedione production in the theca cells. Androstenedione is
then transported to the granulosa cells where it is aromatized to oestrone and finally
converted to oestradiol.
FSH receptors exist exclusively on the granulosa cell membranes. FSH can act directly
to induce cytoproliferation and differentiation via cAMP/PKA pathway. Increased FSH
levels during the late luteal phase results in induction of the CYP19 gene and expression
of P450 aromatase, resulting in large increases in oestradiol secretion by granulosa cells.
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In the mid - late follicular phase, rising systemic oestrogen levels negatively feedback
and diminish FSH secretion from the anterior pituitary (and positively feedback to
stimulate LH secretion). It is ultimately the fall in FSH that is the key to follicular
dominance. The cohort of developing follicles is dependent on FSH for growth and
development and the fall in FSH levels below threshold levels results in apoptosis of
granulosa cells and atresia (Erickson and Shimasaki, 2001). In humans, usually only a
single follicle will continue onward development. By definition this follicle has higher
sensitivity to FSH, by virtue of increased receptor expression, although it is postulated
that it may also act directly on smaller follicles in the cohort to reduce their sensitivity to
gonadotrophins (Driancourt, 2001). Follicular dominance is re-enforced by at least two
local factors: IGF-1, which stimulates LH receptor formation (Chase et al., 1998) and
vascular endothelial growth factor (VEGF), a potent theca-derived promoter of
angiogenesis whose production is stimulated by LH (Garrido et al., 1993).
Competence of the preovulatory follicle to respond to the inductive stimulus of the LH
surge and undergo ovulation also requires expression of LH receptors in granulosa cells.
FSH plays a vital role in LH receptor induction, but expression of LH receptors remains
suppressed until late in the follicular phase of the cycle (Minegishi et al., 1997). There is
compelling evidence that it is the oocyte itself that inhibits the expression of granulosa
LH receptors in the developing antral follicle by release of inhibitory factors until the
onset of the preovulatory stage (Vanderhyden, 1993; Coskun et al., 1995; Vanderhyden
and Tonary, 1995; Li et al., 2000). Shortly after the LH surge, the oocyte resumes
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meiosis, and undergoes maturational cytoplasmic changes that prepare it for fertilisation.
This will be considered in detail later.
In mammals, 99.9% of all the follicles (oocytes) die by atresia, a process that occurs by
apoptosis in both oocyte and granulosa cells (Tilly, 1996). The molecular pathway of
apoptosis was first worked out in Caenorhabditis elegans (Ellis and Horvitz, 1986;
Metzstein et al., 1998) but is well conserved across the species. In mammals, it involves
the evolutionarily conserved Bcl-2 family of proteins, which are located in the
mitochondrial membrane (Green and Reed, 1998). The Bcl-2 family is composed of
both pro- and anti-apoptotic agents (Adams and Cory, 1998). The ratio between them
regulates the caspase cascade, which leads to cell death when activated, and determines,
in part, the susceptibility of cells to a death signal (Gross et al., 1999; Vander Heiden
and Thompson, 1999; Zhang et al., 2000).
A variant FSH receptor has been identified in the ovary that can activate Ca2+ / protein
kinase C (PKC) signalling activity (Babu et al., 2000; Babu et al., 2001). This altered
form of FSH receptor is increased in ovaries of mice treated with pregnant mare serum
gonadotrophin (PMSG). Incidence of follicular atresia is significantly reduced in antral
follicles of ovaries in mammals treated with PMSG (Braw and Tsafriri, 1980; Monniaux
et al., 1984) and it may be that follicular rescue is orchestrated via this modified FSH




Follicle enclosed oocytes are arrested in prophase of the first meiotic division. After a
prolonged resting state, the oocyte in the preovulatory follicle resumes meiosis during
the ovulation sequence. The oocyte nucleus, or germinal vesicle, undergoes a series of
changes that involve germinal vesicle breakdown (GVBD), and progression of meiosis
to metaphase II with extrusion of first polar body. The second meiotic division occurs
without being preceded by DNA synthesis, and results in haploid germ cells. Meiosis is
again arrested and proceeds no further unless the ovulated egg is fertilised.
Maturation of oocytes in vivo occurs after the preovulatory LH surge, and is concurrent
with the final development of the dominant (preovulatory) follicle. The ability to initiate
maturation is closely correlated with increasing follicle size (Trounson et al., 2001) and
requires a complex series of molecular and structural events. Granulosa gene expression
switches from follicular growth to the requirements of ovulation and luteinisation
(Richards, 1994; Richards et al., 1998) and oocyte protein translation actively continues
with accumulation of transcripts and macromolecules, in preparation for meiosis and
early embryonic development (Wickramasinghe and Albertini, 1993; Fair et al., 1995).
Oocyte maturation is defined by both nuclear and cytoplasmic maturation. Nuclear
maturation involves resumption of meiosis. It encompasses condensation of
chromosomes and GVBD, cell cycle progression through metaphase I, anaphase I and
telophase I, ending in meiotic arrest at metaphase II, with alignment of chromosomes
along the metaphase plate and extrusion of the first polar body (Trounson et al., 2001).
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Cytoplasmic maturation is a less easily defined process, but entails molecular and
structural changes to provide a matured oocyte with the capacity to undergo fertilisation,
embryo cleavage and development to blastocyst stage (Kastrop el al., 1990).
Follicular cells, particularly cumulus-granulosa, are crucial to appropriate cytoplasmic
maturation (Kim et al., 1997; Hashimoto et al., 1998; Tanghe et al., 2002) and many
endocrine and paracrine factors have been shown to affect maturation of oocytes, either
directly or signalled via cumulus cells. Transient expression of progesterone receptor
mRNA (Park and Mayo, 1991), and the prostaglandin-endoperoxide synthetase 2 gene
(Ptgs2, also known as COX-2) (Sirois et al., 1992; Sirois et al., 1993) have been
identified following the LH surge. It is possible that these genes may be involved in the
ovulation process itself rather than oocyte maturation. However, increased progesterone
production and induction of progesterone receptor expression in response to LH and
FSH has been demonstrated in porcine cumulus cells in vitro. And inhibition of
progesterone production using aminoglutethimide in the same experimental model
resulted in inhibition of GVBD, an effect overcome by addition of progesterone
(Shimada and Terada, 2002).
During the process of maturation cumulus cells undergo mucification followed by
expansion. The onset of mucification is marked by a dramatic increase in the secretion
of mucopolysaccharides into the extracellular spaces. This leads to the dispersal of
cumulus cells and causes the oocyte-cumulus complex to expand. The process of
cumulus expansion appears to be initiated by the preovulatory increase in FSH. Oocyte-
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derived GDF9 and/or BMP 15 may act on the cumulus granulosa cells to attenuate
estradiol production and promote progesterone and hyaluronic acid production, and
therefore mucification and cumulus expansion (Elvin et al., 1999). Cumulus expansion
is physiologically important not only because it is required for normal ovulation and
fertilisation (Chen et al., 1993; Talbot et al., 2003), but also because disruption of
oocyte-cumulus gap junctions results in termination of bi-directional communication
between the oocyte and its surrounding somatic cells. Inhibition of hyaluronic acid
synthesis or the covalent linking of cumulus cells in vitro results in marked reduction of
ovulation rates (Chen et al., 1993; Hess et al., 1999).
1.6.1 NUCLEAR MATURATION
A complex cascade of phosphorylation and dephosphorylation events is involved in
regulation of meiosis resumption. Activation of maturation promoting factor (MPF) is
responsible for the onset of oocyte maturation and either precedes or occurs
concomitantly with GVBD (Gordo et al., 2001). MPF is a serine-threonine heterodimer
composed of a catalytic subunit, p34cdc2 kinase, and a regulatory subunit, cyclin B
(Labbe et al., 1989; Pines and Hunter, 1989; Gautier et al., 1990). Active MPF is able to
phoshorylate proteins that form the nuclear envelope and those involved in chromatin
condensation and cytoskeletal reorganisation (Moreno and Nurse, 1990). Cyclic MPF
activity is characteristic of oocytes. MPF assembly and activation increases until
metaphase I and decreases during anaphase to telophase transition (Wehrend and
Meinecke, 2001). The activity increases again until the oocyte reaches metaphase II, and
is maintained at a high level by the interaction of cytostatic factor (CSF) and the viral
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oncogene c-mos until fertilisation (Trounson et al., 2001; Wehrend and Meinecke,
2001).
Mitogen-activated protein kinases (MAP kinases) are other serine-threonine kinases
known to be involved in oocyte maturation. MAP kinase is activated at the onset of
oocyte maturation by a protein kinase cascade (Haccard et al., 1990; Verlhac et al.,
1993; Inoue et al., 1995). In mammalian oocytes two isoforms of MAP kinase are
present, known as extracellular-regulated kinase 1 and 2 (ERK1 and ERK2). MAP
kinase activity is required for maintenance of MPF activity, regulation of microtubule
dynamics, spindle assembly and maintenance of Mil arrest (Verlhac et al., 1993;
Colledge et al., 1994; Hashimoto et al., 1994; Verlhac et al., 1994; Dedieu et al., 1996;
Gordo et al., 2001).
The level of cAMP in the oocyte plays a critical role in meiotic maturation. Spontaneous
resumption of meiosis was originally noted to be reduced in mammalian oocytes where
media was supplemented with cAMP (Jagiello et al., 1975) and it is now accepted that
meiotic arrest is maintained in vivo by high levels of cAMP in the oocyte, via the PKA
pathway (Mailer and Krebs, 1977; Mailer and Krebs, 1980; Bornslaeger et al., 1986;
Bilodeau-Goeseels, 2003; Masciarelli et al., 2004). Consistent with this hypothesis,
pharmacological manipulation to increase cAMP levels in mammalian oocytes,
including phosphodiesterase (PDE) inhibitors, blocks oocyte maturation both in vitro
and in vivo (Urner et al., 1983; Conti et al., 1998; Wiersma et al., 1998). FSH retards
nuclear maturation via a cAMP-dependent pathway (Eppig et al., 1983) but enhances
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fertilisation and developmental ability of oocytes when supplemented to a bovine in
vitro maturation system (Izadyar et al., 1998; Tatemoto and Terada, 1998). In addition to
the PKA pathway, protein kinase C may also be involved in meiotic regulation of oocyte
maturation (Su et al., 1999; Downs et al., 2001).
The surge in LH activates adenylate cyclase activity and results in a rapid, but transient,
rise in cAMP (Dekel et al., 1988). As stated earlier, high concentrations of intra-oocyte
cAMP inhibit meiotic maturation, and an oocyte will resume meiosis following removal
of inhibitory actions of cAMP. It would seem, however, that a transient increase in
cAMP concentration after the gonadotrophin surge is required to initiate oocyte
maturation (Dekel et al., 1988; Yoshimura et al., 1992). Thereafter the level of cAMP in
the oocyte falls abruptly and allows commitment to meiosis, possibly by desensitisation
and down regulation of granulosal LH and FSH receptors or by activation of specific
phosphodiesterases that degrade cAMP (Tsafriri et al., 1996; Conti et al., 2002; Mayes
and Sirard, 2002). The LH surge also stimulates rapid increases in intracellular calcium
in granulosa and cumulus cells, via cAMP (Webb et al., 2002). Activation of
phospholipase C (PLC) also results in increased levels of IP3 in both granulosa and
oocyte, and raises intraoocyte calcium as a result of extracellular influx as well as
intracellular calcium mobilisation (Homa, 1995). Transient increases in intracellular
calcium and modification of proteins (phosphorylation, dephosphorylation or activation
of proteases) are responsible for driving the meiotic cell cycle through various control




Cytoplasmic maturation is difficult to define. It encompasses changes in distribution and
organisation of the individual organelles, migration of mitochondria to perinuclear
positions and accumulation of cortical granules along the oolemma. These changes
allow fertilisation to occur and include acquisition of abilities to decondense penetrated
spermatozoa, form a block to polyspermy and to form pronuclei after fertilisation. Most
oocytes that have achieved nuclear maturation are capable of responding to sperm to
form a zygote, but far fewer zygotes develop to blastocyst stage in vitro. Another aspect
of cytoplasmic maturation involves the transcription and translation of specific mRNA
in order to acquire embryonic developmental potential. Deficient mRNA storage during
oocyte maturation results in lower developmental competence (Leoni et al., 2007).
Fertilisation initiates a cascade of cellular events required for embryo and fetal
development. However, the earliest stages of development are largely dependent on
maternally derived messages stored in the oocyte prior to fertilisation. A mature mouse
oocyte contains approximately 200-fold more RNA and 50 - 60-fold more protein than
an average somatic cell (Wassarman and Kinloch, 1992). In addition, the proportion of
mRNA is 15 - 20%, compared to 2 - 3% in a somatic cell (Wassarman and Kinloch,
1992). RNA transcribed during cytoplasmic maturation is very stable. Different degrees
of polyadenylation define transcripts for immediate use, or for storage and utilisation
following elongation of the poly-A tail (Bachvarova, 1992). Active transcription ceases
with resumption of meiosis, but translation of the mRNA pool continues throughout the
final stages of meiosis and beyond (Kinloch et al., 1993). As embryo development
progresses, maternal (oocyte) RNAs and proteins are depleted and embryo-derived
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messages become the key controlling factors. The shift from dependence on oocyte-
derived messages to embryo-produced messages is referred to as maternal to embryonic
transition (MET) and occurs at different stages in a species dependent manner: 2-cell
stage in mice, 4- to 8-cell stage in humans and 8- to 16-cell stage in cattle (Telford et al.,
1990; Memili and First, 2000). Early embryo development, therefore, is the ultimate
manifestation of appropriate cytoplasmic maturation.
1.7 IN VITRO MATURATION
Mammalian oocytes are able to mature in vitro when they are isolated from follicles and
placed in appropriate medium (Pincus and Enzmann, 1935). In vitro maturation (IVM)
of mammalian oocytes, including human, was initially studied and reported by Edwards
in 1965 (Edwards, 1965b; Edwards, 1965a) and offered a source of oocytes for in vitro
fertilisation (IVF). Hormonal stimulation has proved to be a more effective means of
obtaining oocytes, but carries implications, both in terms of the financial expense of
assisted reproduction cycles as well as the risk of potentially serious medical
complications such as ovarian hyperstimulation. IVM of oocytes offers an alternative to
the use of high levels of exogenous gonadotrophins and potentially stands to benefit
patients, particularly those suffering from polycystic ovary syndrome (PCOS), who may
be extremely sensitive to stimulation with exogenous gonadotrophins, or women with
normal ovaries and regular cycles who are referred for IVF due to male factor infertility.
As well as the clinical setting, this technology would also be of benefit to agricultural
breeding programmes. The clinical feasibility of assisted reproduction using immature
oocytes in humans was realised in the early 1990s (Cha et al., 1991; Trounson et al.,
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1994), but early reports of clinical pregnancies had unacceptably low success rates (Cha
et al., 1991; Trounson et al., 1994; Russell et al., 1997). Developmental faults of in vitro
matured oocytes and poor pregnancy outcomes are most likely to be due to impaired
cytoplasmic maturation, and much research effort has, as a result, been directed at
optimising IVM culture conditions. Improvement in methods and technology has
resulted in increasing clinical successes, with recent reported pregnancy rates of 20 -
24% (Le Du et al., 2005; Li et al., 2005; Mikkelsen, 2005), up to 38% per cycle (Rao
and Tan, 2005). The few children born following IVM thus far appear to be healthy
(Mikkelsen, 2005).
Oocytes in culture are affected by the physical conditions of the in vitro environment,
specifically osmolarity (Yamauchi et al., 1999), ionic composition, temperature (Shi et
al., 1998), pH (Downs and Mastropolo, 1997), CO2 (Geshi et al., 1999) and O2 tension
(Takahashi et al., 1996), as well as culture volume. Most researchers agree that impaired
cytoplasmic maturation can be overcome by optimisation of culture conditions (Cha and
Chian, 1998). Addition of various hormones, oestrus maternal serum or follicular cells to
culture medium has been shown to be beneficial for IVM, fertilisation and development
of immature follicular oocytes in mammals (Younis et al., 1989; Armstrong et al., 1991;
Ali and Sirard, 2002). Estradiol has also been shown to support cytoplasmic maturation
changes necessary for fertilisation and early post-fertilisation development (Tesarik and
Mendoza, 1995; Guler et al., 2000). Commonly used supplements, such as fetal serum
and serum albumin, are known to be beneficial to in vitro oocyte maturation and embryo
development but contain numerous factors including growth factors, lipids, albumin,
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hormones, steroids, cholesterol, peptides and, indeed, many undefined substances
(Gardner and Lane, 1993). The highly undefined nature of these supplements, as well as
risk of batch variation, makes them undesirable for research or clinical practice. High-
grade bovine serum albumin (BSA) also carries some degree of variability, but is less
variable than serum itself (Sutton et al., 2003). BSA has also been shown to contain
steroids, notably estradiol, at levels high enough to allow for adequate cytoplasmic and
nuclear maturation such that supplementation with estradiol is unnecessary (Mingoti et
al., 2002). Synthetic macromolecules, such as polyvinyl alcohol, have been used in place
of serum to standardise culture media (Pinyopummintr and Bavister, 1991; Keskintepe
and Brackett, 1996) and some studies in animals have demonstrated that serum-free
conditions can support oocyte maturation in vitro (Eppig et al., 1992; Serta et al., 1995).
This carries important advantages in terms of safety and quality control of culture media.
Many have investigated roles for the myriad of growth factors expressed in developing
follicles, or whose receptors are expressed, and/or that stimulate granulosa and thecal
cell proliferation and differentiation, by their addition to serum-free maturation systems
(Gougeon, 1996). Growth factors beneficial to IVM include those which improve
maturation by a direct effect on oocytes and enhancement of nuclear maturation, such as
activin A, as well as those where maturation appears to improve indirectly as a result of
beneficial effects mediated by cumulus, such as epidermal growth factor (EGF). These
are now considered further.
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Activins and inhibins are produced by granulosa cells and act on both oocytes and
granulosa in a paracrine / autocrine manner, either directly or via gap junctions. All
inhibin / activin subunits and receptor mRNA transcripts are present in oocytes and
granulosa cells (Izadyar et al., 1998; Sidis et al., 1998; Silva et al., 2003) and qualitative
and quantitative changes in expression and distribution of inhibin and activin subunits in
bovine oocytes have been reported during IVM and fertilisation (Izadyar et al., 1998;
Silva et al., 2003). The effect of activin A on meiotic maturation was originally
investigated in oocytes from immature rats treated with PMSG (Itoh et al., 1990), which
found it accelerated maturation of not only follicle-enclosed oocytes and oocyte-
cumulus complexes, but also denuded oocytes, as measured by an increase in the
percentage of oocytes with GVBD. Oocyte maturation is unaffected by activin A in the
presence of an inhibitor of GVBD such as cAMP (Itoh et al., 1990), and the effect of
activin A is also inhibited by its binding protein follistatin (Sadatsuki et al., 1993; Alak
et al., 1996). Activin A is a proven potent stimulator of primate and human oocyte
maturation in vitro (Alak et al., 1996; Alak et al., 1998) and has also been shown to
promote maturation and developmental competence, measured by significantly enhanced
postcleavage development (Stock et al., 1997; Silva and Knight, 1998).
Human oocytes express EGF and its receptor (Maruo et al., 1993; Bennett et al., 1996).
It is also found in follicular fluid (Artini et al., 1994). A number of studies have
implicated EGF in growth and differentiation of the ovarian follicle and steroidogenesis
(Mondschein and Schomberg, 1981; Schomberg et al., 1983), and it is known that
purified EGF induces GVBD and nuclear maturation when added to cumulus-oocyte
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complexes or to intact follicles in culture (Dekel and Sherizly, 1985; Downs et al., 1988;
Downs, 1989). EGF can induce cumulus expansion as efficiently as FSH (Harper and
Brackett, 1993; Lonergan et al., 1996) and enhances nuclear maturation, an effect
mediated by cumulus cells and promoted by gonadotrophins (Lorenzo et al., 1994;
Wang and Niwa, 1995; Lonergan et al., 1996; Goud et al., 1998; De La Fuente et al.,
1999; Guler et al., 2000; Lorenzo et al., 2002; Kim et al., 2004; Kishida et al., 2004).
EGF has been shown to promote steroidogenesis in two different in vitro models of
oocyte-granulosa cell complexes (Jamnongjit et al., 2005), and it may be that steroid
production represents one pathway by which EGF receptor signalling promotes oocyte
maturation in gonadotropin-stimulated follicles. EGF also increases the developmental
potential of in vitro matured oocytes in terms of fertilisation (Goud et al., 1998; Illera et
al., 1998; Kishida et al., 2004) and / or development to blastocyst stage (Harper and
Brackett, 1993; Lonergan et al., 1996; Abeydeera et al., 1998; De La Fuente et al., 1999;
Guler et al., 2000; Merlo et al., 2005).
1.8 FERTILISATION / PARTHENOGENETIC ACTIVATION
Bovine oocytes undergo embryo development up to the blastocyst stage after
parthenogenetic activation (Wang et al., 1999) with the same efficiency yielded by IVF
(Boni et al., 2002). However, mammalian parthenogenetic embryos show different
characteristics to IVF embryos (Winger et al., 1997) and fail to generate viable offspring
(Fukui et al., 1992). Parthenogenetic activation and fertilisation initially share common
mechanisms; both show electrical responses and calcium oscillations (Nuccitelli, 1980;
Schlichter and Elinson, 1981; Swann, 1990; Dale et al., 1996). One of the first events
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occurring at fertilisation, or parthenogenetic activation, is a transient modification of the
electrical properties of the oocyte plasma membrane potential. The electrical events
following fertilisation or parthenogenetic activation are generated by potassium currents
in mammals, and may be calcium-activated (Miyazaki and Igusa, 1982; Dale et al.,
1996) or calcium-independent (Igusa et al., 1983). The potassium ion current results in
hyperpolarisation of the plasma membrane (Gianaroli et al., 1994; Tosti et al., 2002).
Fertilisation triggers a wave of oscillations in the intracellular concentrations of calcium,
which has been characterised in human oocytes following IVF (Taylor, 1994; Tesarik et
al., 1995) as well as intracytoplasmic sperm injection (ICSI) (Tesarik, 1994). Repetitive
calcium oscillations follow the initial wave of calcium release up to extrusion of the
second polar body (Russo et al., 1996; Yoshida et al., 1998) and pronuclear formation
(Strieker,. 1999; Swann and Parrington, 1999). Calcium is derived from intracellular
stores, which may increase during oocyte maturation (Jones et al., 1995) and is
supplemented by extracellular calcium influx through the plasma membrane.
Mature oocytes can be artificially activated by a number of different methods: 1)
addition of chemicals to increase intracellular calcium content, including calcium
ionophores such as ionomycin (Steinhardt and Epel, 1974) or calcium-dependent
adenosine triphosphatase (ATPase) inhibitors such as cyclopiazonic acid and
thapsigargin (Petr et al., 2000), 2) ethanol treatment (Nagai, 1987), which increases
conductance of calcium-activated K+-channels (Dopico et al., 1996), 3) electric shock
(Collas et al., 1993), or 4) caged chelators, which release intra-oocyte calcium in
response to specific wavelengths. The basis behind these various methodologies is to
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mediate extracellular influx and/or intracellular release of free calcium into the oocyte
cytoplasm. The calcium transient is believed to be the upstream event that triggers the
cascade of cellular changes necessary for resumption of meiosis and the cell cycle. Only
the initial calcium surge induced by ionophore, electric shock or other method is
required, as a calcium-induced transient will continue in a self-perpetuating cycle.
Magnesium or other divalent cations, such as strontium and barium may also be
supplemented to the medium and oocyte in lieu of calcium. Increases in intraoocyte
calcium results in inactivation of MPF, and subsequently CSF. Another method of
parthenogenetic activation is targeted at inhibiting protein synthesis using cycloheximide
(Presicce and Yang, 1994b; Liu et al., 1998), and / or reduction of phosphorylation of
cellular proteins such as MPF, CSF and cytoskeletal proteins using 6-
dimethylaminopurine (DMAP), a serine-theonine kinase inhibitor (Neant and Guerrier,
1988). However, agents that increase intracellular calcium or inhibitors of protein
synthesis or phosphorylation alone result in low cleavage and development rates (Liu et
al., 1998). Synergistic effects on activation have been reported in the bovine model by
combining agents that increase intracellular calcium with inhibitors of protein synthesis /
phosphorylation (Presicce and Yang, 1994b; Presicce and Yang, 1994a; Liu et al.,
1998), with optimal bovine parthenogenetic development using a calcium ionophore
followed by incubation in either DMAP or cycloheximide and cytochalasin B (Liu et al.,
1998). This method of parthenogenetic activation (ionomycin, followed by co-
incubation with DMAP and cycloheximide) was used in the experiments performed in
chapter 5.
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1.9 TRANSFORMING GROWTH FACTOR p (TGFP FAMILY)
The TGF(3 superfamily is comprised of >35 proteins that share structural similarity
(Chang et al., 2002). These proteins are synthesised as large precursor proteins that are
proteolytically cleaved to yield the mature protein and include members of the TGFp,
activin / inhibin, GDF and BMP subfamilies as well as proteins such as AMH. They are
composed of an amino-terminal signal sequence, a variable pro-domain and a highly
conserved carboxyl-terminal domain. The signalling part of the molecule is the
carboxyl-terminal domain, which generally contains seven conserved cysteine residues.
Six of these cysteines form three disulphide bonds within each monomer, which interact
to build a structure termed the cysteine knot. This knot contributes to the stabilisation of
various conformations of TGFp superfamily members. The remaining cysteine residue
in each monomer forms an additional disulphide bond, and links two monomers into a
dimer. This cysteine is missing in some members, for example GDF9 and BMP 15, but
multiple hydrophobic contacts between two monomer subunits promote dimerisation,
even in the absence of a disulphide bond (Kingsley, 1994).
1.10 INHIBINS AND ACTIVINS
Inhibins and activins are structurally related gonadal proteins originally identified by
their ability to alter FSH secretion from the pituitary (Vale et al., 1986; Vale et al.,
1988). Inhibin selectively suppresses FSH secretion (Vale et al., 1988), whereas activin
stimulates FSH release (Ling et al., 1986; Schwall et al., 1989). Apart from their action
on FSH secretion, inhibins and activins have been shown to exert paracrine / autocrine
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effects within the gonads (Lin et al., 1989; Chen, 1993) and many other tissues (Spencer
et al., 1990) and have also been proposed to have important paracrine function(s) during
fetal development (Albano et al., 1994). Indeed, many members of the TGFp
superfamily are pivotal in controlling cellular growth and differentiation during fetal, as
well as adult life (Heldin et al., 1997; ten Dijke et al., 2000).
Inhibins are composed of one a subunit and one of two similar but distinct (3 subunits
(PA and (3B). Activins are dimers of two (3 subunits, namely activin A (|3A/|3A), activin
B (PB/|3B) and activin AB (|3A/|3B) (Vale et al., 1988). Two further mammalian activin
subunits have also been cloned, PC (Schmitt et al., 1996) and pE (Fang et al., 1996).
They are mainly derived from hepatic production (Vejda et al., 2002), but their functions
are yet to be determined. Activin was originally isolated from gonadal sources and was
assumed, like inhibin, to have endocrine actions. It is now accepted to predominantly act
as a local growth and differentiation factor, on the basis of distribution of activin and its
receptors in various tissues, as well as the fact that circulating activin appears to be
bound almost irreversibly to follistatin (Schneyer et al., 1994).
1.11 FOLLISTATIN
Follistatins are cysteine-rich (36 cysteine residues) glycoproteins, structurally unrelated
to inhibins but reported to have the ability to suppress FSH secretion (Robertson et al.,
1987; Ueno et al., 1987). They bind activins with high affinity (Kogawa et al., 1991a;
Schneyer et al., 1994). To a lesser extent, they also bind inhibins, because of the
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common (3 subunit, (Shimonaka et al., 1991) but do not bind to activin receptors.
Follistatin is a natural antagonist to the biological activities of activin (Nakamura et al.,
1990; Kogawa et al., 1991b) and is believed to act primarily in an autocrine / paracrine
manner to modulate its availability and bioactivity. Follistatin is found in the pituitary,
testis (Kogawa et al., 1991b) and ovary (Nakamura et al., 1990; Nakamura et al., 1991)
as well as a variety of other tissues, suggesting widespread regulation of the various
biological actions of activin. Follistatin has also been observed to bind other TGFp
superfamily members, including several BMPs and certain members of the GDF family
(Yamashita et al., 1995; Fainsod et al., 1997; Iemura et al., 1998; Gamer et al., 1999;
Otsuka et al., 2001).
Follistatin is synthesised as a precursor of 344 amino acids (Shimasaki et al., 1988), and
exists as a variety of isoforms. Two variants of follistatin are encoded through
alternative splicing at the carboxyl terminus: a 288-residue molecule (FS-288) and a
315-residue form (FS-315), which is extended by an extra exon to include a highly
acidic tail. Both are capable of binding activin, although FS-288 may bind with higher
affinity, and therefore confer higher activin-neutralising activity, than FS-315 (Inouye et
al., 1991; Flashimoto et al., 2000). Secreted FS-315 may be further processed by
enzymatic cleavage to shorter intermediate forms of 300 - 303 residues (FS-300/303),
which are predominantly localised to ovarian follicles (Inouye et al., 1991; Sugino et al.,
1993). Serum and follicular follistatin are biochemically distinct (Schneyer et al., 1996).
Nearly all circulating follistatin is full-length (Khoury et al., 1995; Macias-Silva et al.,
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1996) and bound to activin (Schneyer et al., 1994; McConnell et al., 1998). Whether it
has any physiological or pathophysiological significance remains to be determined.
1.12 ACTIVIN / INHIBIN RECEPTORS
Members of the TGF|3 superfamily use a common mechanism to signal to the cell
nucleus. They bind two types of closely related membrane receptors (designated type I
and type II), which have intracytoplasmic serine-threonine kinase domains. Presently
seven type I receptors (activin receptor-like kinase (ALK) 1 - 7) and five type II
receptors (ActRIIA, ActRJIB, BMPRII, TGF(3RII and AMHRII) have been identified
(de Caestecker, 2004; ten Dijke and Hill, 2004). Type I and type II receptors are
glycoproteins of approximately 55kDa and 70 kDa respectively. Activin signals through
type I and type II receptors each represented by two isoforms: ALK2 / ALK4 and
ActRIIA / ActRIIB respectively, which interact upon ligand binding (Ebner et al., 1993;
ten Dijke et al., 2000). Activin binds a type II receptor first, which then facilitates
binding of a type I receptor. In contrast to BMP receptors, only activin-bound type II
receptors physically interact with type I receptors (Ebner et al., 1993; Franzen et al.,
1993; Bassing et al., 1994; Attisano et al., 1996). Ligand binding leads to assembly of a
heterotetrameric receptor complex, which consists of two type II receptors and two type
I receptors (Macias-Silva et al., 1996; Massague, 1998). Association of type I and type
II receptors is a requirement for mediation of the biological actions of activin (Carcamo
et al., 1994). The receptor complex mediates signalling by phosphorylating proteins of
the Smad family (Heldin et al., 1997; Massague, 2000). There are 8 Smad proteins in
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total, designated Smad 1 - 8. Members of the TGF|3 / activin subfamilies typically
activate Smad 2 and 3 (Baker and Harland, 1996; Chen et al., 1996; Macias-Silva et al.,
1996; Zhang et al., 1996) whereas Smad 1,5 and 8 are activated by members of the BMP
subfamilies (Graff et al., 1996; Hoodless et al., 1996; Liu et al., 1996; Chen et al., 1997;
Yamamoto et al., 1997). In an inactive (non-phosphorylated) state, Smad 2 and Smad 3
exist as monomers (Kawabata et al., 1998). A membrane-associated protein, Smad
anchor for activation (SARA), controls Smad recruitment to the activin receptor
complex (Tsukazaki et al., 1998). SARA presents Smad 2 / Smad 3 to the activated type
I receptor by binding non-phosphorylated Smads as well as binding the receptor
complex. Once phosphorylated, Smad 2 / Smad 3 dissociates from SARA and the activin
receptor complex and combines with Smad 4, the common Smad. The resultant hetero-
oligomers (Kawabata et al., 1998) then translocate to the nucleus where they regulate
transcription of gene targets (Massague, 1998; Massague and Wotton, 2000). Smads 6
and 7 are inhibitory Smads that prevent signalling pathway activation (Imamura et al.,
1997; Bhushan et al., 1998; Ishisaki et al., 1998; Nakayama et al., 1998; Liu et al.,
2002b). Smad proteins are well documented as the central elements in activin receptor
signalling, but may not represent the only pathway activated by this receptor complex.
The Smad signalling system is also modulated by crosstalk with other kinase signalling
cascades (Derynck et al., 1998; Massague and Wotton, 2000; Zimmerman and Padgett,
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Figure 1.3 Diagram illustrating signalling pathways for BMP and TGF-(3 / activin.
Activin binding leads to assembly of a heterotetrameric complex, consisting of two type
II and two type I receptors. The receptor complex then phosphorylates proteins of the
Smad family (Smad 2 or Smad 3). The common Smad, Smad 4, combines with Smad
2/3 and regulates gene transcription once translocated to the cell nucleus. Inhibitory
Smads 6 and 7 prevent signalling pathway activation (Lin et al., 2003).
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A third receptor type, TGF(3RIII, or betaglycan, has also been identified. Betaglycan is a
membrane-anchored proteoglycan that can bind inhibin and facilitate its association with
activin type II receptors, thereby antagonising the actions of activin (Gray et al., 2002)
and potentially a number of BMPs (Wiater and Vale, 2003).
1.13 INHIBINS AND ACTIVINS IN THE OVARY
Extensive literature exists documenting expression and roles of inhibins, activins and
follistatin in adult mammalian ovarian function. Inhibin / activin subunits are
differentially expressed during folliculogenesis (Schwall et al., 1990; McNatty et al.,
1999), and have been demonstrated to regulate growth and development of ovarian
follicles (Woodruff et al., 1990; Findlay, 1993; Li et al., 1995) as well as oocyte
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Figure 1.4 Diagram illustrating involvement and effects of TGF|3 superfamily members
and follistatin during folliculogenesis (Lin et al., 2003).
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Multiple mutant mouse lines have been generated to facilitate study of mammalian
reproduction and development and the associated roles of TGF|3 superfamily members
in vivo. Female knockout mice lacking the inhibin a subunit (.Inha A) are depleted of the
biological effects of inhibins and have increased FSH concentrations. They develop
steroidogenic sex-cord stromal tumours of granulosa cell lineage with an associated
cachexia-like wasting syndrome and typically die by 18 weeks of age (Matzuk et al.,
1992; Matzuk et al., 1994). High levels of FSH (and LH) would appear to be critical to
the process of tumour development; double mutant mice homozygous for the
hypogonadal null mutation in the gonadotrophin releasing hormone (GnRH) gene (hpg)
and the Inha knockout allele do not develop tumours (Kumar et al., 1996), and Fshh and
Inha double knockouts develop tumours with later onset and a less aggressive course
(Kumar et al., 1999). Inhibins are also thought to act independently as tumour
suppressors (Pierson et al., 2000). Superovulation experiments in younger Inha
females indicate that there are defects in late stages of follicle development (Matzuk et
al., 1996). In contrast, female mice that over-express inhibin a have reduced FSH and
elevated LH levels. Females are also subfertile, due to a decrease in the number of
ovulated oocytes, a defect that can be corrected by provision of exogenous
gonadotrophins (Pierson et al., 2000; Cho et al., 2001).
Mice with a null mutation engineered at the activin / inhibin |3A locus (Inhba ) die
neonatally due to craniofacial defects (cleft palate and loss of whiskers, upper incisors,
lower incisors and lower molars) that prevent suckling (Matzuk et al., 1995a; Matzuk et
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al., 1995b; Ferguson et al., 1998). Knockout mice lacking a functional |3B locus {Inhbb '
'') have developmental defects in eyelid closure, prolonged gestation, and a failure of
mothers to nurse their litters (Vassalli et al., 1994; Matzuk et al., 1996). Mice deficient
in both activin |3A and activin |3B develop to term with open eyelids and defects in
whiskers, incisors and secondary palate formation (Matzuk et al., 1995a; Matzuk et al.,
1995b). The additive defects seen in double homozygous mutants suggest that activin
|3A and activin (3B have discrete developmental functions are unable to compensate for
the loss of each other. The Inhba phenotype can, however, be rescued by replacing the
activin / inhibin |3A coding sequence with that of the activin / inhibin |3B gene. Knock-in
mice avoid craniofacial malformations and neonatal lethality, but females demonstrate
enlarged external genitalia, hypogonadism and severely compromised fertility,
demonstrating that activin A is an important ovarian growth factor. Ovaries of mice
homozygous for the knock-in allele contain follicles at all stages of differentiation, but a
substantially reduced number of pre-ovulatory follicles. Ovaries of mice hemizygous for
the knock-in allele are smaller than controls and contain fewer large pre-antral follicles
(Brown et al., 2000). Serum FSH levels in these mice are slightly elevated, although
whether this reflects loss of pituitary inhibin signalling, enhanced activin B signalling or
is simply secondary to gonadal defects remains to be elucidated (Burns and Matzuk,
2002).
Knockout mice lacking activin receptor type II (ActRII) have suppressed pituitary and
serum FSFI levels. LH levels are unaffected. A small proportion of these mutant mice
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have skeletal and facial abnormalities reminiscent of Pierre-Robin Syndrome in humans,
but most lack these defects and develop into adults. Mutant ActRll mice exhibit gonadal
pathologies, including infertility, undeveloped uteri, and developmental block at the
antral follicle stage with associated follicular atresia and reduced number of corpora
lutea. The significance of these findings is difficult to interpret as the phenotype may
represent lack of FSH rather than absence of activin receptor signalling (Matzuk et al.,
1995b; Matzuk, 2000). Null mutations for activin type 1 receptors ALK2 or ALK4 are
embryo lethal. Formation of the primitive streak and mesodermal cells is completely
blocked in knockout mice lacking ALK4 (Gu et al., 1998). Embryos homozygous for
ALK2 mutation are arrested at early gastrulation, with abnormal visceral endoderm
morphology and severe disruption of mesoderm formation (Mishina et al., 1995; Gu et
al., 1999b).
Understanding of inhibin and activin fetal expression and their function during
development remains less than complete. Expression of mRNA and protein for activin
subunits and receptors has been described in fetal primate and human ovaries
(Rabinovici et al., 1991; Flarkness and Baird, 1997; Billiar et al., 2003). High
interspecies conservation of activins, inhibins and activin receptors and the universal
presence of activins in mammals, birds, amphibians and fish suggest an evolutionary
conserved role of these proteins in animal development. Activin is essential to
mesoderm induction in early Xenopus development (Dyson and Gurdon, 1997) and may
play a role in regulation of morphogenesis during mammalian organogenesis (Ritvos et
62
al., 1995). In rat fetal gonad culture experiments, Activin A increases ovarian, but not
testicular, gonadal and mesonephric cell proliferation (Kaipia et al., 1994).
Chapter 3 describes experiments conducted to further define expression and localisation
of activin subunits and receptors in the human fetal ovary during the mid-trimester. The
effect of activin A on germ cell survival and proliferation was investigated using an in
vitro tissue culture model.
1.14 NEUROTROPHINS
Neurotrophins are vertebrate-specific growth factors originally identified in the nervous
system and recognised for their ability to support neuronal differentiation, maturation
and survival (Henderson et al., 1993; Davies, 1994; Snider, 1994). The original
neurotrophin hypothesis states that the survival of developing neurons depends on a
supply of neurotrophic factor, which is synthesised in the target field and in limiting
amounts (Levi-Montalcini and Angeletti, 1968; Thoenen and Barde, 1980).
Neurotrophin synthesis commences with the arrival of the earliest axons in the
peripheral target fields of sensory and sympathetic neurons (Davies, 1987; Korsching
and Thoenen, 1988). The level of neurotrophin present is proportional to the final
innervation density; high levels in future densely innervated areas and low levels in
future sparsely innervated areas (Harper and Davies, 1990). After uptake by sensory and
sympathetic fibres in their target fields, neurotrophins are conveyed by fast axonal
transport to the cell bodies of the innervating neurons where they exert survival-
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promoting effects (Hendry et al., 1974a; Hendry et al., 1974b; Korsching and Thoenen,
1983).
The most extensively studied group of nerve growth factors are members of the
neurotrophin family. Four members of the neurotrophin family have been identified in
mammals, nerve growth factor, brain derived neurotrophic factor, neurotrophin-3 and
neurotrophin-4 (also known as neurotrophin-5) (Lindsay, 1996). All four neurotrophins
share similar primary, secondary, tertiary and quarternary structures (the latter as
homodimers). They mediate their biological actions by binding and activating two
different receptor classes, the tropomyosin-related kinase (Trk) family of receptor
tyrosine kinases (Trk A, TrkB and TrkC) (Kaplan et al., 1991), and the p75 receptor, a
member of the tumour necrosis factor (TNF) receptor superfamily. Individual Trk
receptors have distinct ligand selectivity and cellular expression. TrkA preferentially
binds NGF (Klein et al., 1991a), TrkB binds BDNF andNT4 (Berkemeier et al., 1991;
Klein et al., 1991b; Klein et al., 1992) and TrkC binds NT3 (Lamballe et al., 1991). NT3
is also capable of binding to and signalling through TrkA and TrkB at high
concentrations.
BDNF and NT4 bind to the TrkB and p75 receptors with equal affinity (Klein et al.,
1991b; Klein et al., 1992; Chao, 1994) and exhibit similar biological activities in many
in vitro assays (Davies et al., 1993; Ibanez, 1996). BDNF was identified in 1989
(Leibrock et al., 1989). It was the second neurotrophin cloned, and was linked to NGF
on the basis of similarities in mRNA and protein sequence. NT4 was originally
64
identified in Xenopus and viper (Hallbook et al., 1991) while NT5 was first isolated
from rat (Berkemeier et al., 1991). Ip et al defined the structure ofNT4 and described its
chromosomal location, tissue distribution and receptor specificity (Ip et al., 1992).
Phylogeny and biological data have since shown NT4 and NT5 to be orthologues (Ip et
al., 1993). Thus, mammalian NT4 may also be known as NT5 or NT4/5.
Generation of strains of transgenic mice deficient for various neurotrophins has helped
define their roles. NT4 mice are long-lived and fertile and were originally thought to
show no neurological deficit (Conover et al., 1995). More recently, neurological defects
have been described, including deficient taste bud formation (Liebl et al., 1999) and
impaired long-term memory (Xie et al., 2000). In contrast, BDNF_/" mice die postnatally.
BDNF heterozygous mice are viable and fertile, but lower levels of BDNF result in
effects on eating and social behaviour, specifically hyperphagia accompanied by
significant weight gain in early adulthood and increased aggressiveness. These
behavioural abnormalities are known to correlate with 5-HT dysfunction (Lyons et al.,
1999). Targeted mutation of the BDNF locus also results in severe deficiencies in
coordination and balance, associated with excessive degeneration in several sensory
ganglia including the vestibular ganglion (Ernfors et al., 1994). Slowly adapting
mechanoreceptors, but not other types of cutaneous afferents, require BDNF in postnatal
life for normal mechanotransduction. The neurons lacking BDNF do not die, but instead
show a profound and specific reduction in their mechanical sensitivity, an effect that can
be rescued by postnatal treatment with recombinant BDNF (Carroll et al., 1998). Mice
lacking BDNF also suffer from specific defects of cardiac vasculature (Donovan et al.,
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2000). The contrasting phenotypes of the BDNF- and NT4-deficient mice is believed to
be a result of divergent expression of the two neurotrophins rather than a difference in
biological action of the ligands in vivo, a theory supported by the rescue of the BDNF-
deficient phenotype in mice where NT4 expression is knocked into the BDNF gene
locus (Fan et al., 2000).
Neurotrophins are synthesised as precursor pro-neurotrophins, which are then
proteolytically cleaved to form mature neurotrophins (Seidah et al., 1996). Pro-
neurotrophins comprise 40-60% of the total neurotrophins secreted extracellularly
(Heymach et al., 1996; Mowla et al., 1999; Farhadi et al., 2000; Mowla et al., 2001) and
are capable of ligand signalling. They preferentially bind to the p75 receptor, have
different biological effects compared to their mature form (Lee et al., 2001a) and may
depend upon presence of and binding to a co-receptor (sortilin) to mediate pro-apoptotic
signalling (Nykjaer et al., 2004).
1.15 Trk RECEPTORS
The Trk family of tyrosine kinase receptors was first described in 1986 as the product of
the trk oncogene, a chimeric oncoprotein found in human colon carcinoma (Martin-
Zanca et al., 1986; Martin-Zanca et al., 1989). The extracellular domains of Trk
receptors consist of leucine-rich motifs utilised by other receptors as cell adhesion
components. The intracellular domains of full-length Trk receptors consist of catalytic
tyrosine kinase domains and are highly related, with approximately 80% amino acid
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identity. TrkB and TrkC also exist as splice variants lacking the tyrosine kinase domain,
which is replaced by a short cytoplasmic sequence.
Understanding the roles played by different trk receptors has been facilitated by the
generation of mice carrying disrupted TrkA, TrkB and TrkC loci. The mutant mice
exhibit severe neuronal deficiencies indicative of the key role that these signalling
receptors play in the ontogeny of the mammalian nervous system. TrkA mice are
small, display a wide array of sensory defects and have extensive neuronal cell loss in
trigeminal, dorsal root and sympathetic ganglia (Smeyne et al., 1994). Targeted
disruption of the TrkB gene results in nervous system lesions with resultant deficiencies
in trigeminal and nodose / pedrosal ganglia (Klein et al., 1993). TrkB targeted mice do
not respond to stimuli, are unable to feed and as a consequence die in the neonatal period
(Klein et al., 1993). This, combined with the fact that these mice express truncated TrkB
receptors, has challenged the study of effects of TrkB deletion. Generation of knock out
mice lacking all TrkB receptor isoforms has been more revealing as mice lacking both
full-length and truncated TrkB isoforms can survive up to 3 weeks after birth (Rohrer et
al., 1999). Unlike the targeted TrkA _/" and TrkB mice, TrkC mice develop to birth
and appear normal, respond to painful stimuli and take nourishment. However, after
birth they display abnormal movements, suggesting a defect in proprioception. They
have a limited lifespan (most die by P21) and most of their neuronal defects are in the
dorsal root ganglia and in muscle afferents (Klein et al., 1994).
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1.16.1 TrkB
The TrkB family of transmembrane proteins serve as receptors for BDNF and NT4.
Cloning and chromosomal localisation of the full-length human TrkB receptor was
originally reported in 1995 (Nakagawara et al., 1995). The human TrkB gene is
unusually large and spans at least 590 kilobases (kb). It contains 24 exons. Using
alternative promoters, splicing and polyadenylation sites, at least 100 isoforms can be
created that can encode 10 proteins. Only 3 major isoforms are generated by the gene;
the full-length receptor, a truncated isoform lacking the tyrosine kinase domain (TrkB-
T) and an isoform lacking the tyrosine kinase domain but containing a She binding site
(TrkB-T-Shc). TrkB-T-Shc is generated by the use of an alternative exon 19 and is
expressed solely in brain (Stoilov et al., 2002). As a general rule, full-length TrkB
receptors are located in neuronal tissue and truncated TrkB receptors are distributed in
non-neuronal tissues. BDNF binding to TrkB results in rapid degradation of TrkB
receptors at the cell surface (Sommerfeld et al., 2000). The sequences required for Trk
internalisation have not been identified. In some central nervous system (CNS) neurons,
TrkB receptors appear to be largely sequestered in intracellular vesicles and require a
second signal, such as cAMP or Ca2+, for efficient insertion of receptors into the surface
membrane (Meyer-Franke et al., 1998).
Truncated TrkB receptors without a kinase catalytic region were originally thought to
lack a signalling role, their presence serving to act as a reservoir to bind and inactivate
ligand (Biffo et al., 1995) or to offer inhibitory receptor competition against full-length
TrkB where they are co-expressed (Eide et al., 1996; Ninkina et al., 1996). Two forms
68
of the truncated TrkB receptor have been characterised, designated as TrkB.Tl and
TrkB.T2 and containing intracellular domains of 23 and 21 amino acids respectively
(Middlemas et al., 1991). TrkB.Tl and TrkB.T2 have been shown to be capable of
mediating BDNF-induced signal transduction (Baxter et al., 1997; Rose et al., 2003) and
result in distinct modes of dendritic growth compared to full-length TrkB receptors
(Yacoubian and Lo, 2000).
1.16.2 Trk B RECEPTOR SIGNAL TRANSDUCTION
Despite high conservation of their intracellular domains, including the catalytic tyrosine
kinase (Atwal et al., 2000), the Trk receptors can elicit different biological responses in
the same population of neuronal cells (McAllister et al., 1997; Bradbury et al., 1998;
Baldelli et al., 2000). This is because distinct molecular mechanisms and signalling
interactions are generated by each of the neurotrophins (Yamada et al., 2002).
TrkB receptors are activated by interaction with NT4 or BDNF. Activation is a 2-step
process and involves oligomerisation (dimerisation) of receptor molecules at the cell
surface followed by autophosphorylation of their cytoplasmic tyrosine residues (Jing et
al., 1992). The resulting phosphotyrosines serve as anchors for binding downstream
signalling elements and recruitment of She domain proteins, initiating further cascades
of signalling events (Schlessinger and Ullrich, 1992). Three important features of Trk
signalling are 1) activation of the PI3-kinase pathway and a subsequent block of
apoptosis, resulting in cell survival and differentiation, 2) activation of Ras / Raf /
MAPK/ERK kinase (MEK) / MAPK pathway, resulting in growth and differentiation
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and 3) association with phopholipase Cy to regulate PKC activity and release of Ca
from intracellular stores (Bibel and Barde, 2000) (Figure 1.5).
Apoptosis regulates the number of CNS neurones and is important for the formation and
organisation of brain structures. It is also a key feature in ovarian development and
organisation (Coucouvanis et al., 1993; Pesce et al., 1993; Ratts et al., 1995; Reynaud
and Driancourt, 2000). Neurotrophin activation of Trks and subsequent PI3-kinase














Figure 1.5 Diagram illustrating the main pathways signalled through the Trk receptors
(Bibel and Barde, 2000).
1. Ras / Raf / MEK / MAPK pathway (green) induces differentiation of neurons and
neurite growth. FRS2 tyrosine is phophorylated in response to NGF and BDNF.
2. PKB / AKT pathway (red) phosphorylates Bad / inactivates Bcl2 and mediates
survival by anti-apoptotic action.
3. PLCy (blue) catalyses cleavage of the substrate PIP2 to DAG, which induces
activation of PKC and IP3 leading to release of calcium from internal stores
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1.16.3 p75 RECEPTOR
The p75 receptor is a member of the TNF receptor superfamily and can bind all
neurotrophins with similar nanomolar affinity (Frade and Barde, 1998). The ability of
p75 to bind NGF was originally detected in the 1970s, but the receptor was not fully
described and cloned until ten years later (Chao et al., 1986; Radeke et al., 1987). The
p75 receptor is a single transmembrane protein consisting of 425 amino acids with an
intracellular carboxy-terminus and shares a similar intracytoplasmic domain structure
(featuring a death domain with six a helices) to Fas and tumor necrosis factor receptor 1
(Myers et al., 1994). The defining motifs of the TNF receptor family are cysteine
repeats in the extracellular domain, where ligands bind. With the exception of the
neurotrophins, all other known ligands of this receptor family are trimeric proteins that
lead to trimerisation of the receptor following binding.
The p75 receptor is expressed widely in neurons of both the central and peripheral
nervous system, and in a variety of nonneuronal cells, including ovary (Amano et al.,
1991; Wheeler and Bothwell, 1992; Dissen et al., 1996; Anderson et al., 2002b).
Knockout mice lacking p75 show behavioural defects and decline in performance in
Morris water maze testing, suggesting absence of p75 receptor signalling results in
defects in cognitive function and/or global sensorimotor impairment. Stereological
analysis of p75 mice brains shows a 25% reduction in basal forebrain volume with
associated loss of basal forebrain neurons, compared to wild-type mice (Peterson et al.,
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1999). Complete ablation of the p75 receptor also results in defects of blood vessel
formation (von Schack et al., 2001).
Several different biological activities involve p75 receptor signalling, which requires
multiple effector proteins. It is capable of, paradoxically, mediating cell death - either on
ligand binding (Rabizadeh et al., 1993; Rabizadeh and Bredesen, 1994), or on
withdrawal of ligand (Barrett and Georgiou, 1996) - or of mediating cell survival. These
effects are dependent not only on local expression of Trk receptors and ligand
presentation but also on available downstream mediators (Rabizadeh and Bredesen,
2003). Cell cycle progression, axonal elongation (Yamashita et al., 1999) and synaptic
transmission (Yang et al., 2002) also involve p75 receptor signalling.
The p75 receptor has the additional capacity to regulate binding affinity between Trks
and their cognate ligands resulting in increased specificity of neurotrophin-receptor
interactions (Benedetti et al., 1993; Mahadeo et al., 1994). Although p75 and Trk
receptors do not bind to each other directly, there is some evidence that complexes are
formed between the two receptors (Bibel et al., 1999; Yano and Chao, 2000) and may
interact to discriminate between neurotrophins. Indeed, BDNF, NT3 and NT4 can each
bind to TrkB but in the presence of p75 only BDNF provides a functional response
(Bibel et al., 1999). BDNF triggers sympathetic neuron apoptosis by binding to p75
when TrkB is absent (Bamji et al., 1998) and Agerman et al illustrated that BDNF and
NT4 can elicit opposite outcomes in the same cell through interactions mediated by
TrkB and p75 combined (Agerman et al., 2000).
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1.16.4 p75 RECEPTOR SIGNAL TRANSDUCTION
The p75 neurotrophin receptor is devoid of intrinsic catalytic activity and signal
transduction necessitates the recruitment of cytoplasmic effectors. Interaction of
neurotrophins with p75 can, therefore, result in activation of several different
intracellular signalling pathways by utilising various effectors (Dobrowsky et al., 1994;
Dobrowsky et al., 1995; Carter et al., 1996; Bamjieto/., 1998; Yoon et al., 1998;
Bhakar et al., 1999; Yamashita et al., 1999). The nuclear factor-KB (NF-kB) pathway
appears to promote survival (Ye et al., 1999; Gentry et al., 2000), whereas the jun N-
terminal kinase (JNK)-p53-Bax pathway and sphingomyelin hydrolysis promote
apoptosis. p75 signalling can also be regulated or modified by Trk receptor signalling
(Dobrowsky et al., 1995; Yoon et al., 1998). Pro-apoptotic responses to the p75 receptor
are largely suppressed in the presence of Trk signalling, and retention of p75 receptor
activation of NF-kB makes a synergistic contribution to survival (Maggirwar et al.,
1998; Hamanoue et al., 1999).
The p75 receptor also binds non-neurotrophin ligands including the neurotoxic fragment
of prion protein PrP-(106-126) (Della-Bianca et al., 2001), the Ab peptide of the
amyloid precursor protein, the predominant component of senile plaques in Alzheimer's
disease (Yaar et al., 1997; Kuner et al., 1998; Perini et al., 2002) and the rabies virus
glycoprotein (Tuffereau et al., 1998).
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1.17 NEUROTROPHINS IN THE OVARY
Although originally discovered in the nervous system, expression of neurotrophins and
their receptors has been described in a variety of non-neuronal tissues including the
cardiovascular, immune, endocrine and reproductive systems. BDNF and TrkB have
been identified in the adult avian ovary (Jensen and Johnson, 2001) and NT4 expression
has also been localised to the oocyte in both rodent (Dissen et al., 1995) and Xenopus
(Ibanez et al., 1992). NT4, and its receptors TrkB and p75 have been demonstrated in
the human fetal ovary (Anderson et al., 2002b), with expression of TrkB localised to the
germ cells. The ovary, in fact, contains all neurotrophins NGF, BDNF, NT3 and NT4
(Ernfors et al., 1990; Lara et al., 1990; Berkemeier et al., 1991; Hallbook et al., 1991;
Dissen et al., 1995; Dissen et al., 1996) and expresses all neurotrophin receptors TrkA,
TrkB, TrkC and p75 (Klein et al., 1989; Lamballe et al., 1991; Ojeda et al., 1992).
Before follicle formation is initiated, mRNA encoding neurotrophins and their respective
receptors is present in the mammalian ovary (Dissen et al., 1995; Anderson et al.,
2002b) and an increase in expression of genes encoding NT4 and TrkB, but not BDNF,
has been found to occur with the initiation of folliculogenesis (Dissen et al., 1995). Full-
length TrkB receptors are expressed at low and seemingly unchanging levels in the
oocytes and granulosa cells of both primordial and growing follicles. In contrast,
truncated TrkB is selectively expressed in oocytes, where it is targeted to the cell
membrane as primary follicles initiate growth (Paredes et al., 2004). Knockout mice
lacking all TrkB receptor isoforms, or those lacking both NT4 and BDNF, do not
initially show follicular disruption, nor increase in ovarian cell apoptosis, indicating that
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TrkB signalling may not be crucial to initial follicular assembly in the rodent. Absence
of TrkB receptors does, however, result in a stage-selective deficiency in early follicular
development that compromises the ability of follicles to grow beyond the primary stage,
with decreased proliferation of granulosa cells and decreased FSH receptor expression
(Paredes et al., 2004). Ligand signalling via TrkB also appears to be central to oocyte
survival during early follicular growth (Spears et al., 2003; Paredes et al., 2004).
Knockout mice lacking the p75 gene appear to have normal numbers of ovarian follicles
(unpublished data cited in (Dissen et al., 1995)).
Mice carrying a null mutation of the NGF gene show deficient development of
primordial follicles (Dissen et al., 2001). NGF may be responsible for inducing
expression of functional FSH receptors in newly formed follicles (Romero et al., 2002),
and its production increases proportionally with increase in follicle size (Mattioli et al.,
1999). TrkA and NGF are expressed in periovulatory follicules at the time of the
preovulatory LH surge and are thought to play a role in processes leading to mammalian
ovulation (Dissen et al., 1996; Mayerhofer et al., 1996). BDNF is normally present in
follicular fluid (Seifer et al., 2003) and a beneficial effect of BDNF on oocyte
maturation in vitro has been reported (Seifer et al., 2002a). Evidence for improved
cytoplasmic maturation and developmental competence as well as nuclear maturation
will be discussed in further detail in Chapter 5.
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1.18 SUMMARY
In summary, this literature review has examined current knowledge pertinent to the
subjects of germ cell survival, ovarian development and oocyte maturation.
Consideration has been given to activins, inhibins and neurotrophins, and their various
receptors, as growth factors likely to be involved in the regulation of the development of
the human fetal ovary as well as maturation of the bovine oocyte.
1.19 AIMS
The specific aims of this study were therefore to:
1. Investigate the expression and localisation of activin and the activin / inhibin
receptors in the human fetal ovary, amd to examine the effect of activin on germ
cell proliferation / survival
2. Clarify expression of BDNF and NT4, and their receptors TrkB and p75, in the
human fetal ovary and investigate their role in germ cell survival
3. Investigate the expression and localisation of BDNF and its receptors in the adult
ovary and cumulus-oocyte complex and examine a potential role for BDNF in





2.1 HUMAN FETAL TISSUE COLLECTION
Human fetal ovaries were obtained following medical termination of pregnancy.
Women gave consent according to national guidelines (Polkinghorne, 1989) and the
study was approved by the Lothian Paediatrics / Reproductive Medicine Research Ethics
Sub-Committee. Termination of pregnancy was induced by treatment with 200mg oral
mifepristone followed 48 hours later by prostaglandin (Gemeprost; Beacon
Pharmaceuticals, Tunbridge Wells, UK) lmg 3 hourly per vaginum. None of the
terminations were for reasons of fetal abnormality, and all fetuses appeared
morphologically normal. Gestational age was determined by ultrasound examination
prior to termination and confirmed by subsequent direct measurement of foot length.
Ovaries were dissected and either snap frozen and stored at -70°C, placed in 500pl
RNAlater (Ambion (Europe) Ltd, Huntingdon, Cambs, UK), fixed for
immunohistochemical analysis, or further dissected and placed into culture. Fixation
was carried out in Bouin's fluid for 5 hours, followed by transfer to 70% ethanol prior to
processing into paraffin using standard methods.
2.2.1 ISOLATION OF RNA AND SYNTHESIS OF cDNA
Small amounts of RNA are present within tissues and must be amplified in order to
identify and study gene expression. RNA is first converted to complimentary DNA
(cDNA) using the enzyme reverse transcriptase. Polymerase chain reaction (PCR) can
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then be performed on the cDNA using specific primers to manufacture copies of the
required sequence.
Total RNA was isolated from fetal ovary (14 - 19 weeks) using either the RNeasy Mini
Kit (Qiagen, Crawley, UK) for PCR, or TRIReagent for quantitative PCR analysis.
Using the RNeasy Mini Kit, tissue was homogenised and lysed in a volume of buffer
proportional to the amount of tissue. The buffer contains guanidine isothiocyanate
(GITC) and (3-mercaptoethanol ((BME), which rapidly inactivates endogenous RNases.
This mixture was centrifuged and 70% ethanol then added to the supernatant to provide
appropriate binding conditions. The mixture was agitated, then added to an RNeasy spin
column and centrifuged at 12,000 G at room temperature (RT), allowing adsorption of
the RNA onto the silica gel based membrane. The column was washed twice with
washing buffer before eluting RNA with RNase-free sterile water. Alternatively, tissue
was homogenised in 1ml TRIReagent, and allowed to settle prior to addition of
chloroform, which separates the homogenate into aqueous and organic phases: RNA
remains exclusively in the aqueous phase, DNA in the interphase and proteins in the
organic phase. The aqueous phase was aspirated, transferred to a fresh collection tube
and RNA then precipitated by addition of isopropanol. The pellet was washed with
ethanol, briefly allowed to dry and then solubilised by adding RNase-free water.
RNA from both preparation methods was quantified using a spectrophotometer. RNA
was then treated with DNase (Gibco, Paisley, UK) and reverse transcription performed
using a first strand cDNA synthesis kit (Roche Diagnostics, Lewes, UK) Briefly, 3p,g
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DNase treated RNA was incubated with oligo (dT)is primer for 10 minutes at 65°C and
then placed on ice. A reaction mix comprising buffer, reverse transcriptase, lOOmM
dithiothreitol (DTT), lOmM deoxynucleotide triphosphate (dNTP) and ribonuclease
inhibitor was added to each tube to a final volume of 40pJ. Tubes were incubated at
40°C for 2 hours and then cooled to 4°C. Resultant cDNA was then used for PCR
amplification or stored at -20°C.
2.2.2 POLYMERASE CHAIN REACTION (PCR)
PCR is a method of in vitro nucleic acid synthesis, whereby a specific sequence of DNA
is replicated. It is based on the DNA polymerisation reaction and requires two
oligonucleotide primers, which are designed to lie either side of the DNA fragment to be
amplified. These primers hybridise to opposite strands of the target sequence and are
orientated so that DNA synthesis proceeds across the region between the primers. PCR
involves repeated cycles of heat (95°C) to denature DNA, followed by temperatures to
allow annealing of the primers to their complimentary sequences (50 - 60°C in the
experiments described in the following chapters) and extension of the annealed primers
with DNA polymerase (72°C). Since the extension products themselves are also capable
of binding primers, successive cycles of amplification essentially double the amount of
target DNA synthesised the previous cycle and result in an exponential accumulation of
the specific target fragment.
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PCR reactions were performed using ljxl cDNA samples, 5|xM forward and reverse
oligonucleotide primers and 2 x thermostart PCR mastermix (Abgene, Epsom, UK) in a
total volume of 25pl Use of thermostart DNA polymerase eliminates the possibility of
non-specific priming during reagent preparation prior to PCR because the enzyme is
inactive until high temperature incubation (95°C for 15 minutes). The mastermix format
also offers benefits in terms of time taken for PCR preparation and reduces chances of
preparation errors, therefore giving reliable and reproducible results. Specific primers
were used, and these and the resultant product sizes are given in the relevant chapters.
Primers were designed to span an intron to ensure that genomic DNA was not amplified.
PCR cycling was carried out using MJ Research PTC-100 thermal cycler, for 35 cycles.
The annealing temperature varied, depending on product and primers used. Control
tubes were run in parallel for each PCR, one in which water replaced RNA and a second
RT- sample in which reverse transcriptase was omitted, to ensure there was no genomic
DNA contamination. After PCR, the size of product yielded was ascertained using
electrophoresis. PCR products (10p,l product + 2p,l 6x loading buffer) and PCR marker
(1Kb ladder; Invitrogen) were loaded on a 1.7% agarose gel containing ethidium
bromide, placed in a tank containing 1 x Tris, boric acid, EDTA (TBE) buffer and
electrophoresed at 90 - 110 V for 45 minutes. Products were visualised using ultraviolet
light. The identity of all PCR products were confirmed by direct sequencing using an
Applied Biosystems 373A automated sequencer.
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2.2.3 LIGHTCYCLER QUANTITATIVE PCR
Quantitative PCR, also known as real-time PCR, enables either absolute or relative
quantification of cDNA or RNA. It is based on the detection of a fluorescent reporter
molecule (SYBR Green 1) that increases as a PCR product accumulates with each
amplification cycle. SYBR Green 1 binds all double-stranded DNA and is monitored by
measuring the increase in fluorescence throughout the cycle.
Quantitative PCR was performed using the Lightcycler system (Roche Molecular
Biochemicals, Sussex, UK) to investigate changes in expression of the activin [3A
subunit over a range of gestations. Reverse transcribed RNA samples were diluted in
water as indicated. 1 |xl diluted first-strand cDNA was added to a final volume of 1 Oql
containing 2mM MgCf and ().5uM each of forward and reverse primer in 1 x
LightCycler Fast Start DNA MasterSYBR Green 1 Master Mix (Roche Molecular
Biochemicals). Signal acquisition was performed for each of 45 amplification cycles
followed by continuous melt curve analysis to ensure product accuracy. Primers used
are detailed in chapter 3.
Glyceraldehyde-3-phosphate dehydrogenase (GAPD) is an enzyme involved in
glycolysis, and is important for multiple cell functions including membrane fusion,
microtubule bundling, phosphotransferase activity, nuclear RNA export, DNA
replication, DNA repair and apoptosis. It is constitutively expressed in almost all tissues
at high levels. GAPD is used in quantitative PCR as a reference control for gene
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expression between different ovary samples. Using a 16-week fetal ovary, a series of
first-strand cDNA dilutions were made (1:10 to 1:100) and used to derive standard
curves for GAPD and activin (3A. The number of cycles needed to yield a fluorescent
signal above background (the cross-over point, Cp) was plotted against the log of
relative concentration using LightCycler software (Molecular Dynamics Ltd,
Buckinghamshire, UK) yielding a straight line for each product. Quantification of
ovarian (3A mRNA expression was subsequently performed. For each experiment, both
GAPD and activin (3A amplification reactions were performed in duplicate for every
cDNA sample used. Calculations for activin (!A mRNA concentration were made
relative to GAPD from the same sample to allow comparison between ovaries.
Allowances for difference in amplification rate for GAPD and activin |3A was achieved
by determining the actual amount of amplification required to yield a signal for each
target.
2.3.1 IMMUNOHISTOCHEMISTRY
The technique of immunohistochemistry involves localisation of an antigen (protein)
within a section of tissue using a specific antibody, which is either labelled itself or
detected by use of a secondary labelled antibody. A variety of different detection
systems, including enzymatic reaction, radioactivity signal or fluorescent dyes, can be
used to detect and visualise staining. A standard and widely used technique for
immunohistochemical staining is the Avidin-Biotin Complex (ABC) method. Avidin is a
large glycoprotein that has a high affinity for biotin and can be labelled with peroxidase.
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Biotin is a vitamin B complex and can be conjugated to a variety of biological molecules
including antibodies. The ABC method involves three stages: 1) application of
unlabelled primary antibody, 2) application of biotinylated secondary antibody followed
by 3) application of avidin-biotin-horseradish peroxidase (ABC-HRP) complex. The
peroxidase is then developed by 3,3'-diaminobenzidine tetrahydrochloride (DAB) to
produce a colorimetric end product.
False positive or non-specific staining may occur, and can be due to variety of reasons.
Firstly, an antibody may bind non-specifically to other epitopes in a tissue or may be
contaminated with other antibodies due to impure antigen used to immunize the host
animal. This is particularly applicable to polyclonal antibodies. A good antibody is key,
and this problem can be minimalised by careful selection. Secondly, tissues may contain
endogenous peroxidase, which catalyses enzymatic detection and will produce DAB
staining at the site of endogenous enzyme. To avoid this problem, tissues are exposed to
dilute methanol prior to addition of primary antibody, saturating endogenous peroxidase
and rendering it inactive. Endogenous biotin can also bind to primary antibodies. This is
overcome by applying unconjugated avidin to the tissue, which binds endogenous biotin,
and subsequent application of biotin to bind the avidin. Lastly, secondary antibodies
may bind to epitopes in the original tissue as well as to the primary antibody. This is
minimalised by applying the secondary antibody diluted in serum from the species that it
was raised against.
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Sections (5pxn) were mounted on BDH Superfrost Plus slides (BDH Laboratory
Supplies) and dried overnight at 50°C before processing for immunohistochemistry.
Firstly, slides were dewaxed in xylene (5 minutes) and rehydrated by washes through
ascending grades of ethanol (absolute ethanol, 95% industrial methylated spirits (IMS)
and 70% IMS) to distilled water (20 second washes). Fleat induced epitope retrieval
(HIER) was used for some antibodies. Pre-treatment with citrate can break protein cross¬
links formed by formalin (Bouins) fixation and can uncover hidden antigenic sites.
Where applicable, slides were immersed in boiling citrate (0.01M, pH 6.0) for 2 minutes
and then cooled and washed with tap water. They were then washed in Tris-buffered
saline (TBS; 0.05mol/l Tris, 0.85% NaCl, pH 7.6). All slides were incubated in 3% H2O2
in methanol for 30 min, to inhibit endogenous peroxidase activity. After rinsing in
distilled water, slides were transferred into TBS for 5 min and blocked for 30 min in
appropriate serum (Diagnostics Scotland, Carluke, UK) diluted 1:5 in TBS containing
5% bovine serum albumin. Sections were then blocked with avidin (0.01M; 15 min) and
biotin (0.001 M; 15 min) with 5 minute washes in TBS in between. Various primary
antibodies were used, as described in relevant chapters. Optimal antibody concentrations
were established in a series of preliminary experiments. Positive controls used tissue
sections known to show positive staining for the antibodies tested, either human fetal
testis (for activin/ inhibin subunits and receptors) or rat brain (for neurotrophins).
Negative controls were used to confirm specificity of antibodies under investigation. In
the case of monoclonal primary antibodies, the method substituted incubation with
buffer in place of primary antibody, whilst primary antibody was replaced with non-
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immune serum (from the same species) in the case of polyclonal antibodies under
investigation. Negative control for BDNF experiments was created by pre-incubation of
BDNF antibody with a specific BDNF blocking peptide (Santa Cruz, CA, USA). All
were incubated in a humidified atmosphere at 4°C overnight. The following day,
sections were washed and incubated for 30 min with a biotinylated secondary antibody
at a dilution of 1:500 in the appropriate serum. Following washes in TBS, sections were
incubated with ABC-HRP linked complex (Dako) according to the manufacturer's
instructions. Bound antibody was visualised using DAB (Dako), which produces brown
staining. Sections were counterstained with haematoxylin, dehydrated in graded ethanols
and histoclear and then soaked in xylene. Slides were mounted with Pertex mounting
medium and visualised by light microscopy. Images were captured using an Olympus
Provis microscope (Olympus Optical Co., London) equipped with Kodak DCS330
camera (Eastman Kodak).
2.3.2 NUCLEAR DIAMETER MEASUREMENT
The size distribution of germ cells expressing activin pA subunit was determined in
specimens of 18 - 19 weeks gestation. Sections (5p.m) were mounted on BDFI
Superfrost Plus slides (BDH Laboratory Supplies) and dried overnight at 50°C before
processing for immunohistochemistry as described above (section 2.5.1). Briefly, slides
were incubated in 3% H2O2 in methanol for 30 min, to inhibit endogenous peroxidase
activity. After rinsing in distilled water, slides were washed in TBS for 5 minutes and
then blocked for 30 minutes in normal rabbit serum (Diagnostics Scotland, Carluke, UK)
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diluted 1:5 in TBS containing 5% bovine serum albumin. Sections were then blocked
with avidin (0.01M; 15 min) and biotin (0.001M; 15 min) with 5 minute washes in TBS
in between. Monoclonal primary antibody to the inhibin / activin |3A subunit (E4), gift
of NP Groome, was used at 1:1000 and incubated overnight at 4°C. Sections were then
washed and incubated with rabbit anti-mouse biotinylated secondary antibody, at a
dilution of 1:500. Following washes in TBS, sections were incubated with ABC-HRP
linked complex (Dako) according to the manufacturer's instructions. Bound antibody
was visualised using DAB (Dako), to produce brown staining. TBS was used in place of
primary antibody for negative controls. Sections were counterstained with haematoxylin,
dehydrated in graded ethanols and histoclear and then soaked in xylene and mounted
with Pertex mounting medium.
Slides were visualised using the Provis image analysis system (Olympus Optical Co.,
London). To avoid bias, sequential non-overlapping frames were captured using the
Provis image analysis system, and the diameter of all germ cell nuclei within the frame
measured. Nuclear diameter, rather than germ cell diameter, was measured as this was
easier to accurately define. Analysis in Professor Anderson's laboratory has, however,
demonstrated a very close correlation between nuclear and germ cell diameter in the
human fetal ovary (results unpublished, Ms N Fulton). Diameters of a total of 527 germ
cell nuclei were measured. Strongly immunostained germ cells were classified as PA
positive, all other germ cells as negative. For graphical representation, numbers of
immunopositive and immunonegative cells were grouped in 1 pm increments of nuclear
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diameter. Data were analysed by the Mann-Whitney U test as the distribution deviated
from normal. The Mann-Whitney U test is a non-parametric test used to assess whether
two samples of observations come from the same distribution. The two samples must be
independent, and observations ordinal or continuous. The null hypothesis assumes that
two samples drawn from a single population will have equal probability distributions.
The test involves the calculation of a statistic, U, whose distribution under the null
hypothesis is known. In the case of larger samples, as in this case, there is a good
approximation of U to a normal distribution.
2.3.3 HAEMATOXYLIN AND EOSIN STAIN (H & E STAIN)
H & E staining was utilised to check tissue morphology as well as to count germ cell
number for time 0 samples relating to tissue culture experiments. Tissue sections were
dewaxed in xylene for 5 minutes, rehydrated in graded alcohols (absolute ethanol 20
seconds, 95% IMS 20 seconds and 70% IMS 20 seconds) and rinsed in tap water prior
to staining with Haematoxylin (5 minutes). Next, slides were rinsed in 1% acid alcohol
(5 seconds), Scott's tap water (40 seconds) then Eosin (5 - 20 seconds), with rinses in
tap water between each stage. Finally, slides were dehydrated in graded alcohols (70%
IMS 20 seconds, 95% IMS 20 seconds, absolute alcohol 20 seconds x 2) then soaked in
Histoclear (5 minutes) followed by xylene (5 minutes) before mounting in Pertex.
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2.4 TISSUE CULTURE
Human fetal ovary tissue was dissected and cultured in a-minimal essential medium (a-
MEM) with phenol red (GibcoBRL, Life Technologies). This medium has been shown
to be most effective at supporting human ovarian tissue in culture (Wright et al., 1999),
possibly because it contains amino acids, vitamins, ribonucleosides and
deoxyribonucleosides that are not present in simple salt solutions. a-MEM was
supplemented with 2mM pyruvate, 2mM glutamine, 1 x insulin / transferrin / selenium
(ITS) supplement and 3mg/ml BSA, and with Penicillin, Streptomycin and
Amphotericin. Serum albumin and ITS have been shown to be effective replacements
for serum in culture (Wright et al., 1999), and allow testing of growth factor effects in a
serum-free environment.
Fetal ovaries were dissected in pre-warmed medium. Fetal ovaries were initially halved
and one half removed as 'time 0' uncultured control tissue before further dissection to
yield tissue fragments approximately 1mm3. 'Time 0' tissue was immediately washed in
phosphate buffered saline (PBS) and fixed in Bouin's fluid for 1 hour, then transferred to
70% ethanol followed by processing into paraffin using standard methods. Tissue
fragments were cultured in 400ul medium, enough to just cover but not submerge them.
4-6 fragments were transferred to designated wells containing inserts (Millicell-CM;
Millipore UK Ltd, Watford, UK) in a 24 well tissue culture plate. Further wells were
partially filled with medium to maintain humidity in the culture plate.
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A total of 7 fetal ovaries were used in the first set of culture experiments (chapter 3).
Tissue was cultured for 17 hours in a humidified incubator at 37°C and 5% C02. For
each experiment, two treatment groups were cultured with lOOng/ml recombinant human
activin A (R&D systems, Abingdon, UK). Two further groups acted as controls.
Bromodeoxyuridine (BrdU) was supplemented to culture media at lOgl/ml as a marker
of cell proliferation. In each experiment BrdU was present in the media of one control
and one treatment group for the duration of the experiment. BrdU was added to the other
control and treatment group for the final 4 hours of tissue culture only. Analysis of germ
cell number in these parallel cultures confirmed that changing the medium 4 hours
before the end of the culture period did not influence the results.
In a second set of experiments, a further 5 fetal ovaries were used (chapter 4). Tissue
was cultured for 24 hours in a humidified incubator at 37°C and 5% C02. As a
modification of the method used previously, ovaries were completely dissected into
tissue fragments measuring approximately 1mm3. In each experiment, 4-6 tissue
fragments were randomly selected as 'time 0' uncultured control tissue, immediately
washed in PBS and fixed in Bouin's fluid for 1 hour before transferring to 70% ethanol
and processing into paraffin using standard methods. Further fragments were then
transferred to designated wells containing inserts in a 24 well tissue culture plate. Six
groups were cultured in total, five different treatment groups and one control group.
Treatment groups were supplemented with either lOOng/ml NT4 (Peprotech EC Ltd),
lOpg/ml anti-NT4, lOOng/ml NT4 and 10pg/ml anti-NT4, lOOng/ml BDNF (Peprotech
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EC Ltd) or lOOng/ml BDNF and lOpg/ml anti-NT4. Additionally, lOpl/ml BrdU was
used in all groups as an indicator of cell proliferation. No media exchange or
supplementation was performed during these experiments.
At the end of culture, tissue fragment groups were washed in PBS, fixed in Bouin's fluid
for 1 hour, transferred to 70% ethanol followed by processing into paraffin using
standard methods.
2.5 QUANTIFICATION AND ANALYSIS OF CULTURED TISSUE
Serial sections (5pm), 4 sections per slide, were mounted on BDH Superfrost Plus slides
(BDH Laboratory Supplies) and dried overnight at 50°C. Mounting 4 tissue sections per
slide reduced the number of slides required, and only every 4th slide was processed for
immunohistochemistry (as per section 2.5.1). Formalin grade a-BrdU monoclonal
antibody (Roche, UK) was used at a dilution of 1:30 and incubated at 4°C overnight. On
completion of the immunohistochemistry protocol sections were counterstained with
haematoxylin (2 minutes), dehydrated and mounted.
Sections of uncultured 'time 0' and cultured tissue were analysed to investigate the
effect of culture and of supplemented growth factors on the number and proliferation of
germ cells and non-germ cells. Analysis of every 4th slide equated to analysis of tissue at
intervals of over 80 pm, ensuring that the same cells could not be counted more than
once. Analysis was carried out blind using the Area Fraction Probe in the Stereologer
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software programme (Systems Planning and Analysis Inc, Alexandria, VA, USA) and
using an Olympus BH-2 microscope (Olympus UK Ltd., London, UK) fitted with a
Prior automatic stage (Prior Scientific Instruments Ltd., Cambridge, UK). This
programme randomly selects frames within an outlined tissue fragment area, and thus
minimises observer bias. In the first set of experiments, counting was performed using a
121-point grid in the eyepiece of the microscope. Cells lying directly beneath the
intersection on the grid were identified as germ cell or non-germ cell and recorded. Cell
classification as germ cell was made on the basis of histological appearance - larger cell,
larger nucleus, visible chromatin, located within germ cell nest - or non-germ cell (pre-
granulosa / endothelial cell / blood cell). Numbers proliferating (ie. immunostained for
BrdU) for each cell type was also recorded. The number of points lying outside the
tissue in any grid was also recorded and the total cell numbers were corrected for this
(using the formula: cells counted x 121 / points on tissue). Areas selected by the
randomised stage with less than 50 % grid points overlying tissue were not analysed.
Average number of germ cells per grid was calculated for each experimental condition.
In the second set of experiments, stereology software had been up-graded, and analysis
was performed using Image-Pro Plus 4.5.1 with Stereologer-Pro 5.1 plug-in software
(Media Cybernetics UK, Wokingham, Berkshire, UK). As previously described, tissue
areas were identified by outline and subsequently analysed following randomised
selection. The area to be analysed was displayed on a computer screen (instead of
visualising down the microscope), which was overlaid by a 63-point grid. Cells lying
directly beneath the intersection on the grid were counted and classified as germ cell /
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non-germ cell, as well as documenting presence or absence of BrdU staining. The
number of points lying outside the tissue in any grid was also recorded and total cell
numbers corrected for this (using the formula: cells counted x 63 / points on tissue).
Areas selected by the randomised stage with less than 50 % grid points overlying tissue
were not analysed.
Data was imported from stereology results recording to excel spreadsheets for statistical
analysis. Each repetition of the experiment was initially analysed separately to derive
mean number of germ cells and non-germ cells for time 0 tissue, as well as number of
stained germ cells, unstained germ cells, stained non-germ cells and unstained non-germ
cells for culture control and treatment groups. Results were then averaged across repeat
experiments, calculating mean results (and standard error of the mean, SEM) for cell
types (stained or unstained) for time 0, control and culture treatment groups.
In the activin culture experiments, statistical analysis comparing control and treatment
groups was performed using Student's t-test. In the neurotrophin culture experiments,
results were analysed using analysis of variance (ANOVA) with post hoc Bonferroni
correction. The t-test could have been used to test differences between means of the control
and different treatment groups, but would have led to inflation of type I error rate
(because the likelihood of finding something by chance is increased by making multiple
comparisons). ANOVA was therefore used to test for significant differences among the
means of control and treatment groups. This has the advantage of avoiding increasing the
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type I error rate, but only identifies a significant difference between groups, not which
groups are significantly different from each other. Post-hoc comparison was then used to
find which groups were significantly different from each other and which were not.
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2.6 BOVINE OVARY COLLECTION
Bovine ovaries were obtained from Galashiels abattoir. Ovaries were recovered from the
animals, stored at 37°C after collection and transported to the laboratory in a thermos
flask with pre-warmed heat packs. Ovaries were then washed in warm PBS and either
snap frozen and stored at -70°C, fixed for immunohistochemical analysis or follicles
aspirated to yield immature cumulus-oocyte complexes (COCs) for maturation culture.
Fixation of bovine ovaries was carried out in Bouin's fluid overnight, followed by
transfer to 70% ethanol prior to processing into paraffin using standard methods. To
facilitate their handling prior to fixation, COCs were first embedded in 50pl droplets of
collagen solution, using a method described by Izadyar et al (Izadyar et al., 1998).
Collagen solution was prepared by dissolving 4.2mg type I rat-tail collagen in 1ml 0.1M
acetic acid (BDFI) and mixing with an equal volume of 2x tissue culture medium 199
(TCM 199), pH 7.2 immediately before use. Droplets containing COCs were incubated
at 37°C for 10 minutes to set, then fixed in Bouin's fluid for one hour and transferred to
70% ethanol prior to processing into paraffin using standard methods.
2.7 BOVINE CUMULUS-OOCYTE COMPLEX (COC) COLLECTION
COCs were aspirated from 4 - 8mm antral follicles visible on the surface of the ovary
using a syringe and 18G needle. Studies suggest that oocytes obtained from follicles less
than 3mm diameter have significantly lower rates of maturation and development to
blastocyst stage (Pavlok et al., 1992; Lonergan et al., 1994b; Blondin and Sirard, 1995).
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All ovaries obtained were aspirated, despite presence or absence of corpora lutea. Cows
in follicular or luteal phases of the ovulatory cycle, or even pregnant at the time they are
killed, do not show any marked difference in the maturational competence of oocytes
(Trounson et al., 2001). Follicular aspirate was maintained at 38°C and allowed to settle.
The cellular debris was then transferred to a grid-marked 100mm petri-dish containing
5ml 4-(2-hydroxyethy)-l-piperazineethanesulfonic acid (HEPES)-buffered TCM 199
with 10% (heat inactivated) fetal calf serum (FCS) to allow sorting and selection of
COCs. All procedures were carried out in a laminar flow hood using a Leica microscope
with heated stage at 38°C.
2.8.1 ISOLATION OF RNA AND SYNTHESIS OF cDNA
RNA was extracted from whole bovine ovary, quartered for ease of handling, using the
Rneasy mini kit (Qiagen, Crawley, UK) as previously described (section 2.4.1).
RNA was extracted from bovine COCs, cumulus and single oocytes as per method
described by Young et al (Young et al., 1998), using the QIAshredder cell lysate
homogeniser (Qiagen, Crawley, UK) followed by the RNeasy mini kit (Qiagen,
Crawley, UK). COCs, cumulus or single oocytes were vortexed in 350pl buffer
containing GITC and |3ME to inactivate endogenous RNases. Buffer was also added to
an empty tube, designated non-embryo control (NEC), which was used to control for
reagent contamination. Samples, including NEC, were then homogenised by adding to a
QIA shredder column and centrifuging for 2 minutes at 13,000rpm. An equal volume of
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70% ethanol was added to the homogenised lysate and mixed well. Samples were
applied to RNeasy mini spin columns and centrifuged for 30 seconds at 10,000rpm.
Columns were washed twice with wash buffer as per manufacturer's instructions and
RNA was eluted with 50pl RNase free water. RNA precipitation was performed using
Pellet Paint (Novagen). Pellet Paint is a visible dye-labelled reagent formulated
specifically for use in alcohol precipitation of nucleic acids. Once RNA is precipitated
from solution, the pink pellet is easily located and prevents loss during handling. Pellet
Paint (2pl) was added to each tube of RNA and mixed with 5pl (0.1 volume) 3M sodium
acetate. Thereafter lOOpl (2 volumes) 100% ice cold ethanol was added to each tube and
vortexed briefly. Samples were incubated for 2 minutes at room temperature, and
subsequently centrifuged at 14,000rpm for 30 minutes at 4°C. The supernatant was
removed and the pellet rinsed with 500pl ice cold 70% ethanol, which was vortexed
briefly and then centrifuged at 14,000rpm for 20 minutes at 4°C. The supernatant was
aspirated, the tube spun again briefly and any further supernatant aspirated to remove as
much ethanol as possible. Pellets were air-dried on ice for approximately 10-15
minutes. Each pellet was then re-suspended in RNase free water, and transferred to a
PCR tube for reverse transcription.
RNA was heated to 65°C for 10 minutes to denature, then chilled on ice. Reverse
transcription was performed using a bulk first strand cDNA synthesis kit (Amersham,
UK), whereby 5pl bulk first-strand reaction mix was mixed with 1 pi random hexamer
primer (pd(N)e) and 1 pi DTT and added to the denatured RNA. The mixture was
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incubated at 37°C for 1 hour and cooled to 4°C thereafter. A control tube in which
reverse transcriptase was omitted, designated RT-, was also included to ensure there was
no genomic DNA contamination. Resultant cDNA was either used immediately for PCR
amplification, or stored overnight at -20°C.
2.8.2 SINGLE CELL PCR
PCR used 2^il cDNA samples and 2 x thermostart PCR mastermix (Abgene, UK).
Specific primers were used, at a concentration of 250nM, and these and the resultant
product sizes are given in chapter 5. PCR cycling was carried out using a Hybaid
Omnigene thermal cycler, for 40 cycles. The annealing temperature varied, depending
on product and primers used. Control tubes were run for each PCR to ensure there was
no genomic DNA contamination, one in which water replaced cDNA, and a second RT-
sample in which reverse transcriptase was omitted. Reagent blank control tube for RNA
extraction (NEC) was also included. After PCR, the size of product yielded was
ascertained using electrophoresis. PCR products (lOpl product + 2pl 6x loading buffer)
and PCR marker (1 Kb ladder; Invitrogen) were loaded on a 1.7% agarose gel containing
ethidium bromide (0.5p,g/ml), placed in a tank containing 1 x TBE buffer and run at 90
- 110 V for 45 minutes. Products were visualised using ultraviolet light. The identity of
all PCR products was confirmed by direct sequencing.
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2.9 IMMUNOHISTOCHEMISTRY
Sections of bovine ovary or collagen-embedded COCs (5 pm) were mounted on BDH
Superfrost Plus slides (BDH Laboratory Supplies) and dried overnight at 50°C before
processing for immunohistochemistry as previously described (section 2.5.1). Briefly,
slides were incubated in 3% H2O2 in methanol for 30 min to inhibit endogenous
peroxidase activity. After rinsing in distilled water, slides were washed twice in TBS for
5 min and blocked for 30 min in appropriate serum (Diagnostics Scotland, Carluke, UK)
diluted 1:5 in TBS containing 5% bovine serum albumin. Sections were then blocked
with avidin and biotin (both from Vector, Peterborough, UK) with washes in TBS in
between. The following primary antibodies were used: BDNF (N20) (Santa Cruz, CA,
USA), which was used at 1:100; TrkB (chicken polyclonal, Promega, Southampton, UK)
used at 1:25; Truncated trk B (Santa Cruz, CA, USA) used at 1:50; p75 (Neomarkers,
CA, USA) used at 1:25. All were incubated at 4°C overnight. Sections were then washed
and incubated for 30 min with biotinylated secondary antibody as appropriate, at a
dilution of 1:500. Following washes in TBS, sections were incubated with avidin-biotin-
horseradish peroxidase linked complex (Dako) according to the manufacturer's
instructions. Bound antibody was visualised using 3,3'-diaminobenzidine
tetrahydrochloride (Dako). Pre-absorbed BDNF blocking peptide (Santa Cruz, CA,
USA) or non-immune serum was used in place of primary antibody for negative
controls.
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Sections were counterstained with haematoxylin, dehydrated, mounted and visualised by
light microscopy. Images were captured using an Olympus Provis microscope (Olympus
Optical Co., London) equipped with Kodak DCS330 camera (Eastman Kodak).
2.10 IN VITRO MATURATION
Maturation medium used was a modification of a recipe described by Moor et al in 1977
originally used to successfully mature sheep oocytes (Moor and Trounson, 1977) and
based on tissue culture medium 199 (TCM 199), a medium that has been demonstrated
to contain components necessary for optimal bovine oocyte maturation (Lonergan et al.,
1994a; Gandhi et al., 2000).
COCs were transferred through three wash plates containing 1.5ml HEPES-buffered
TCM 199 with 10% fetal calf serum, before transfer in minimal volume to 1.5ml
maturation wash comprising serum-free bicarbonate-buffered TCM 199 supplemented
with O.OliU/ml FSH (Ovagen), 0.125iU/ml LH and 2ug/ml (3-estradiol. COCs were
then randomly selected into groups and transferred into 500pl maturation medium in 4-
well Nunc plates. There were six different maturation treatment groups: medium was
either 1) serum-free or supplemented with 2) 10% fetal calf serum, 3) 1 OOng/ml
recombinant human BDNF (PeproTech EC Ltd), 4) lOng/ml recombinant human
BDNF, 5) 5 p,g/ml monoclonal cx-human BDNF or 6) both lOng/ml recombinant human
BDNF and 5p,g/ml monoclonal a-human BDNF.
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COCs were cultured under mineral oil at 38.5°C in a humidified incubator with 5% CO2.
After 26 hours maturation culture COCs were stripped and either processed for
immunocytochemistry to assess meiotic progression or activated to produce parthogenic
embryos. Cumulus was stripped by mechanical vortex (repeated aspiration using a
Gilson pipette) and incubation in 300iU/ml hyaluronidase in serum-free HEPES
buffered Synthetic Oviduct Fluid (E1SOF) consisting of 108 mM NaCl, 7.2 mM KC1, 1.2
mM KH2PO4, 5 mM NaHC03, 20 mM HEPES, 0.33 mM Na-Pyruvate, 1.7 mM CaCl2,
0.5 mM MgCl2, 3.3 mM Na-Lactate, 1.5 mM glucose, 3 mg/ml BSA (fatty acid free),
pH7.4, osmolarity 265-275 (Thompson et al., 1995) for 60 - 90 seconds. Enzymatic
action was neutralised by transferring oocytes through subsequent washes of HSOF
supplemented with 10%FCS.
In a second group of experiments, oocytes were stripped of cumulus prior to maturation.
Only completely denuded oocytes were selected and washed in serum-free base
maturation medium (see above). Five cumulus-free maturation treatments were
evaluated consisting of serum-free medium (negative control), or medium supplemented
with 10% FCS (positive control), 10 ng/ml of recombinant human BDNF, 5 pg/ml
monoclonal anti-human BDNF or both lOng/ml recombinant human BDNF and 5 pg/ml
anti-human BDNF. In each experimental replicate a sixth group of cumulus enclosed
oocytes were matured in base maturation media supplemented with 10% FCS (cumulus
positive control). As previously, oocytes were cultured at 38.5°C in a humidified
incubator with 5% CO2 for 26 hours and subsequently either processed for
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immunocytochemistry to assess meiotic progression or activated to produce
parthenogenetic embryos.
2.11 IMMUNOCYTOCHEMISTRY
Stripped oocytes were fixed and immunostained for microtubules and microfilaments
using a modification of the method described by Messinger and Albertini (Messinger
and Albertini, 1991). Maturation to Mil was assessed by immunocytochemical staining
to visualise spindle morphology, condensed chromatin and segregation of the first polar
body. Microtubule stabilising buffer comprising 5xSB (0.1M Pipes, 5mM MgCl2,
2.5mM ethylene glcol bis ((3 aminoethyl ether)-NNN'N'-tetra acetic acid (EGTA),
pH6.9 in NaOH), 1M DTT, deuterium oxide (Aldrich) and distilled water was incubated
with Triton XI00 (BDH) and 37% formaldehyde to make Complex Fix. Triton X-100 is
a detergent that is used for improving antibody penetration. Stripped oocytes were
incubated in Complex Fix for 30 minutes at 37°C and then washed 3 times in 0.1% goat
serum before blocking in 10% goat serum for 1 hour at room temperature. Each
maturation group of oocytes was processed individually. Oocyte groups were then
incubated in the dark at 37°C for 1 hour in 50pl droplets of 5% goat serum with
rhodamine phalloidin and a-tubulin F1TC, washed 3 times in 10% goat serum and then
mounted in Vectashield and 4'6-diamidino-2-phenylindole (DAPI; Vector,
Peterborough, UK). Oocytes were partially squashed with a coverslip that was then
sealed using clear nail varnish.
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2.12 ANALYSIS OF IMMUNOCYTOCHEMISTRY
Slides were visualised using fluorescent microscopy and each oocyte scored for meiotic
progression (Figure 2.12.1). Rhodamine phalloidin binds and stabilises microfilaments
and is seen as red under fluorescence. FITC (fluorescein) is a small organic molecule
conjugated (in this case) to a-tubulin monoclonal antibody in order to visualise spindle
filaments. It is seen as green under fluorescence. DAPI is a fluorescent stain that binds
strongly to double-stranded DNA and is excited with ultraviolet (UV) light (blue
emission).
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Figure 2.12.1 Oocyte immunocytochemistry demonstrating microfilaments (red),
microtubules (green) and chromatin (blue). A, metaphase I. Chromosomes aligned along
spindle. B, anaphase I. Homologous chromosomes separated to opposites poles of
spindle. C - F, metaphase II. Chromatin aligned at metaphase plate by spindle fibres.
Polar body containing chromatin also seen
















Stripped oocytes were activated for 5 minutes at room temperature with 5pM ionomycin
in HSOF with 10% FCS. lonomycin is a calcium ionophore used to increase the level of
intracellular Ca2+. Stripped oocytes were subsequently washed twice in HSOF with 10%
FCS and then washed in SOFaaBSA (HEPES-free SOF supplemented with ImM L-
Glutamine, 8 mg/ml fatty acid free bovine serum albumin, 1 x essential amino acids, lx
nonessential amino acids, pH7.4, osmolarity 265-275) (Thompson et al., 1995; Walker
et al., 1996). Oocytes were then incubated for 4 hours in SOFaaBSA containing 2.5mM
DMAP and lOpg/ml cycloheximide at 38.5°C in humidified low O2 and 5% CO2
conditions. DMAP is a serine-threonine protein kinase inhibitor that blocks germinal
vesicle breakdown and cell cycle progression in immature oocytes, and reduces
phosphorylation of cell cycle regulatory proteins including MPF and CSF.
Cycloheximide is an inhibitor of protein biosynthesis. Following activation, oocytes
were washed three times in SOFaaBSA and finally transferred into 4-well Nunc plates
for culture in 500pl SOFaaBSA under mineral oil. Embryos were examined for cleavage
at 24 hours post activation (dayl), had 10% FCS supplemented to media on day 5 of
culture and were assessed for blastocyst development on day 7.
2.14 QUANTIFICATION AND ANALYSIS OF BLASTOCYST FORMATION
Blastocysts were stained by incubation with lOpg/ml Hoechst 33342 (bisbenzimide) for
15 minutes. Hoechst 33342 binds to nuclear DNA with high specificity and
photostability, and is seen as blue under UV wavelengths. Blastocysts were then
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mounted on glass slides and nuclear number assessed by counting under fluorescent
microscopy (Figure 2.14).
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Figure 2.14 Analysis of blastocyst nuclear number.
Blastocyst seen under light microscopy (A). Blastocyst visualised under fluorescent
microscopy following staining with Hoechst (B). Note: nuclear counts were performed
whilst the blastocyst was intact. Minor alterations in microscope focus enable all stained
nuclei to be counted. The blastocyst was subsequentially squashed by application of a
cover slip, and nuclear counts repeated to confirm results. Superimposed image of





EXPRESSION AND DISTRIBUTION OF
INHIBIN / ACTIVIN SUBUNITS AND RECEPTORS




Germ cell survival is key to the reproductive lifespan of the ovary and is determined by
the continuing presence of oocytes within primordial follicles. These are formed during
fetal life in the human. The number of follicles formed is dependent upon the balance
between early germ cell proliferation and loss, as well as the interaction between oocyte
and somatic cells (Hirshfield, 1991; McLaren, 1991). The pathways regulating this
crucial process are largely unknown, although a number of genes necessary for the
formation of a normal complement of primordial follicles have been identified (Matzuk,
2000; Amleh and Dean, 2002). During the period leading up to primordial follicle
formation there is massive oogonial mitotic proliferation, both during and after
migration from the yolk sac to the nephrogonadoblastic ridge. The oogonia associate
with somatic cells resulting in syncitial nests of germ cells intermingled with
pregranulosa cells and surrounded by a meshwork of ovarian stroma (Byskov, 1986;
Pepling and Spradling, 2001; Sawyer et al., 2002). The germ cells subsequently enter
meiosis only to arrest at diplotene of the first meiotic division. By mid-gestation, the
human fetal ovary contains its maximal number of germ cells. This peak is followed by
widespread germ cell loss, by apoptosis, (De Pol et al., 1997; Vaskivuo et al., 2001) so
that less than 20% survive by the time of birth (Baker, 1963). Primordial follicles are
formed as oocytes become individually surrounded by somatic cells (Hirshfield, 1991)
and it is this interaction that has been identified as the event that determines oocyte
survival and presumably protection against apoptosis. A number of locally derived
growth factors have been identified to be crucial to germ cell survival at early
developmental stages, such as BMP4 (Fujiwara et al., 2001a) and kit ligand (Manova et
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al., 1990; Godin et al., 1991), and following primordial follicle formation, such as GDF9
(Dong et al., 1996). However, little information is available regarding factors regulating
oogonial proliferation and primordial follicle formation, particularly in the human.
Activins and inhibins are members of the TGF|3 family. The component a and (3
subunits can be combined into biologically active a(3 inhibin or |3|3 activin dimers with
generally opposing functional effects, and are produced in both gonad and pituitary
(Burger and Igarashi, 1988; Chen, 1993; Mather et al., 1997). Members of the TGF|3
superfamily can influence many facets of cell lineage and activity including
proliferation, differentiation, adhesion, motility and apoptosis. Many are involved in
embryonic development as well as adult tissue homeostasis (Mishina et al., 1999;
Padgett and Patterson, 2001). The activins, together with other members of the TGF|3
superfamily, signal through membrane-bound serine-threonine kinase receptors. They
bind to a type II receptor (ActRIIA or ActRIIB), which recruits and phosphorylates a
type I receptor with subsequent modulation of gene expression via Smad protein
activation (Massague, 1998). Several type I receptors, termed activin-like kinases
(ALKs) have been identified. ALK4 (ActRIB) and ALK2 (ActRIA) are believed to be
the preferential activin receptors. Whilst the Smad proteins are the central elements in
the activin receptor signalling pathway, other signalling pathways may mediate at least
some of the diverse biological responses of the TGF(3 superfamily, including MAPK
pathways (Massague, 2000; Mulder, 2000). The initial steps coupling the activin type II
serine-threonine kinase receptor to MAPK are yet to be defined, although signalling via
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TGFfyactivated kinase 1 (TAK1) results in activation of stress-activated p38 and
activating transcription factor 2 (ATF2), which can interact with Smad3 and Smad4 to
mediate transcription (Cocolakis et al., 2001; Derynck et al., 2001).
A substantial body of evidence has accrued that activins and inhibins are regulatory
factors in the adult ovary involved in a wide range of functions, including
folliculogenesis, granulosa and theca cell proliferation, and steroidogenesis, (Mizunuma
et al., 1999; Knight and Glister, 2001; Findlay et al., 2002) as well as oocyte maturation
(Alak et al., 1998; Izadyar et al., 1998). Activin is expressed in the human gonad at very
early stages of development (Harkness and Baird, 1997) and there are limited data
indicating the expression of activin and inhibin in the developing human ovary
following primordial follicle formation (Rabinovici et al., 1991; Flarkness and Baird,
1997). However no data are available regarding the presence of activin and its cognate
receptors prior to primordial follicle formation in the human ovary. The expression and
distribution of inhibin/activin subunits in the human fetal ovary during the period of
oogonial proliferation leading up to primordial follicle formation were therefore
explored. Location of activin receptors, as well as the inhibin receptor betaglycan
(Lewis et al., 2000), were also investigated to identify potential sites of action of these
regulatory factors during this period of development. As oogonia in the mid-trimester
human fetal ovary were found to express activin subunits and receptors, the effect of
activin A on germ cell survival and proliferation was investigated using an in vitro tissue
culture model.
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3.2 MATERIALS AND METHODS
Tissues
Human fetal ovaries and testes were obtained following medical termination of
pregnancy. Women gave consent according to national guidelines (Polkinghorne, 1989)
and the study was approved by the Lothian Paediatrics / Reproductive Medicine
Research Ethics Sub-Committee. Gestational age was determined by ultrasound
examination prior to termination and confirmed by subsequent direct measurement of
foot length (Section 2.1).
Isolation of RNA and synthesis of cDNA
Total RNA was extracted from fetal ovary and (14 - 19 weeks) and cDNA synthesis
performed (Section 2.2.1)
Amplification of specific cDNAs by PCR
PCR was performed using lpl cDNA samples, 5pM forward and reverse
oligonucleotide primers and 2 x thermostart PCR mastermix in a total volume of 25pl
(Section 2.2.2). Specific primers were used, and these and the resultant product sizes are
given in Table 3.1 below. PCR amplification conditions for subunits and type II
receptors all consisted of an initial hot start denaturation step at 95°C for 15minutes,
followed by 35 cycles of denaturation at 95°C for 30 seconds, annealing at 60°C for 30
seconds and extension at 72°C for 45 seconds. A final extension period at 72°C for 5
minutes completed the amplification. Control tubes were run in parallel for each PCR,
one in which water replaced RNA and a second RT- sample in which reverse
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transcriptase was omitted, to ensure there was no genomic DNA contamination. After
PCR, the size of product yielded was ascertained using electrophoresis. The identity of
all PCR products was confirmed by sequencing.
Lightcycler Quantitative PCR
Quantitative PCR was performed using the Lightcycler system to investigate changes in
expression of the activin (3A subunit over a range of gestations (Section 2.2.3). A total
of 29 specimens were used, between 14 and 19 weeks gestation. Primers used, and the
resultant product sizes, are given in Table 3.1.
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GENE PRIMER SEQUENCE (5' - 3') PRODUCT SIZE
Base pairs (bp)
ActRIIA 5' GCAAAATGAATACGAAGTCTA 435
3' GCACCCTCTAATACCTCTGGA
ActRIIB 5' CAACTTCTGCAACGAGCGCTT 283
3' GCGCCCCCGAGCCTTGATCTC
Inhibin a 5' TGAGGGCCCTGTTCTTGGATG 278
3' CTGGCGGCTGCGTGTATGCTG
Inhibin / activin (3A 5' GAACTTATGGAGCAGACCTCGG 274
3' TTGCCATCACACTCCAAGCC
Inhibin / activin pB 5' GCCAGGAGCGCGTTTCCGAAATC 325
3' CCGCTCGCCCCGCTCAAACAAG
GAPD 5' GACATCAAGAAGGTGGTGAAGC 212
3' GTCCACACCCTGTTGCTGTAG
Table 3.1. Sequences of PCR primers for inhibin / activin subunits, type II activin
receptor and constitutively expressed gene GAPD.
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Immunohistochemistry
Immunohistochemistry was performed on paraffin embedded sections of fetal ovary and
testis to localise expression of activin and inhibin subunits and receptors, as well as
follistatin, a natural antagonist to activin. Expression of activin type II receptors
ActRIIA and ActRIIB, type I receptors ALK2 and ALK4 and the inhibin receptor
betaglycan was also investigated (Section 2.3.1). The conditions for individual
antibodies are described below. Fetal testis was used as positive control tissue in all
experiments. Negative controls omitted application of primary antibody in the case of
monoclonal antibodies, and substituted primary antibody incubation with non-immune
serum in the case of polyclonal antibodies.
INHIBIN a SUBUNIT
After dewaxing and rehydrating, antigen retrieval was carried out. Tissue was immersed
in boiling 0.01M citrate buffer pH 6.0 for 2 minutes, then cooled by addition of cold tap
water. Non-specific binding was eliminated by pre-blocking with normal rabbit serum
(NRS) (diluted 1:5 in TBS containing 5% bovine serum albumin). Monoclonal primary
antibody to the inhibin a subunit (173.9k), gift ofNP Groome (School of Biological and
Molecular Sciences, Oxford Brookes University, Oxford), was used at a range of
dilutions 1:1000 to 1:100 (incubated overnight at 4°C). Secondary rabbit anti-mouse
biotinylated antibody was added at 1:500.
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INHIBIN / ACTIVIN p SUBUNITS
Non-specific binding was eliminated by pre-blocking with NRS (diluted 1:5 in TBS
containing 5% bovine serum albumin). Sections were incubated overnight at 4°C with
monoclonal primary antibodies to the inhibin / activin (3A subunit (E4) used at 1:1000 or
|3B subunit (12/13) used at 1:100, both the gift ofNP Groome. Secondary rabbit anti-
mouse biotinylated IgG antibody was added at 1:500. An alternative antibody directed
against the (3B subunit was also used, with similar results. Non-specific binding was
eliminated by pre-blocking with normal swine serum (NSS) (diluted 1:5 in TBS
containing 5% bovine serum albumin). Rabbit polyclonal |3B (80-112)-NH2 PBL#197,
gift of W Vale (Clayton Foundation Laboratories for Peptide Biology, The Salk Institute
for Biological Studies, La Jolla, California, USA), was used at and incubated overnight
at 4°C. Negative controls substituted application of primary antibody. Secondary swine
anti-rabbit biotinylated antibody was added at 1:500.
FOLLISTATIN
After dewaxing and rehydrating, antigen retrieval was carried out. Tissue was placed in
0.01 M citrate buffer pH 6.0 and microwaved for 20 minutes, then left to stand in buffer
for a further 20 minutes. Non-specific binding was eliminated by pre-blocking with NRS
(diluted 1:5 in TBS containing 5% bovine serum albumin). Monoclonal antibody
directed against recombinant follistatin FS288, which recognises follistatin even when
bound to activin, was used at a range of dilutions 1:200 to 1:25 (incubated overnight at
4°C), gift ofNP Groome (School of Biological and Molecular Sciences, Oxford Brookes
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University, Oxford). Secondary rabbit anti-mouse biotinylated antibody was added at
1:500.
ACTIVIN RECEPTORS
Non-specific binding was eliminated by pre-blocking with normal goat serum (NGS)
(diluted 1:5 in TBS containing 5% bovine serum albumin). Rabbit antibodies to
ActRlIA and ActRIIB were kindly donated by Dr C-H Heldin (Ludwig Institute for
Cancer Research, Uppsala, Sweden), and used at a concentration of 1:600 and 1:400
respectively. Rabbit antibodies to ALK2 and ALK.4 were also kindly donated by Dr C-H
Heldin and both used at concentration 1:150. All were incubated overnight at 4°C, and
1:500 secondary goat anti-rabbit biotinylated antibody added thereafter.
BETAGLYCAN
Non-specific binding was eliminated by pre-blocking with NRS (diluted 1:5 in TBS
containing 5% bovine serum albumin). Goat antibody to betaglycan (Santa Cruz
Biotechnology, CA, USA) was used at a dilution of 1:25 (incubated overnight at 4°C).
Secondary rabbit anti-goat biotinylated antibody was added at 1:500.
BrdU
After dewaxing and rehydrating, antigen retrieval was carried out. Tissue was immersed
in boiling 0.01 M citrate buffer pH 6.0 for 2 minutes, then cooled by addition of cold tap
water. Non-specific binding was eliminated by pre-blocking with NRS (diluted 1:5 in
TBS containing 5% bovine serum albumin). Mouse monoclonal primary antibody
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(Roche diagnostics, Lewes) was used at a dilution of 1:30, and incubated at 4°C
overnight. Secondary rabbit anti-mouse biotinylated antibody was added at 1:500.
Nuclear diameter measurement
The size distribution of germ cells expressing activin |3A subunit was determined in
specimens of 18 - 19 weeks gestation using the Provis image analysis system (Section
2.3.2).
Primary cell culture
Ovaries from 7 fetuses, ranging from 14 to 17 weeks gestation, were dissected using a
sterile technique. They were initially bisected transversely and one half further dissected
# "3
to yield tissue fragments approximately 1mm . The intact half ovary was immediately
fixed for histological analysis. Tissue fragments were cultured for 17 hours in control
media or control media supplemented with lOOng/ml recombinant human activin A
(Section 2.4). BrdU was used as a marker of cell proliferation. In each experiment BrdU
was present in the media of one control and one treatment group for the duration of the
experiment. BrdU was added to the other control and treatment group for the final 4
hours of tissue culture only. At the end of culture, tissue was fixed, transferred to 70%
ethanol and embedded in paraffin wax for histological analysis.
Tissue was sectioned at 5pm thickness and processed for immunohistochemistry to
detect BrdU staining as described (Section 2.3.1). On completion of the
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immunohistochemistry protocol, sections were counterstained with haematoxylin,
dehydrated and mounted.
Analysis of cultured tissue
Sections of uncultured control and cultured tissue were analysed to quantify the effects
of culture and activin A on the number and proliferation of germ cells (Section 2.5).
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3.3 RESULTS
Expression of mRNAs for activin/inhibin subunits and receptors
PCR detected mRNA for all activin/inhibin subunits and type II receptors (Figure 3.1).
Amplicons of expected sizes corresponding to the inhibin a (278 bp), inhibin / activin
|3A (274 bp) and (3B (325 bp) subunits and the activin receptors ActRIIA (435 bp) and
ActRIIB (283 bp) were detected in ovaries studied across 14 to 19 weeks gestation.
Product identity was confirmed by direct sequencing.
Quantitative PCR
Changes in the expression of the activin |3A subunit mRNA between 14 and 19 weeks
gestation were investigated by quantitative PCR. There was an approximately 2-fold
increase in the relative expression of the (3A subunit mRNA expression between 14 and
19 weeks gestation (ANOVA, p<0.001). The increase in expression was not continuous
across the gestational range examined, but mostly occurred between 17 and 19 weeks
(Figure 3.2).
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Figure 3.1 Expression of mRNA for inhibin / activin subunits and type II activin
receptors in the human fetal ovary. PCR analysis of samples extracted from human fetal
ovaries at 14, 16 and 19 weeks gestation. Expression of mRNA for inhibin / activin
subunits and receptors ActRIIA and ActRIIB as indicated. Lanes marked 14-, 16- and
19- contained samples in which reverse transcriptase was omitted. The size of each
amplicon is indicated on the right.
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Figure 3.2 Quantitative PCR analysis of (3A expression in the fetal ovary. Expression of
PA subunit mRNA was quantified in human fetal ovary specimens over the gestational
range 14 to 19 wk. Data calculated as PA mRNA expression relative to GAPD for
ovaries of 14, 15, 16, 17, 18 and 19 wk gestation (n= 6, 5, 5, 5, 3 and 5 respectively,
mean ± SEM). *, p <0.001 by ANOVA.
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Immunohistochemistry
Inhibin / Activin Subunits
Expression of the |3A inhibin / activin subunit protein was detected in the fetal ovary at
all gestations investigated. It was specifically localised to the germ cell cytoplasm at all
gestations studied, but a marked change in the pattern of immunostaining was seen
across the gestational range (Figure 3.3 D-F). At 14 weeks gestation a gradient of
distribution was observed. Oogonial immunostaining was detected throughout the ovary,
but was most marked at the periphery particularly in germ cells in the outermost few
layers of the gonad. At 17-19 weeks gestation a different distribution of immunostaining
had emerged with a discrete sub-population of germ cells showing intense staining.
These germ cells tended to be larger oocytes, and were distributed in small clusters of
less than ten largely located in the medullary region of the ovary. However, oocytes
within newly formed primordial follicles showed only weak or no immunostaining for
activin (3A.
Differential expression of (3A subunit by larger germ cells was confirmed by direct
measurement of nuclear diameter. A total of 527 germ cells were measured, of which 79
(15%) were intensely immunopositive for the |3A subunit. These |3A-expressing germ
cells were significantly larger than those only weakly immunopositive or
immunonegative (11.3pm +/- 0.2 vs 9.8pm +/- 0.1, p=0.0001) although the very largest
germ cells with nuclear diameter >16pm, i.e. those within primordial follicles, were
immunonegative (Figure 3.4).
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Expression of |3B inhibin / activin subunit protein was also detected throughout the
ovary across the range of gestations examined. Immunostaining was widespread, with
both germ cells and stromal cells expressing the |3B subunit (Figure 3.3 G-I). However
at the periphery of the ovary some germ and somatic cells did not express the (3B
subunit. There was no difference in distribution of immunostaining of either stromal or
germ cells between 14 and 18 weeks gestation.
Immunostaining for the inhibin a subunit was not detected in any cell type in the human
fetal ovary across a range of gestations and despite using a wide range of antibody titres.
Fetal testes was used as a positive control and showed immunostaining in both Leydig
cells in the interstitium and Sertoli cells in the seminiferous tubules as previously
described (Figure 3.3 A-C) (Anderson et al., 2002a).
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Figure 3.3 Immunohistochemical localization of inhibin / activin subunits in human
fetal ovary.
A, inhibin a subunit, 14 week ovary. B, inhibin a subunit, 19 week ovary. C, inhibin a
subunit positive control, 19 week testis. D, pA subunit ,14 week ovary. E, (3A subunit,
17 week ovary (inset shows negative control). F, |3A subunit, 17 week ovary at higher
magnification. G, pB subunit, 14 week ovary. H, pB subunit, 18 week ovary (inset
shows negative control). I, pB subunit, 18 week ovary at higher magnification. Positive
staining in all panels is brown and sections are counterstained with haematoxylin.
o Oogonium; s Stroma; t Tubule; i Interstitium.
Scale bars in A, B, C, D, E, G and H, 50pm; F and I, 20pm
126
D E






»e ;•! §■$ —
V* ..... -<r ■ 5 '-
• ■
t '■ "
I * .' -•• -
G H
~o





l7 />* <x ;•'■*
•
• ">» :a., vJ
▲ t ; S-*ir* >. <r ,.v- -®f,- *
✓ ; *■ tv ■• ^•-'
^ *, '' -v .A '
Figure 3.4 Size distribution of (3A immunopositive germ cells in the human fetal ovary.
Histogram shows the frequency of distribution of nuclear diameter of cells strongly
immunopositive for PA subunit (filled columns) and those either weakly
immunopositive or immunonegative for PA subunit (open columns) in human fetal












Activin and inhibin receptors
Expression of the type II receptor ActRIIA was detected at all gestations from 14 to 21
weeks and was localised specifically to germ cell cytoplasm (Figure 3.5 C-D). There
was no immunostaining in stromal cells or the pre-granulosa cells of primordial
follicles, nor cells at the ovarian surface. There was no significant difference in
distribution across the gestational range studied.
ActRIIB immunoexpression was distributed widely within the fetal ovary at all
gestations from 14 weeks to 21 weeks (Figure 3.5 E-F). Immunostaining was detected in
both stromal and germ cells but not in the cells at the ovarian surface. Intense
immunostaining was noted in larger germ cells at later gestations and expression
persisted in cytoplasm of oocytes organising into primordial follicles.
Expression of ALK4 protein, the preferential activin type I receptor, was detected
throughout the ovary predominantly in stromal and pre-granulosa cells but also with
weak expression in germ cells (Figure 3.5 A). At 14 weeks gestation, ALK4
immunostaining clearly demarcated a meshwork of ovarian stromal cells with weaker
immunostaining of the oogonia intermingled with more strongly immunopositive pre-
granulosa cells. At later gestations (18 weeks) the ovarian stroma was less strongly
immunopositive, and the predominant site of ALK4 expression was the pre-granulosa
cells surrounding individual and grouped oogonia, although oogonia remained weakly
immunopositive.
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In contrast to ALK4, expression of ALK2 protein was exclusively localised to the
stromal cells at 14 to 18 weeks gestation, with no immunostaining identified in germ
cells at any gestation (Figure 3.5 B). Intense immunostaining was particularly notable in
many pre-granulosa cells between and outlining germ cells. This pattern of stromal cells
immunostaining appeared to increase with increasing gestation and the formation of
primordial follicles.
No expression of (3-glycan protein was detected in any mid-trimester gestation ovary
studied. Intense immunostaining was detected in the peritubular cells of fetal testes used
as a positive control (Figure 3.5 G-H).
In all cases negative controls showed no immunostaining. Fetal testis sections were used
as a positive control, and showed distinct immunostaining as previously described
(Anderson et al., 2002a).
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Figure 3.5 Immunohistochemical localization of inhibin / activin receptors in human
fetal ovary.
A, ALK2, 14 week ovary. B, ALK4, 18 week ovary. C, ActRIIA, 14 week ovary. D,
ActRIIA, 21 week ovary (inset shows negative control). E, ActRIIB, 14 week ovary. F,
ActRlIB, 21 week ovary (inset shows negative control). G, betaglycan, 14 week ovary.
H, betaglycan positive control, 15 week testes.
Positive staining in all panels is brown and sections are counterstained with
haematoxylin.
s Stroma; g Pre-granulosa cell; o Oogonium; pf Primordial Follicle; t Tubule; p
Peritubular cells.
Scale bars: 50pm in all panels.
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Tissue Culture
A total of 7 separate experiments were carried out to investigate the effect of activin on
germ cell survival and proliferation in vitro, using ovaries between 14 and 17 weeks
gestation. Comparison of germ cell number in control cultures showed good oogonial
survival (46 ± 2 oocytes per grid after 17 hr culture vs 68 ± 2 in uncultured and
undissected tissue) and there was no effect of changing the medium 4 hours before the
end of the culture period in those experiments where BrdU was added at that time point
(45 ± 4 germ cells per grid in controls vs 46 ± 3 in those in which the medium was
changed). Treatment with lOOng/ml activin A resulted in a significant increase in total
number of germ cells. Activin A treated groups showed a mean increase of 20% in the
total number of germ cells from 45 ± 4 to 56 ± 4 per grid, p=0.001. Very similar results
were obtained in the cultures in which BrdU was present for 4 hours (Figure 3.6 A).
When BrdU was present in the culture medium for the duration of culture (17 hours),
more germ cells were immunopositive than when BrdU was present for only the final 4
hours of culture, as expected (6.4 ± 1 vs 2.8 ± 0.4 stained germ cells per grid when
exposed to BrdU for only 4 hours). Activin A treatment also resulted in a significant
increase in number of BrdU immunopositive germ cells. There was a 44% increase in
number of immunostained germ cells (9.2 ± 1.3 vs 6.4 ± 0.8 per grid, p=0.01) when
cultured with activin A and BrdU for 17 hours. Immunostained germ cells were
increased by 89% (5.3 ± 0.9 vs 2.8 ± 0.4 per grid, p<0.05) when cultured with activin A
for 17 hours and exposed to BrdU for only the final 4 hours of culture (Figure 3.6 B,
Figure 3.7).
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Figure 3.6 Analysis of the effect of activin A on the number of germ cells in human
fetal ovary.
A, Number of germ cells per grid for time 0 tissue (shaded column), and groups cultured
for 17 hours without (control groups, open columns) or with lOOng/ml recombinant
activin A (filled columns) (mean ± SEM). Student's t-test * p <0.05; ** p =0.001 vs
control.
B, Number of BrdU immunopositive germ cells per grid: control groups (open columns),
with lOOng/ml recombinant activin A (filled columns) (mean ± SEM). In both A and B
treatment and control groups were exposed to BrdU for either 4 hours or for the duration
of culture (17 hours). Student's t-test *, p<0.05; **, p=0.01 vs control.
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80
Time 0 4hr BrdU 17hrBrdU
Treatment groups
4 hours BrdU 17 hours BrdU
Treatment Groups
Figure 3.7 Representative photomicrographs of control (C) and activin-treated (D) 17
week human fetal ovary cultured with BrdU for 17 hr, and immunostained for BrdU.
Positive staining in all panels is brown and sections are counterstained with
haematoxylin.
o Oogonium; b BrdU-immunopositive oogonium.
Scale bar: 50[xm.
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3.4 DISCUSSION
High interspecies conservation of activins, inhibins and activin receptors and the
universal presence of activins in mammals, birds, amphibians and fish suggest an
evolutionarily conserved role of these proteins in animal development. Activins have
potent effects on early amphibian embryonic events during mesoderm-forming
(Nieuwkoop) induction both in vitro and in vivo (Dyson and Gurdon, 1997). In
mammals, activins have also been demonstrated to have morphogenetic effects, notably
in renal tubule development (Ritvos et al., 1995). However, there are few published data
available concerning the presence, expression and potential roles of activins, inhibins
and their receptors during mammalian gonadal development. Whilst activin is thought to
act primarily in an autocrine and/or paracrine manner, inhibin acts primarily as an
endocrine feedback regulator of pituitary FSH release (Welt et al., 2002). Our data
demonstrate the presence and localisation of activin receptors and subunits within the
developing human ovary, and suggest a role for activin A in the regulation of germ cell
proliferation during the developmental period leading up to primordial follicle
formation.
Transgenic mice have been generated in order to study physiological models deficient in
inhibins, activins and their receptors (Burns and Matzuk, 2002). Gene knockout
experiments have been inconclusive in determining activin function in vivo, but
functional analysis would suggest that activins are not essential for mammalian
mesoderm formation. A number of reasons are cited to explain the lack of definitive
conclusions from this body of work; some knockout mutations are lethal, deficient
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activin ligand or receptor signalling results in a phenotype with suppressed FSH and
consequential reproductive and developmental defects, and there may be some
functional overlap between TGF(3 superfamily ligand and receptor signalling. Mutations
in the gene encoding the PA subunit are lethal. Mutant mice develop to term but have
secondary palate defects and lack whiskers and lower incisors (Matzuk et al., 1995b).
The mutant mice die within 24 hours of birth due to feeding difficulties and there are
thus no conclusions regarding ovarian follicular development. Mice lacking the PB
subunit suffer eye lesions as a result of failed eyelid fusion. Mutant females do not show
a disruption in follicular development but manifest impaired reproduction characterised
by perinatal lethality of their offspring (Vassalli et al., 1994). Highly increased PA
expression was noted in the ovaries of these pB deficient female mice, suggesting the
possibility of functional compensation within the TGFp superfamily. Using a gene
knockin approach, it has been found that activin pB can rescue the craniofacial defects
and neonatal lethal phenotype of PA deficient mice. However activin pB is unable to
substitute for all the functions of pA as other phenotypic abnormalities in the gonads
and external genitalia, as well as delayed lethality, remain in these mice (Brown et al.,
2000). There is also some evidence that it is the second messenger (Smad) signalling
that is more crucial to specific embryonic and extra-embryonic development pathways
than particular ligand and receptor interactions (Chang et al., 2001). Lastly, it is
interesting to note that mice carrying a null mutation in the ActRII gene do not
phenocopy activin-deficient mice, although they suffer defective reproductive
performance as a result of diminished FSH levels (Matzuk et al., 1995a).
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Activin subunits and receptors showed a differential distribution within the developing
ovary. Activins bind to a type II receptor (ActRIIA or ActRIIB), which recruits and
phosphorylates a type I receptor with subsequent modulation of gene expression via
Smad protein activation (Massague, 1998). Several type I receptors, termed ALKs have
been identified. ALK4 (ActRIB) is believed to be the preferential activin receptor. The
activin (3A subunit was specifically expressed by germ cells, whereas both somatic and
germ cells expressed the |3B subunit. ActRIIA was specifically localised to germ cells,
whereas ActRIIB and ALK4 were both expressed by stromal and germ cells. The
distinct distribution of both activin subunits and receptor subtypes between germ cells
and somatic cells suggest that activin may have several distinct roles in ovarian
development and organisation, and more specifically in germ cell regulation. This is
supported by observations of an increase in |3A mRNA expression as well as changes in
the pattern of (3A protein expression across the mid-trimester. With increasing gestation,
intense |3A expression was found in small clusters of larger, more mature germ cells.
However the largest oocytes, within primordial follicles, show little or no (3A
expression. This pattern suggests that the increase in |3A subunit expression may be
transient as the germ cells mature, with reduction of gene expression following
primordial follicle formation. Increased expression may, however, be associated with
differences in subsequent survival, consistent with the effects of activin on oogonial
survival as demonstrated in the tissue culture experiments here described.
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Despite detecting inhibin a subunit mRNA by PCR, we were unable to demonstrate the
protein by immunohistochemistry. Previous studies suggest that activin but not inhibin is
present in the human fetal ovary at mid-gestation (16-23 weeks) (Rabinovici et al.,
1991). Rabinovici et al localised the |3A subunit to primordial follicles by
immunohistochemistry, but did not observe immunostaining for |3B or a subunits. In
contrast, immunostaining for all three subunits was detected in late gestation fetal rhesus
monkey ovary, which contained primordial and early growing follicles. Furthermore,
culture medium from mid-gestation human fetal ovaries was found to contain
undetectable levels of inhibin-a by radioimmunoassay. Recent immunolocalisation
studies performed in baboons revealed minimal to non-detectable levels of a subunit in
mid and late gestation ovaries (Billiar et al., 2003) and there is also indirect evidence
from in situ hybridisation studies on primate ovaries that follicles preferentially
synthesise activin rather than inhibin in the early stages of development (Schwall et al.,
1990; Yamoto et al., 1993). The putative inhibin receptor betaglycan (Lewis et al.,
2000) was also not detected in the midtrimester human fetal ovary. The fact that neither
the a subunit nor betaglycan receptor were identified by immunohistochemistry in mid-
trimester human fetal ovaries indicates that inhibin is not a regulatory factor at this stage
of development, but becomes of importance later during follicular growth (Welt et al.,
2002).
An in vitro tissue culture model was used to investigate the effect of activin on oogonial
survival and proliferation. Activin A treatment resulted in an increase in germ cell
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proliferation and survival in fetal ovary tissue fragments. This concurs with the earlier
demonstration that activin A stimulated [3H] thymidine incorporation in vitro in the
differentiating rat ovary (Kaipia et al., 1994). BrdU was used as a marker for cell
proliferation. It is interesting to note that immunostaining was observed predominantly
towards the edge of cultured ovarian fragments. This may represent a diffusion effect,
but may also partly reflect the organisation of the tissue. Mitotically dividing germ cells
tend to be placed peripherally in the mid-trimester fetal ovary with a gradient of maturity
across the developing ovary such that relatively more mature cells are found in the
medulla compared to the cortex (Byskov, 1986). A recent study of follicle formation
during fetal development in sheep also noted a cortical pattern of distribution of BrdU
staining following in vivo administration (Sawyer et al., 2002), which became more
pronounced up to primordial follicle formation.
In the adult ovary, activin A induces expression of genes signalling cellular
differentiation and maturation. In the developing fetal ovary key events involve germ
cell proliferation, organisation and survival by somatic cell interaction and primordial
follicle formation (Hirshfield, 1991; McLaren, 1991). The present data support a role of
activin A in germ cell survival and proliferation. The Bcl-2 family of proteins are key
regulators of apoptosis in many cell types. This family comprises pro-apoptotic (Bax,
Bad and Bak) and anti-apoptotic (Bcl-2, Bc1-Xl and Mcl-1) subfamilies. Mcl-1 is a
rapidly inducible short-term effector of cell viability and is expressed in a subset of
oocytes at the time of primordial follicle formation (Hartley et al., 2002). The
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distribution of Mcl-1 in the fetal ovary is similar to that of activin (3A subunit and it is
possible that activin A promotes cell survival by signalling via Mcl-1, as has been
demonstrated in a leukaemia cell line (Fukuchi et al., 2001). While both activin A and
Mcl-1 expression are most marked in larger oogonia preceding primordial follicle
expression, oocytes within primordial follicles continue to express Mcl-1 whereas
activin |3A expression is low once that developmental stage is reached. It is possible
that activin and Mcl-1 constitute part of the signalling pathway that determines survival
for a small proportion of the oogonia in the mid trimester ovary.
In conclusion, the human fetal ovary is a site of expression of activin subunits and
receptors prior to the formation of primordial follicles. Protein expression of the inhibin
a subunit and the betaglycan receptor was not detected. The distribution of activin
subunits and receptors suggests that whilst somatic cells may produce any of the activin
forms, oogonia only produce activin A, and is consistent with an autocrine and/or
paracrine mode of action for activins within the developing ovary. Increased expression
of (3A by larger/more mature oogonia may reflect selection for follicle formation and
data from tissue culture experiments supports activin A as a regulatory factor in fetal
germ cell proliferation and survival. These data suggest that activin may be of particular








Mammalian ovarian development is characterised by a sequential pattern of mitotic
proliferation of oogonia, initiation then arrest of meiosis, and primordial follicle
formation. Waves of atresia of oogonia have been identified at particular stages of
development (Baker, 1963; Speed, 1988; Pepling and Spradling, 2001) but the factors
and pathways determining whether oocytes survive or die are largely unknown. Adult
reproductive potential is determined by presence of primordial follicles, which offer a
source of oocytes to mature, ovulate and fertilise. Thus, early regulation of germ cell
proliferation and survival in the form of primordial follicles is crucial to human
reproductive potential.
Neurotrophins are a small family of closely related peptide factors. NGF was the first to
be discovered; BDNF, NT3, and NT4 have since been identified in mammals (Snider,
1994). The neurotrophins bind selectively to glycoprotein tyrosine receptor kinases, Trk
receptors, which consist of an extracellular domain containing the neurotrophin binding
site, a short transmembrane sequence and an intracellular domain that encodes a tyrosine
kinase. There are three members of the Trk receptor family: Trk A, the receptor for
NGF, TrkB, the receptor for BDNF and NT4 and TrkC, the receptor for NT3. Truncated
isoforms of TrkB and TrkC, which lack the intracellular tyrosine kinase domains, have
also been identified (Klein et al., 1990; Dechant, 2001). In addition to the Trk receptors,
all neurotrophins bind to a membrane receptor known as p75, a member of the tumour
necrosis receptor superfamily. Effects of neurotrophins on cell survival and growth are
thought to be mediated by the Trk receptors, which form homodimers on ligand binding
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and autophosphorylate to trigger intracellular signalling cascades (Segal and Greenberg,
1996). Ligand binding activates Trk receptors and initiates a signalling cascade resulting
in either neuronal differentiation or mitogenic stimulation (Kaplan and Stephens, 1994).
The neurotrophin family are known to have a critical role in cell proliferation,
migration, differentiation and survival in the nervous system (Henderson et al., 1993;
Davies, 1994; Snider, 1994). BDNF promotes maturation of sensory neurons before
they become dependent on neurotrophins for survival (Wright et al., 1992), and can
stimulate differentiation of embryonic neural crest cells (Kalcheim and Gendreau, 1988;
Sieber-Blum, 1991). Neurotrophins also have important functions in non-neuronal
tissue, including the mammalian ovary where they appear to be involved in
folliculogenesis (Dissen et al., 1995; Dissen et al., 2001; Romero et al., 2002) and
ovulation (Dissen et al., 1996; Mayerhofer et al., 1996), as well as oocyte maturation
(Seifer et al., 2002a; De Sousa et al., 2004; Kawamura et al., 2005; Martins da Silva et
al., 2005). BDNF is secreted by cumulus granulosa of the human ovarian follicle (Seifer
et al., 2002a; Seifer et al., 2006) and is a physiological growth factor in follicular fluid
(Seifer et al., 2003).
NT4 and BDNF are also expressed in the developing mammalian ovary (Spears et al.,
2003). Initially NT4 is present in oocytes, but this site of expression predominantly
switches to granulosa cells at, or around the time of, primordial follicle assembly
(Anderson et al., 2002a). In rats, expression of TrkB (the preferential receptor for NT4
and BDNF) mRNA increases sharply during the period of follicle formation (Dissen et
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al., 1995). Thereafter, TrkB receptors are expressed at low, and seemingly unchanging
levels in oocytes and granulosa cells of both primordial and growing follicles. Truncated
TrkB appears to be selectively expressed in oocytes, and targeted to the cell membrane
as primary follicles initiate growth (Paredes et al., 2004). Expression and distribution of
NT4 and BDNF in the human fetal ovary during the period of oogonial proliferation
leading up to primordial follicle formation was investigated. Localisation of TrkB,
truncated TrkB and p75 receptors during this period of ovarian development was also
explored, in order to identify potential sites of action of these regulatory factors. It is
hypothesised that TrkB signalling is important in primordial follicle assembly and / or
oocyte survival, and as oogonia in the mid-trimester human fetal ovary express the TrkB
receptor, the effect of NT4 and BDNF on germ cell survival and proliferation was
investigated using an in vitro tissue culture model. In addition to treatment with the two
ligands, the effect of removal of the influence of endogenous NT4 was investigated
using an antibody against NT4. Furthermore, co-incubation of the antibody treatment
with either NT4 or BDNF supplements investigated the effects of ligand replacement.
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4.2 MATERIALS AND METHODS
Tissues
Human fetal ovaries were obtained following medical termination of pregnancy.
Women gave consent according to national guidelines (Polkinghorne, 1989) and the
study was approved by the Lothian Paediatrics / Reproductive Medicine Research Ethics
Sub-Committee. Gestational age was determined by ultrasound examination prior to
termination and confirmed by subsequent direct measurement of foot length (Section
2.3).
Immunohistochemistry
Immunohistochemistry was performed on paraffin embedded sections of fetal ovary to
localise expression of NT4 and BDNF. Expression of TrkB, truncated TrkB and p75
receptors was also investigated (Section 2.3.1). The conditions for individual antibodies
are described below. Rat brain (donated from Dr P Saunders, MRC Human
Reproductive Sciences Unit, Centre for Reproductive Healthl, Edinburgh) was used as
positive control tissue. Negative controls omitted application of primary antibody in the
case of monoclonal antibodies, and substituted primary antibody incubation with non¬
immune serum in the case of polyclonal antibodies.
NT4
Non-specific binding was eliminated by pre-blocking with NSS (diluted 1:5 in TBS
containing 5% bovine serum albumin) for 30 minutes at room temperature. Rabbit
polyclonal primary antibody (Santa Cruz, CA, USA) was added at 1:100 (in diluted
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swine serum) and incubated at 4°C overnight. Secondary swine anti-rabbit biotinylated
IgG antibody was subsequently added at 1:500 (in dilute swine serum, 30 minutes, room
temperature).
BDNF
After dewaxing and rehydrating, antigen retrieval was carried out. Tissue was immersed
in boiling 0.01 M citrate buffer, pH 6.0, for 2 minutes, and then cooled by addition of tap
water. Non-specific binding was eliminated by pre-blocking with NSS (diluted 1:5 in
TBS containing 5% bovine serum albumin) for 30 minutes at room temperature. Rabbit
polyclonal antibody (Santa Cruz, CA, USA) was added at 1:50 (diluted in swine serum)
and incubated overnight at 4°C. Secondary swine anti-rabbit biotinylated IgG antibody
was added at 1:500 (in dilute swine serum, 30 minutes, room temperature).
TrkB
After dewaxing and rehydrating, antigen retrieval was carried out by immersing in
boiling 0.01 M citrate buffer, pH 6.0, for 2 minutes. Tissue was then cooled by addition
of tap water. Non-specific binding was eliminated by pre-blocking with normal donkey
serum (diluted 1:5 in TBS containing 5% bovine serum albumin) for 30 minutes at room
temperature. Chicken polyclonal antibody (Promega, Southampton, UK) was added at
1:25 (diluted in donkey serum) and incubated at 4°C overnight. Secondary donkey anti-
chicken biotinylated IgG antibody (Jackson laboratories, Bar Harbor, ME) was
subsequently added at 1:500 (in dilute swine serum, 30 minutes, room temperature).
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Truncated TrkB
After dewaxing and rehydrating, antigen retrieval was carried out by immersing tissue
sections in boiling 0.01M citrate buffer, pH 6.0, for 2 minutes, then cooling by addition
of tap water. Non-specific binding was eliminated by pre-blocking with NSS (diluted
1:5 in TBS containing 5% bovine serum albumin) for 30 minutes at room temperature.
Rabbit polyclonal antibody (Santa Cruz, CA, USA) was added at 1:50 or 1:100 (diluted
in swine serum) and incubated overnight at 4°C. Secondary swine anti-rabbit
biotinylated IgG antibody was subsequently added at 1:500 (in dilute swine serum, 30
minutes, room temperature).
p75
After dewaxing and rehydrating, antigen retrieval was carried out. Tissue was immersed
in boiling 0.01 M citrate buffer, pH 6.0, for 2 minutes and then cooled by addition of
cold tap water. Non-specific binding was eliminated by pre-blocking with NRS (diluted
1:5 in TBS containing 5% bovine serum albumin). Mouse monoclonal primary antibody
(Stratech Scientific Ltd., Soham, Cambridgeshire, UK) was used at a dilution of 1:30,
and incubated at 4°C overnight. Secondary rabbit anti-mouse biotinylated antibody was
added at 1:500.
BrdU
Antigen retrieval was carried out by immersion in boiling 0.01M citrate buffer, pH 6.0,
for 2 minutes, then cooling by addition of cold tap water. Non-specific binding was
eliminated by pre-blocking with NRS (diluted 1:5 in TBS containing 5% bovine serum
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albumin). Mouse monoclonal primary antibody (Roche Diagnostics, Lewes, UK) was
used at a dilution of 1:30, and incubated at 4°C overnight. Secondary rabbit anti-mouse
biotinylated antibody was added at 1:500.
Primary tissue culture
In five separate experiments, ovaries from fetuses, ranging from 15 to 17 weeks
gestation, were dissected using a sterile technique to yield tissue fragments
approximately 1 mm3. Several pieces were randomly chosen and immediately fixed for
histological analysis. Tissue fragments were cultured for 24 hours in control media or
control media supplemented with lOOng/ml NT4 (Peprotech EC), lOpg/ml antiserum
directed against NT4 (anti-NT4), lOOng/ml NT4 and 10pg/ml anti-NT4, lOOng/ml
BDNF (Peprotech EC) or lOOng/ml BDNF and lOpg/ml anti-NT4 (Section 2.4). BrdU
was used in all groups as an indicator of cell proliferation at a concentration of lOpl/ml.
At the end of culture, tissue was fixed in Bouin's fluid for 1 hour, transferred to 70%
ethanol followed by processing into paraffin using standard methods.
Tissue was sectioned at 5pxn thickness and processed for immunohistochemistry to
detect BrdU staining as described (Section 2.3.1). On completion of the
immunohistochemistry protocol, sections were counterstained with haematoxylin,
dehydrated and mounted.
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Analysis of cultured tissue
Using stereology, sections of uncultured control and cultured tissue were analysed to
quantify the effects of culture and NT4, BDNF, anti-NT4 or a combination of NT4 and
anti-NT4 and BDNF and anti-NT4 on the number and proliferation of germ cells




NT4, as well as TrkB and p75 receptor protein expression was detected by
immunohistochemistry across the mid-trimester. In addition, BDNF was detected by
immunohistochemistry at 14 - 19 weeks gestation.
Oogonia showed weak cytoplasmic immunostaining for NT4 at all gestations. Intense
staining was detected in pregranulosa cells among and immediately surrounding the
nests of germ cells, outlining the germ cells both individually and in clusters. Stromal
cells also showed slight staining, although this was more marked in cells at the edge of
the stroma and in close proximity to oogonial clusters. The most intense expression of
NT4 protein was seen in the cytoplasm of flattened granulosa cells of primordial follicles
at later gestations. This pattern of staining clearly demarcated primordial follicles
predominantly located in the medullary region of the ovary from the more peripheral
oogonia; thus, a medullary/cortical gradient was observed (as previously reported
(Anderson et al., 2002b)). Only a limited series of experiments were performed, as this
was confirmatory of previous published data (Figure 4.1).
Oogonia showed cytoplasmic staining for BDNF at all gestations examined. At earlier
mid-trimester gestations, immunostaining was variable and noted to be more intense in
some germ cells than others, although there was no obvious pattern or gradient identified
with this. At 19 weeks, all germ cells demonstrated cytoplasmic immunostaining, with
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greatest intensity surrounding the nucleus. Stromal and pre-granulosa cells also showed
weak immunostaining beyond, but not before, 18 weeks gestation (Figure 4.2).
Full-length TrkB receptor protein was immunolocalised to the cytoplasm of ovarian
germ cells across the gestational range examined. In particular, clear staining ofthe
cytoplasm of oocytes in primordial follicles was observed, with faint staining of the
cytoplasm of pregranulosa cells (Figure 4.1). Limited experiments attempting to localise
truncated TrkB receptor protein detected no immmunostaining in mid-trimester human
fetal ovary.
The p75 receptor was not detected in germ cells at any gestation examined. It was,
however, localized to cells ofthe ovarian stroma. Staining clearly demonstrated the
branching pattern of the stroma from the medulla toward the surface of the ovary and
surrounding clusters of germ cells. Only a limited series of experiments were performed,
as this was confirmatory of previous published data (Figure 4.1).
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Figure 4.1 Copy of figure showing previously published in situ hybridisation (A -C)
and immunohistochemical localisation (D -L) of NT4, TrkB and p75 receptors in human
fetal ovary (reproduced with permission (Anderson et al., 2002)).
A, NT4 mRNA, 16 week ovary (antisense probe; inset shows result for sense RNA
probe). B, NT4 mRNA, 16 week ovary at higher magnification. C, NT4 mRNA, 21
week ovary.
D, NT4, 13 week ovary (arrow indicates positive staining in stromal cells). E, NT4, 21
week ovary. F, NT4, 21 week ovary at higher magnification. G, TrkB, 18 week ovary.
H, TrkB, 21 week ovary (inset shows same ovary at higher magnification). I, p75
receptor, 17 week ovary. J, p75 receptor, 21 week ovary. K, p75 receptor, 21 week
ovary at higher magnification. L, fetal ovary, negative control omitting primary
antibody.
Positive staining in all panels is brown and sections are counterstained with
haematoxylin.
Oo oogonia; o oocyte; pf primordial follicle; gc granulosa cell; os ovarian stroma.
Scale bar in D and G represents 250pm and applies to H, J, L and A inset. Scale bar in E
represents 1000pm and applies to I and A. Scale bar in F represents 100pm and applies
to K and H inset. Scale bar in C represents 50pm and applies to B.
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Figure 4.2 Immunohistochemical localization of BDNF in human fetal ovary.
A, 14 week ovary. B, 17 week ovary. C, 18 week ovary. D, 19 week ovary at higher
magnification. E, rat brain (positive control). F, 14 week ovary negative control.
Positive staining in all panels is brown and sections are counterstained with
haematoxylin.
s Stroma; g Pre-granulosa cell; o Oogonium.
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Tissue Culture
A total of 5 separate experiments were carried out to investigate the effect ofNT4 on
germ cell survival and proliferation in vitro, using ovaries between 15 and 17 weeks
gestation.
Comparison of germ cell number in time 0 and control cultures showed no significant
difference between groups, demonstrating good oogonial survival in control culture
conditions (31 ± 1.5 oocytes per grid after 24 hr culture v. 31 ± 1.1 in uncultured tissue).
A significant difference in total number of germ cells was seen after 24 hours culture
with the various treatment conditions (ANOVA p=0.02). Germ cell counts following
culture treatments were: 100 ng/ml NT4, 32 ± 1.6 per grid; 100 ng/ml BDNF, 32 ± 0.8
per grid; 10 p,g/ml anti-NT4, 30 ± 1.9 per grid; 100 ng/ml NT4 and 10 p,g/ml anti-NT4
combined, 31 ± 2.3 per grid; and 100 ng/ml BDNF and 10 p,g/ml anti-NT4 combined, 27
±1.1 per grid. Comparison of treatment with 100 ng/ml BDNF with groups treated with
100 ng/ml BDNF plus 10 ug/ml anti-NT4 showed a mean decrease of 16% in the total
number of germ cells from 32 ± 0.8 to 27 ± 1.1 per grid, p=0.004 (Figure 4.3A). There
was also a significant difference in germ cell BrdU immunostaining (ANOVA;
p=0.001). Results for stained germ cells counted per grid (and percentage stained out of
total germ cell count) were as follows: control, 6.5 ± 1.0 (20% ± 3.2); 100 ng/ml NT4,
5.8 ± 0.6 (18% ± 1.4); 100 ng/ml BDNF, 6.0 ± 0.8 (18% ± 2.2); 10 pig/ml anti-NT4, 6.3
± 1.1 (21% ± 4.2); combination of 100 ng/ml NT4 and 10 p,g/ml anti-NT4, 5.6 ± 1.1
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(17% ± 3.3); and 100 ng/ml BDNF and 10 pg/ml anti-NT4 combined, 4.6 ± 0.6 (17% ±
1.6). A 23% decrease in number of immunostained germ cells was seen in groups treated
with 100 ng/ml BDNF and 10 pg/ml anti-NT4, compared to 100 ng/ml BDNF (4.6 ± 0.6
v. 6.0 ± 0.8 per grid, p=0.001) (Figure 4.3B). Overall, however, there was no significant
difference in proportion of germ cells immunostained, suggesting that the decreased
germ cell number seen in groups treated with 100 ng/ml BDNF and 10 pg/ml anti-NT4
was not a result of diminished proliferation but rather due to germ cell loss, either by
necrosis or apoptosis (Figure 4.3C).
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Figure 4.3 Analysis of the effect of NT4 on the number of germ cells in the human
ovary.
A, Number of germ cells per grid for time 0 tissue, and various treatment groups
cultured for 24 hours: control, lOOng/ml NT4, lOpg/ml anti-NT4 blocking antibody,
both 100ng/mlNT4 and lOpg/ml anti-NT4, lOOng/ml BDNF and lOpg/ml anti-NT4,
lOOng/ml BDNF alone (mean ± SEM). * ANOVA p=0.004
B, Number of BrdU immunopositive germ cells per grid for various treatment groups
cultured for 24 hours: control, lOOng/ml NT4, 10pg/ml anti-NT4 blocking antibody,
both 100ng/mlNT4 and lOpg/ml anti-NT4, lOOng/ml BDNF and lOpg/ml anti-NT4,
lOOng/ml BDNF alone (mean ± SEM). * ANOVA p=0.001
C, Percentage germ cells stained out of total germ cell count per grid for each of culture
treatment groups: control, lOOng/ml NT4, 1 Oug/ml anti-NT4 blocking antibody, both
lOOng/ml NT4 and 10jig/mi anti-NT4, lOOng/ml BDNF and lOpg/ml anti-NT4,
lOOng/ml BDNF alone (mean ± SEM). No significant differences detected. Similarity in
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Significant differences were also seen in non-germ cell counts (ANOVA p=0.02).
Following culture treatments, non-germ cell counts were: control, 32 ±1.5 per grid; 100
ng/ml NT4, 31 ± 1.6 per grid; 100 ng/ml BDNF, 31 ±0.8 per grid; 10 pg/ml anti-NT4,
33 ± 1.9 per grid; 100 ng/ml NT4 and 10 pg/ml anti-NT4 combined, 32 ± 2.3 per grid;
and 100 ng/ml BDNF and 10 pg/ml anti-NT4 combined, 36 ± 1.1 per grid. Groups
treated with 100 ng/ml BDNF and 10 ug/m I anti-NT4 showed a 16% increase in total
number of non germ-cells when compared to treatment with 100 ng/ml BDNF,
increasing from 31 ± 0.8 to 36 ± 1.1 non-germ cells per grid, p=0.001 (Figure 4.4A).
Non-germ cell BrdU immunostaining (and percentage non-germ cells stained) was as
follows: control, 2.0 ± 0.5 (7% ± 1.7); 100 ng/ml NT4, 1.5 ± 0.3 (5% ± 0.7); 100 ng/ml
BDNF, 1.8 ± 0.3 (6% ± 1.1); 10 pg/ml anti-NT4, 2.2 ± 0.5 (7% ± 1.5); combination of
100 ng/ml NT4 and 10 pg/ml anti-NT4, 1.5 ± 0.5 (5% ± 1.7); and 100 ng/ml BDNF and
10 pg/ml anti-NT4 combined, 1.9 ± 0.4 (5% ± 1.4). Using ANOVA, there was no
significant difference in non-germ cell BrdU immunostaining, nor was there any
significant difference in percentage of non-germ cells immunostained (Figure 4.4B-C),
indicating that the reciprocal increase in non-germ cell number seen in groups treated
with 100 ng/ml BDNF and 10 pg/ml anti-NT4 reflects loss of germ cells from the tissue
mass, rather than an increase in non-germ cell proliferation.
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Figure 4.4 Analysis of the effect of NT4 on non-germ cells in the human ovary.
A, "Number of non-germ cells per grid for time 0 tissue, and various treatment groups
cultured for 24 hours: control, lOOng/ml NT4, lOpg/ml anti-NT4 blocking antibody,
both 100ng/mlNT4 and 1 Opg/ml anti-NT4, lOOng/ml BDNF and lOug/ml anti-NT4,
lOOng/ml BDNF alone (mean ± SEM). * ANOVA p=0.001
B, Number of BrdU immunopositive non-germ cells per grid for various treatment
groups cultured for 24 hours: control, lOOng/ml NT4, 10p,g/ml anti-NT4 blocking
antibody, both lOOng/ml NT4 and 10|^g/ml anti-NT4, lOOng/ml BDNF and 10pg/ml
anti-NT4, lOOng/ml BDNF alone (mean ± SEM). No statistically significant differences
detected.
C, Percentage germ cells stained out of total germ cell count per grid for each of culture
treatment groups: control, 100ng/mlNT4, lOpg/ml anti-NT4 blocking antibody, both
lOOng/ml NT4 and lOug/ml anti-NT4, lOOng/ml BDNF and 1 Opg/ml anti-NT4,
lOOng/ml BDNF alone (mean ± SEM). No significant differences detected.
Increase in non-germ cell number (seen after treatment with lOOng/ml BDNF and
10|xg/ml anti-NT4), with no increase in BrdU staining and absence of an increase in the
percent of non-germ cells immunostained, reflects germ cell loss from the tissue mass
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4.4 DISCUSSION
These experiments have identified expression of NT4 and BDNF ligands in the mid-
trimester fetal ovary and localised them, by immunohistochemistry, predominantly to
pre-granulosa and germ cell compartments respectively. Subtle evolution in
immunostaining is seen with advance in gestation, concurrent with embryological
development and ovarian organisation. Immunohistochemical localisation of NT4 and
BDNF, as well as the TrkB receptor, supports the existence of a functional NT4 / BDNF
/ TrkB signalling system within the developing ovary at the time of follicular assembly.
It is now well-established that complex autocrine / paracrine interactions exist between
oocytes and surrounding granulosa cells once organised as follicles. It is reasonable to
assume that these interactions exist between cell types earlier in development, and are
likely to be as crucial to earlier organisation and cell survival as to follicular assembly.
In support of the concept of oocyte / somatic cell interaction by autocrine / paracrine
communication during development, an increase in NT4, but not BDNF, mRNA occurs
at the time of follicular assembly in the rodent, co-incident with appearance of TrkB
mRNA (Dissen et al., 1995). In situ hybridization studies show NT4 mRNA expression
in a subpopulation of oocytes, suggesting that it may be a signalling ligand utilised by
the oocyte to communicate with granulosal cells at the time of follicular formation
(Dissen et al., 1995) (Spears et al., 2003).
Data from the culture experiments indicate neither a positive or negative effect on germ
cell survival, or entry into meiosis, during mid-trimester development prior to primordial
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follicle formation when culture conditions are supplemented with either NT4 or BDNF,
or where the effect of endogenous NT4 is reduced by use of anti-NT4 antibody. This
approach was taken because of the differential distribution of the two neurotrophins,
suggesting separate physiological roles. The results demonstrate a unique feature of
TrkB signalling, with a differential response to NT4 and BDNF ligands. A negative
effect on germ cell survival is seen in conditions where BDNF is supplemented in the
absence of NT4, suggesting that BDNF may act as a pro-apoptotic agent in germ cells in
the absence of signalling by endogenous NT4. This also lends support to the theory that
NT4, derived from pre-granulosa cells, is an important paracrine factor required for
germ cell survival. While a differential effect of the two neurotrophins may seem
surprising, there is considerable supporting evidence for this.
Structural similarities between the Trk receptor intracellular domains, including the
catalytic tyrosine kinase and She binding site, originally led to the assumption that
downstream signalling pathways would be shared. It is now understood that the various
Trk receptors preferentially signal via distinct pathways (Atwal et al., 2000; Yamada et
al., 2002), and that differential association / dissociation kinetics, competition for
binding among different downstream substrates or recruitment of unique target proteins
represent ways by which receptors differentially use common substrates for signalling
(Qian et al., 1998; Meakin et al., 1999).
The p75 receptor binds all neurotrophins, but also possesses the capacity to increase
ligand -Trk receptor affinity (Brennan et al., 1999). Trk and p75 receptors do not bind
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directly to each other, but can be complexed together (Bibel et al., 1999; Lee et al.,
2001 a). The association of the two receptor types results in a greater discrimination
between neurotrophins and higher affinity ligand binding, and could potentially enable
interaction of signalling pathways triggered by both receptors (Vesa et al., 2000;
Kanning et al., 2003). BDNF, NT3 and NT4 can each bind to the TrkB receptor, but in
the presence of p75 only BDNF provides a functional response (Bibel et al., 1999).
Signalling via the p75 receptor has been identified to mediate apoptosis in certain
situations (Casaccia-Bonnefil et al., 1996; Bamji et al., 1998; Dowling et al., 1999;
Roux et al., 1999; Chang et al., 2000) possibly by activation of the caspase cascade (Gu
et al., 1999a; Wang et al., 2001). Apoptotic loss of neurons during periods of
developmental programmed cell death carries similar analogies to germ cell loss during
mammalian ovary development, and it may be that this function of p75 receptor
signalling is initiated in the absence of survival trophic factors (Majdan and Miller,
1999). Indeed, BDNF causes sympathetic neuronal death by binding p75 when TrkB is
absent (Bamji et al., 1998). Likewise, NT4 causes p75-mediated cell death in BDNF-
dependent trigeminal neurons (Agerman et al., 2000). However, ovarian p75 is
immunolocalised to mesenchymal cells (Anderson et al., 2002b), rather than to the
granulosa cells or oocytes that are subjected to apoptotic demise in the developing ovary
(Hsueh et al., 1994).
There are also examples of cell death mediated by Trk receptor activation. Death of
medulloblastoma cell lines can be promoted by activation of Trk receptors (Muragaki et
al., 1997; Kim et al., 1999) and necrosis of cultured cortical neurons can be provoked by
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BDNF, an effect mediated by TrkB (Ishikawa et al., 2000) that can be overcome by
inhibiting TrkB using TrkB antisense oligonucleotides or the Trk tyrosine kinase
antagonist K252a (Kim et al., 2003). A similar phenomenon occurs in cultures of spinal
cord neurons or pure motor neurons where exogenously provided, or endogenously
produced, BDNF renders neurons vulnerable to excitotoxic insult (Fryer et al., 2000; Hu
and Kalb, 2003). This effect is mediated by TrkB, but not p75, receptor signalling (Hu
and Kalb, 2003). Potential mechanisms by which Trk receptors could increase cellular
vulnerability to death signals have thus far eluded identification, but may rest with
subtle alterations in membrane electrical properties (Kalb, 2005). Another possible
explanation could rest with findings from a study that demonstrates a protective effect of
neurotrophins in the pathogenesis of cerebral ischaemia. Mice lacking both alleles for
NT4, or deficient in a single allele for BDNF, have increased susceptibility to cerebral
ischaemic damage (Endres et al., 2000; Endres et al., 2003). Exclusion of endogenous
NT4 by the use of anti-NT4 in the culture conditions may promote germ cell
susceptibility to ischaemia and thus loss by necrosis, although only when culture
conditions were also supplemented with supra-physiological levels of BDNF.
Knockout mice lacking the full-length TrkB receptor cannot be used to define the role of
TrkB in postnatal ovarian organisation because most animals die at birth (Klein et al.,
1993). A less severe phenotype is, however, observed in mice lacking both full-length
and truncated receptor isoforms, as these animals can survive for up to 3 weeks after
birth (Rohrer et al., 1999). Ovarian follicular growth is arrested at an early (primary
follicle) stage of development in the absence of both full-length and truncated TrkB
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receptors, a phenotype similar to mice lacking GDF9 (Paredes et al., 2004). This
deficiency is accompanied by reduced granulosa cell proliferation (without obvious
apoptosis) and results in disruption of crucial germ cell-somatic cell autocrine /
paracrine communication processes, which are required for co-ordinated follicular
growth and development. Consistent with this, transplanted trkB'1' ovaries (from
knockout mice lacking the full-length TrkB receptor) show failure of follicular
development beyond the preantral stage and widespread degradation of follicular
organisation due to oocyte death and an inability to support follicular growth. Loss of
oocytes would suggest that a functional NT4 / BDNF / TrkB signalling complex is
essential for oocyte survival during preantral follicle development.
NT4"/_ mice are viable and fertile, with only mild sensory deficit (Conover et al., 1995;
Liu et al., 1995). BDNF_/~ mice die during early postnatal stages with severe neuronal
deficits and behavioural symptoms (Ernfors et al., 1994; Jones et al., 1994). Knocking
the NT4 gene into the BDNF locus rescues BDNF deficient mice and reveals distinct
NT4 and BDNF activities, with NT4 being more effective than BDNF at promoting
neuron survival and synapse formation (Fan et al., 2000). Mice carrying a deletion of
both NT4 and BDNF genes also show a similar deficiency of follicular growth to trkB'1'
mice. Loss of NT4 or BDNF signalling through TrkB receptors is thus likely to be the
mechanism underlying the trkB'1' phenotype, with the oocyte as the primary target of
ligand-dependent receptor activation. In addition, the normal number of secondary
follicles detected in mice lacking only NT4 suggests that, in the absence of this ligand,
BDNF may assume a compensatory role.
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In conclusion, this data has identified the importance of a balance between NT4 and
BDNF signalling in determining germ cell survival during mid-trimester development
prior to primordial follicle formation. These results are underpinned by the differential
expression patterns of NT4 and BDNF ligands, as well as the presence of their
preferential signalling receptor trkB, and support the importance of a functional NT4 /
BDNF / TrkB signalling complex in the developing human ovary.
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CHAPTER 5
EXPRESSION AND DISTRIBUTION OF BDNF AND
RECEPTORS IN BOVINE OOCYTES AND CUMULUS
AND THE
EFFECT OF BDNF ON OOCYTE MATURATION
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5.1 INTRODUCTION
Oocyte competence to support development after fertilisation or parthenogenetic
activation is acquired gradually over the course of oogenesis and folliculogenesis and is
completed during meiotic maturation (Eppig, 2001; Liu et al., 2002a; Liu etal., 2003).
At this time the meiotic segregation of chromatin is accompanied by critical changes in
oocyte cytoplasm that remain poorly defined. The significance of these changes is
illustrated by the wide differences observed in embryo developmental competence
following variations in oocyte in vitro maturation culture conditions (Keskintepe and
Brackett, 1996; Krisher and Bavister, 1999; Watson et al., 2000). A broad range of
factors has been found to improve meiotic maturation in vitro and subsequent embryo
developmental potential. These include supplementation of culture media with follicular
fluid or serum, or specific gonadotrophins, steroid and thyroid hormones, retinoids, and
different energy substrates and nutrients. These can benefit oocytes directly or via
cumulus cells (reviewed by (Sutton et al., 2003) (Chian et al., 2004)). Specific growth
factors identified as intra-ovarian regulators of oocyte maturation that have been shown
to be beneficial to bovine oocyte developmental competence in in vitro studies, include
EGF, IGF-I, activin A, inhibin A, and Midkine, a heparin-binding growth factor
(Lonergan et al., 1996; Stock et al., 1997; Rieger et al., 1998; Silvaand Knight, 1998;
Ikeda et al., 2000).
There is increasing evidence of a role for neurotrophins in ovarian development and
function, including oocyte maturation. Neurotrophins are a family of related growth
factors initially identified to be important for regulation of neuronal survival and
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differentiation, but which have also been described in a variety of non-neuronal tissues
including the cardiovascular, immune, endocrine and reproductive systems (Yamamoto
et al., 1996). They include NGF, BDNF, and neurotrophins 3 and 4 (NT3 and NT4).
Neurotrophins are unique in that they utilise 2 different receptors to mediate their
biological actions: Trk receptors encoded by the trk proto-oncogene family (Trk A-C
and truncated isoforms), and the p75 receptor, a member of the TNF receptor
superfamily (Bibel and Barde, 2000; Rabizadeh and Bredesen, 2003). The p75 receptor
is widely expressed and binds all neurotrophins. By contrast, the Trk receptors show
selective affinity for different neurotrophins (i.e. TrkA for NGF, TrkB for BDNF and
NT4 and TrkC for NT3). Splice variants and truncated isoforms of Trk receptors lacking
intracellular tyrosine kinase domains have also been identified (Bibel and Barde, 2000)
BDNF and TrkB have been identified in the adult avian ovary (Jensen and Johnson,
2001) and NT4 expression has also been localised to the oocyte in both rodent (Dissen et
al., 1995) and Xenopus (Ibanez et al., 1992). TrkB expression appears to be central to
the normal formation of primordial follicles that occurs in the ovary in the few days
following birth in the rodent (Spears et al., 2003), and for oocyte survival during early
follicular growth (Paredes et al., 2004), an effect that may be predominantly mediated
by truncated TrkB receptors. Mice carrying a null mutation of the NGF gene show
deficient development of primordial follicles (Dissen et al., 2001). A direct effect of
BDNF on murine oocyte maturation in vitro has also been reported, with increased 1st
polar body extrusion rate in oocytes stripped of cumulus prior to maturation (Seifer et
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al., 2002a). BDNF is present in human follicular fluid (Seifer et al., 2003), and there is
evidence for increased secretion of BDNF by cumulus cells, but not mural granulosa
cells, in response to cAMP (Seifer et al., 2002a). These data suggest that cumulus-
derived BDNF may be involved in oocyte maturation, and it is possible that its
production is stimulated by gonadotrophins.
This study investigates the effects of BDNF on bovine oocyte maturation, as well as
implications for embryo development after parthenogenetic activation. Parthenogenesis
provides a means of assessing oocyte cytoplasmic competence to elicit development
independently of sperm mediated factors, and is an accepted standard to assess oocyte
viability for cloning and nuclear reprogramming (De Sousa et al., 2002; Liu and Aoki,
2002). As cumulus cells and oocytes may have different capacities to respond to
neurotrophin signalling, the expression and localisation of BDNF, and its receptors, is
investigated.
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5.2 MATERIALS AND METHODS
Tissues
Bovine ovaries were collected from a local abattoir and kept warm during transportation
(Section 2.6).
Extraction of RNA and synthesis of cDNA
Total RNA was extracted from whole bovine ovary, quartered for ease of handling, and
cDNA synthesis performed.
RNA was extracted from COCs, stripped oocytes and cumulus and cDNA synthesis
performed. NEC control tube was used a blank for Qiagen reagents. (Section 2.8.1)
Amplification of cDNA
PCR was performed using 1 - 2pl cDNA samples, 5uM forward and reverse
oligonucleotide primers and 2 x thermostart PCR mastermix in a total volume of 25pJ
(Section 2.8.2). Specific primers were used, and these and the resultant product sizes are
given in Table 5.1 below. Gene specific primers were designed based on homology to
Genbank sequences specified by the following accession numbers: BDNF (X97914),
Trk B (NM 006180), Truncated Trk B (AF508964), p75 (AF228020). PCR
amplification conditions consisted of an initial hot start denaturation step at 95°C for 15
minutes, followed by 35 - 40 cycles of denaturation at 95°C for 30 seconds, annealing at
50 - 60°C for 30 seconds and extension at 72°C for 45 seconds. A final extension period
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at 72°C for 5 minutes completed the amplification. The annealing temperature varied,
depending on product and primers used. The identity of all PCR products was confirmed
by sequencing.
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GENE PRIMER SEQUENCE (5' - 3') PRODUCT SIZE (bp)
BDNF 5' CATGGGACTCTGGAGAGCAT 198
3' CAAAGGCACTTGACTGCTGA






p75 5' TGGACAGCGTGACCTTCTC 153
3' TCGTCTCGTCCTGGTAATAGC




Immunohistochemistry was performed on sections of whole bovine ovary and collagen-
embedded COCs (Section 2.9). The conditions for individual antibodies are described
below. Rat brain (donated from Dr P Saunders, MRC Human Reproductive Sciences
Unit, Centre for Reproductive Healthl, Edinburgh) was used as positive control tissue.
Immunohistochemistry method for negative controls omitted application of primary
antibody in the case of p75 monoclonal antibody, substituted primary antibody with non¬
immune serum incubation in the case of TrkB polyclonal antibody and used a technique
of pre-absorption of a blocking peptide (BDNF blocking peptide, Santa Cruz, CA, USA)
in the case of BDNF.
BDNF
Non-specific binding was eliminated by pre-blocking with NSS (diluted 1:5 in TBS
containing 5% bovine serum albumin). Rabbit polyclonal to BDNF (N20) (Sigma,
Poole, Dorset) was used at 1:100 (incubated overnight at 4°C). Secondary swine anti-
rabbit biotinylated antibody was added at 1:500.
TrkB
Non-specific binding was eliminated by pre-blocking with normal donkey serum
(diluted 1:5 in TBS containing 5% bovine serum albumin). Chicken polyclonal
(Promega, Southampton, UK) to TrkB was used at 1:25 (incubated overnight at 4°C).
Secondary donkey anti-chicken biotinylated antibody was added at 1:500.
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p75
Non-specific binding was eliminated by pre-blocking with NRS (diluted 1:5 in TBS
containing 5% bovine serum albumin). Mouse monoclonal antibody to p75
(Neomarkers, CA, USA) was used at 1:25 and incubated at 4°C overnight. Rabbit anti-
mouse biotinylated secondary antibody was used at a dilution of 1:500.
Oocyte Maturation In Vitro
Follicular aspirate cellular debris was sorted to identify and select COCs. COCs were
transferred through three washes of HEPES-buffered TCM199 containing serum, then
washed in serum-free base maturation medium, and randomly allocated into maturation
treatment groups thereafter (15-25 oocytes per group). The base medium for cumulus
enclosed and denuded (see below) oocyte maturation consisted of bicarbonate-buffered
TCM199 supplemented with FSH, LH and oestradiol. In vitro maturation treatments
comprised serum-free negative control, 10% FCS (positive control), 10-100 ng/ml
recombinant human BDNF (PeproTech EC Ltd, London UK), 5 pg/ml monoclonal anti-
human BDNF or both lOng/ml recombinant human BDNF and 5 pg/ml monoclonal
anti-human BDNF (Section 2.10).
In a second group of experiments oocytes were stripped of cumulus prior to maturation
(Section 2.10). Only completely denuded oocytes were selected for maturation culture.
Five cumulus-free maturation treatments were evaluated: serum-free base medium
(negative control), or base medium supplemented with either 10% FCS (positive
control), 10 ng/ml recombinant human BDNF, 5 pg/ml monoclonal anti-human BDNF
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or both lOng/ml recombinant human BDNF and 5 pg/ml anti-human BDNF. In each
experimental replicate a sixth group of cumulus enclosed oocytes were matured in base
maturation media supplemented with 10% FCS (cumulus positive control) (Section
2.10).
COCs and oocytes were cultured for 26 hours maturation and subsequently either
processed for immunocytochemistry to assess meiotic progression or activated to
produce parthenogenetic embryos.
Immunocytochemical analysis of meiotic progression
Maturation to Mil was assessed by immunocytochemical staining of microtubules to
visualise spindle morphology, of microfilaments to visualise cortical membranes and
segregation of the first polar body, and by using DAPI to visualise condensed chromatin
(Section 2.11). Slides were visualised using fluorescent microscopy and each oocyte
scored for meiotic progression. Oocytes were scored as metaphase II arrested if they
exhibited a normal alignment of chromatin along the centre of the spindle and extrusion
of a single polar body containing chromatin.
Parthenogenetic Activation and Embryo Culture
Cumulus-free oocytes were parthenogenetically activated by sequential exposure to
5pM ionomycin, followed by 2.5mM DMAP and lOpg/ml cycloheximide. Oocytes
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were washed following activation, then transferred into 4-well Nunc plates for final
culture in 500 ml SOFaaBSA under mineral oil (Section 2.13).
Embryos were examined for cleavage at 24 hours post activation (dayl), and for
blastocyst development on day 7. Blastocyst cell nuclei were stained by addition of
Hoescht 33342 to culture medium and embryos subsequently mounted on glass slides
and visualised by fluorescence microscopy to determine their nuclear number (Section
2.14).
Statistical Analysis
The developmental data (proportion of oocytes reaching Mil and blastocysts) were
analysed by logistical regression. Effects of replicate and treatment and their interaction
were fitted. Also, the treatment effect was split into contrasts between one or two
treatments and the rest in order to examine the differences between them. Interaction
between treatment and replicate was not significant. Results from all replicates were
pooled for presentation. The data on blastocyst nuclei count were analysed by ANOVA
to look for treatment and replicate effects.
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5.3 RESULTS
BDNF and receptor mRNA expression
Amplification products of the expected size corresponding to BDNF (198 bp), TrkB
(206 bp), truncated TrkB (430 bp) and p75 (153 bp) receptors were detected in RNA
extracted from bovine ovarian tissue and confirmed by DNA sequencing. All gene
transcripts were also detected in RNA isolated from COCs, and cumulus cells alone
(Figure 5.1). Neither full length or truncated TrkB was ever detected in oocytes in 6
independent trials, which simultaneously confirmed their presence in COCs and cumulus
RNA. In contrast, both BDNF and p75 could be detected in maturing and metaphase II
arrested oocytes sampled 26 h post IVM in 5 independent trials.
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Figure 5.1 Expression of BDNF, p75, and TrkB mRNA isoforms in bovine cumulus and
oocyte complexes.
RT-PCR analysis of samples prepared from biopsied bovine ovary, cumulus-oocyte
complexes (COC), cumulus only or single oocytes. Oocytes collected following 26
hours IVM culture, examined for presence / absence of polar body and identified as
mature (Mil) or maturing (non-MII). As negative controls, PCR was performed on
water, tissue / cell extract with omission of bulk first-strand cDNA synthesis (RT-) and
reagent blank non-embryo control (NEC). The size of each amplicon is indicated.
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Immunohistochemistry for BDNF and associated receptors
BDNF specific staining was evident in both oocytes and granulosa cells of preantral and
antral follicles, and in expanded cumulus and oocytes following in vitro maturation
(Figure 5.2). While BDNF expression in oocyte cytoplasm was only faint in ovarian
tissue sections, it was more marked in isolated cumulus-oocyte complexes (Figure
5.2C). Cumulus cells also exhibited strong immunostaining. Some immunostaining of
the theca cell layer surrounding antral follicles was also evident, as was prominent
staining of vascular endothelial cells (Figure 5.2B). No staining was detected in
negative controls, following preabsorption of the primary antibody with BDNF peptide
(Figure 5.2 D-F).
Similar to BDNF, the p75 receptor was expressed by granulosa cells of preantral and
antral follicles (Figure 5.2 G-H), with faint staining of theca cells surrounding antral
follicles (Figure 5.2H). Oocytes of isolated cumulus-oocyte complexes were positive
for p75-specific immunohistochemical staining (Figure 5.21).
We were unable to obtain clear specific immunostaining for TrkB, although staining
was detected in rat brain as a positive control (not shown).
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Figure 5.2. Immunohistochemical staining for BDNF and p75 in bovine ovarian
follicles and cumulus oocyte complexes.
BDNF specific immunostaining was evident in both oocytes (o) and granulosa (g) cells
of preantral (A) and antral (B) follicles and in cumulus (c) and oocytes following in vitro
maturation of isolated cumulus-oocyte-complexes (C). Some immunostaining of the
theca (t) cell layer surrounding antral follicles was also evident, as was prominent
staining of vascular (v) endothelial cells. In matched serial sections, this staining was
blocked (D-F) if the primary antibody was first pre-incubated with the BDNF blocking
peptide.
Immunostaining for p75 (G-I) which was above that observed following omission of the
primary antibody (J, H), was also detected in the granulosa and thecal cell layer of
preantral (G) and antral follicles (H), and in oocytes and cumulus cells of in vitro




Effect of BDNF on maturation of cumulus-enclosed oocytes to Mil
To evaluate the effect of BDNF on bovine oocyte maturation, cumulus-enclosed oocytes
were matured in the presence (positive control) or absence (negative control) of 10%
FCS, or in serum-free media supplemented with lOng/ml or lOOng/ml BDNF, 5pg/ml
anti-BDNF blocking antibody, or both lOng/ml BDNF and 5pg/ml anti-BDNF blocking
antibody. All oocytes in each treatment group had undergone GVBD by the time they
were analysed.
From reviewing tabulated data, it was clear that success rate for COCs reaching Mil
varied between replicate experiments. It was anticipated that COCs matured with FCS
would show highest Mil rates and this was taken into account when choosing the
method of analysis. Logistic regession models were fitted to test for differences between
treatments, the difference between FCS and other the treatments, differences between
replicates and a possible interaction between treatment effect and replicate. No evidence
of an interaction was found. The differences between replicates was significant, but the
success rates for all treatments were found to vary over replicates; there was no change
to the relative success rates between treatments. In total 77% of COCs in maturation
medium containing FCS were scored as Mil arrested after 26 h of culture. This was 2-3
fold greater (p<0.01) than that observed in all other treatment groups. No significant
difference in outcome was found between any other treatment group (Figure 5.3). Thus,
supplementation of serum-free maturation medium with BDNF was insufficient to
substitute for the known benefit of serum to support nuclear maturation, when assessed
at a point in time when bovine oocytes should have reached MIL Furthermore, a
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blocking antibody to BDNF did not have any additive detrimental effect on nuclear
maturation above that observed for serum-free maturation in general.
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Figure 5.3. Effect of BDNF on maturation of cumulus-enclosed oocytes to MIL
COCs were matured in the presence (positive control) or absence (negative control) of
10% FCS, or in serum-free media supplemented with lOng/ml or lOOng/ml BDNF,
5pg/ml anti-BDNF blocking antibody, or lOng/ml BDNF and 5pg/ml anti-BDNF. The
experiment was repeated 4 times to arrive at the average proportion of oocytes at Mil
after 26h of culture. Number of COC per group: serum-free n=49; 10% FCS n=43;
lOng/ml BDNF, n=49; lOOng/ml BDNF, n=47; 5pg/ml anti-BDNF, n=48; lOng/ml
BDNF and 5pg/ml anti-BDNF, n=47.
Significantly higher proportion Mil found in COCs cultured with FCS (denoted a)
versus all other groups (denoted b; p<0.01).
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Effect of BDNF during maturation of cumulus enclosed oocytes on parthenogenetic
embryo development
In the next two experimental series parthenogenetic embryo development to cleavage
and blastocyst stages was evaluated following activation of oocytes matured as COCs in
the previously defined treatment groups. In these trials, no attempt was made to score
maturation status of oocytes following in vitro maturation, thus most oocytes except
those damaged during removal of cumulus subsequently underwent parthenogenetic
activation, irrespective of maturation status. In a first series consisting of three replicate
trials, COCs matured without serum and activated (total n= 83) were compared with
those matured with FCS (n=103) or either lOng/ml (n=95) or 100 ng/ml BDNF (n=91;
Figure 5.4 A-C). The proportion of activated oocytes undergoing first cleavage after 24
hours showed no significant differences across treatment groups (serum-free 63%; FCS
65%; lOng/ml BDNF 65%; lOOng/ml BDNF 74%; Figure 5.4A). By contrast, the
proportion of activated oocytes forming blastocysts following maturation with lOng/ml
BDNF was over 1.5 fold higher (p<0.01) than with FCS, which was equivalent to the
higher concentration of BDNF. Blastocyst yields in all treatment groups were also
significantly higher than oocytes matured without serum (serum-free 10%; FCS 15%;
lOng/ml BDNF 24%; lOOng/ml BDNF 18%; p<0.01; Figure 5.4B). Improved blastocyst
development following maturation with the lower concentration of BDNF was also
apparent if calculated relative to the number of cleaved embryos (serum-free 15%; FCS
22%; lOng/ml BDNF 37%; lOOng/ml BDNF 24%; p<0.01; Figure 5.4C).
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Figure 5.4 Development of parthenogenetic embryos following in vitro maturation of
cumulus-enclosed oocytes with BDNF.
COCs were matured in the presence (positive control) or absence (negative control) of
10% FCS, or in serum-free media supplemented with lOng/ml or lOOng/ml BDNF then
activated. Data from three replicate trials were pooled. Number of activated oocytes per
group: 10% FCS, 103; serum-free, 83; lOng/ml BDNF, 95; lOOng/ml BDNF, 91.
A, Proportion of activated eggs undergoing cleavage. No significant difference detected
between treatment groups.
B, Proportion of activated eggs forming blastocysts. Statistically significant increased
number blastocysts achieved after maturation withlOng/ml BDNF versus all other
groups (a; p<0.01) COCs matured with serum or lOOng/ml BDNF were
comparable(denoted b), but achieved statistically significantly higher proprtion of
blastocysts than maturation in absence of serum (denoted c; p<0.01).
C, Proportion of cleaved embryos forming blastocysts. Significant differences also
apparent where blastocyst development calculated relative to number of cleaved
embryos. As before, different superscripts denote significant differences (p<0.01)
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In a second series of three replicate trials, the development of COCs matured without
serum was compared against those matured with lOng/ml BDNF (the best treatment in
the previous series), lOng/ml BDNF and 5pg/ml anti-BDNF blocking antibody, or
5ug/ml anti-BDNF alone. The proportion of activated oocytes undergoing first cleavage
after 24 h was significantly lower following maturation with the blocking antibody alone
(30%, n=81) versus all of the other treatment groups (serum-free 64%, n=83; lOng/ml
BDNF 60%, n=85; lOng/ml BDNF and 5pg/ml anti-BDNF 63%, n=76; p<0.01).
Blastocyst yields in this experimental series were generally poorer than that observed in
the first series, possibly due seasonal variations in oocyte quality commonly encountered
with abattoir derived ovaries. Despite this, treatment with 1 Ong/ml BDNF yielded
significantly more blastocysts per activated oocytes compared to any of the other
treatment groups (lOng/ml BDNF 9%; serum-free 2%; 1 Ong/ml BDNF and 5ug/ml anti-
BDNF 4%; anti-BDNF alone 4%; p<0.01). Evaluating blastocyst nuclear counts for each
treatment within and between experiment trials revealed no significant differences. For
each treatment group, mean +/- S.E.M: serum-free 68 ± 8, n=12; FCS 68 ± 5, n=15;
1 Ong/ml BDNF 65 ± 6, n=31; lOOng/ml BDNF 77± 6, n=16; lOng/ml BDNF and
5pg/ml anti-BDNF 54 ± 6, n=3; 5pg/ml anti-BDNF alone 63 ± 10, n=3.
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Effect of BDNF on maturation of cumulus-free oocytes to Mil
To evaluate the effect of BDNF on bovine oocyte maturation without cumulus, germinal
vesicle oocytes were denuded at the time of collection and matured in medium with or
without 10% FCS, or in serum-free media supplemented with lOng/ml BDNF, lOng/ml
BDNF and 5pg/ml anti-BDNF, or 5pg/ml anti-BDNF antibody alone. These were
compared against cumulus enclosed oocytes matured with 10% FCS (positive control).
At the time of analysis all oocytes had undergone GVBD. It was anticipated that COC
and denuded oocytes matured with FCS would be the most successful treatments and the
overall tabulated results confirmed this. The same analysis was used as before, except
that the COC and FCS treatments were considered as potentially different from the rest.
There was no significant interaction between treatment and replicate and no significant
difference between replicates. Similar to the first maturation experiment evaluating
BDNF on cumulus enclosed oocytes, 71% (n=73) of COCs matured with FCS were
scored as Mil arrested after 26 h of culture. This was significantly higher than cumulus-
free oocytes matured with FCS (39%, n=69; p<0.01), which in turn was approximately
double (p<0.01) that observed in all of the other treatment groups (serum-free 22%,
n=69; lOng/ml BDNF 25%, n=71; lOng/ml BDNF and 5pg/ml anti-BDNF 19%, n=36;
and 5pg/ml anti-BDNF alone 18%, n=49). Thus, although progression to Mil is
generally poorer in the absence of cumulus cells, exogenous BDNF cannot substitute for
serum to support nuclear maturation in the presence or absence of cumulus cells.
Furthermore, a blocking antibody to BDNF did not have any additive detrimental effect
on nuclear maturation beyond that observed for serum-free maturation in general.
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Effect of BDNF during maturation of cumulus free oocytes on parthenogenetic
embryo development
In a final series of experiments, parthenogenetic embryo development to cleavage and
blastocyst stages was evaluated following activation of oocytes matured in the absence
of cumulus cells as described above. As with the activation experiments involving
cumulus-enclosed maturation, the maturation status of oocytes was not scored and all
morphologically intact oocytes were activated. This design was repeated in 5 replicate
trials, each of which also included a positive control of COCs matured with 10% FCS
(Figure 5.5 A-C). The proportion of activated oocytes that had cleaved by 24 h was
significantly higher for COCs and stripped oocytes matured with FCS and stripped
oocytes matured with BDNF, compared to any other treatment group (COCs (serum)
61%, n=l 14; stripped 10% FCS 53%, n=l 19; stripped serum-free 32%, n=l 15; lOng/ml
BDNF 43%, n=116; lOng/ml BDNF and 5pg/ml anti-BDNF 29%, n=l 18; 5pg/ml anti-
BDNF antibody alone 28%, n=120; p<0.05). Similarly, the proportion of activated
oocytes forming blastocysts was significantly highest for COCs matured with serum
(33%). Cumulus-free oocytes matured with serum (13%) or lOng/ml BDNF (7%) were
in turn significantly different from BDNF with blocking antibody (4%), and serum-free
(2%), with no blastocysts formed by treatment with blocking antibody alone (p<0.01). A
similar relationship between treatment groups was observed if blastocyst yields were
expressed relative to numbers of cleaved embryos (p<0.01), with the exception that there
no longer was a significant difference between BDNF and BDNF with blocking
antibody. Irrespective of differences in the proportion of embryos forming blastocysts
186
there were no differences in blastocyst nuclear counts between cumulus-free treatment
groups (mean ± S.E.M, stripped 10% FCS 61 ± 4, n=15; stripped serum-free 53 ± 13,
n=2; lOng/ml BDNF 57 ± 6, n=8; lOng/ml BDNF and 5pg/ml anti-BDNF 59 ± 5, n=5).
However, blastocyst nuclear counts for COCs matured in medium containing serum
were significantly higher than cumulus-free groups (85 ± 8, n=38; p<0.01). These
findings suggest that BDNF can substitute for serum but not cumulus cells during IVM
in order to support oocyte competence to form parthenogenetic blastocysts. The capacity
of IVM treatment with blocking antibody to completely block blastocyst formation
suggests that BDNF may also exert an influence on oocytes directly.
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Figure 5.5 Development of parthenogenetic embryos following in vitro maturation of
cumulus-free oocytes with BDNF or blocking antibody.
Oocytes were denuded at the time of collection and matured in medium with or without
10% FCS (serum), or in serum-free media supplemented with lOng/ml BDNF, lOng/ml
BDNF and 5pg/ml anti-BDNF blocking antibody, or 5pg/ml anti-BDNF antibody alone
prior to activation. Data from five replicate trials were pooled. Number of activated
oocytes per group: COCs 10% FCS, 114; stripped oocytes 10% FCS, 119; stripped
oocytes serum-free, 115; lOng/ml BDNF, 116; lOng/ml BDNF and 5pg/ml anti-BDNF,
118; 5pg/ml anti-BDNF alone, 120.
A, Proportion of activated eggs undergoing cleavage. Significant differences detected
between COC, FCS and lOng/ml BDNF treatments (denoted a) versus other groups
(denoted b). p<0.05.
B, Proportion of activated eggs forming blastocysts. COC maturation yields highest
number of blastocysts versus all other groups (a; p<0.01). Stripped oocytes matured
with FCS or lOng/ml BDNF (denoted b) show statistically significant better results than
stripped oocytes matured without serum or with lOng/ml BDNF plus blocking antibody
(denoted c; p<0.01). No statistical significant differences between FCS and lOng/ml
BDNF, or between no serum and lOng/ml BDNF plus blocking antibody.
C, Proportion of cleaved embryos forming blastocysts. Significant differences denoted
by different superscripts as previously (p<0.01).
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A bovine oocyte in vitro maturation and parthenogenesis model was used to investigate
the role of BDNF in conferring oocyte developmental competence. Both oocytes and
cumulus express mRNA transcripts and protein for BDNF and the p75 receptor that has
affinity for all neurotrophins, but transcripts for the full length and truncated forms of
the specific TrkB receptor are confined to cumulus. BDNF cannot substitute for serum
in supporting meiotic progression to Mil during in vitro maturation of cumulus enclosed
or free oocytes. Despite this it can increase or approach the yield of parthenogenetic
blastocysts relative to serum mediated maturation of cumulus enclosed or free oocytes,
respectively, via signalling pathways that are sensitive to a BDNF specific blocking
antibody. These results suggest that BDNF plays a role in conferring oocyte
cytoplasmic competence to support early embryo development, independently of nuclear
maturation, and that this may involve both autocrine and paracrine signalling within
cumulus oocyte complexes.
This study relied on parthenogenesis rather than fertilisation to assess oocyte
competence for embryonic development. In mammals parthenogenesis can yield viable
offspring provided that parent-specific imprints regulating gene expression are overcome
to permit the formation of a functional placenta (Kono, 2006). Without such
manipulations, parthenogenesis still provides a valuable measure of oocyte competence
to initiate a developmental program since development to the blastocyst stage is
independent of epigenetic imprinting (Latham et al., 1994). Accordingly, it is commonly
used to assess oocyte competence to support early development following somatic or
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pronuclear transfer (Liu et al., 2001) (De Sousa et al., 2002). The method of
parthenogenetic activation used in our study has previously been characterised to yield
equivalent rates of development to the blastocyst stage in a direct comparison with
fertilised oocyte cohorts, although with a significant reduction in resulting cell number,
similar to the present results (De La Fuente and King, 1998).
Important roles for Trk B receptors in oocyte survival in both the perinatal period of
primordial follicle formation and during the early stages of follicle growth have been
demonstrated using mouse knockout models (Spears et al., 2003) (Paredes et al., 2004).
Unfortunately these models fail to illuminate the roles for these receptors or BDNF in
the later stages of ovarian follicle development and for oocyte competence, due to the
neonatal lethalities that they invoke (Klein et al., 1993; Ernfors et al., 1994). BDNF,
NT-4 and NT-3 have all been detected in adult human follicular fluid (Seifer et al.,
2002b; Seifer et al., 2003). In vitro studies on human cumulus cells have also found that
BDNF secretion can be stimulated by treatment with cAMP and human chorionic
gonadotropin (hCG), but not recombinant FSH (Feng et al., 2003). Both BDNF and NT-
4, but not NT-3 also promoted 1st polar body extrusion in cumulus-free mouse oocytes
matured in vitro, compared with those matured in the absence of serum or hormones
(Seifer et al., 2002b; Seifer et al., 2002a). These publications report that most mouse
oocytes are immunopositive for TrkB, the BDNF and NT-4 receptor tyrosine kinase, but
not TrkC, the respective receptor for NT-3. The RT-PCR data in this study identify p75,
but not TrkB isoform mRNAs, in bovine oocytes. Furthermore, there were no significant
differences between BDNF and serum-free treatment groups in the proportion of oocytes
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reaching Mil, both of which were inferior to supplementation with serum. This may
reflect a species difference.
Our current study provides the first evidence that BDNF may benefit oocyte competence
for embryonic development without necessarily benefiting maturation. Whereas
approximately 80% of oocytes matured with FCS (positive control) reached Mil, this
was apparently reduced to 30 % in all FCS-free experimental treatments, including those
with BDNF. However, in succeeding trials there was no difference between
supplementation with BDNF and FCS in the proportion of parthenogenetic embryos that
cleaved (-60%), with blastocyst yields improved or matched by BDNF treatment.
Although serum-free IVM has previously been shown to result in a significant reduction
in the proportion of oocytes reaching Mil, our yield in the absence of serum was still
lower than the 50-60% reported by others (Lonergan et al., 1994a; Ali and Sirard, 2002).
However, our observations were consistent across replicate trials, with FCS
supplemented cohort oocytes providing expected Mil yields. The fact that in subsequent
trials there was no difference in parthenogenetic embryo cleavage between FCS
containing and free IVM treatments suggests that our immunocytochemical method for
evaluating Mil may have underestimated this event. This presumes however, that
parthenogenetic embryo cleavage is linked to Mil in the same way that fertilised embryo
cleavage is. This is unknown but not necessarily the case, considering differences
between the two situations in signal transduction and resulting spindle dynamics (Navara
et al., 1994). Cumulatively, our results substantiate a role for BDNF in enabling both
early cleavage development, driven by maternal factors in the oocyte, and blastocyst
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formation, requiring the activation and maintenance of zygotic transcription. For both
cumulus enclosed and free maturation, the effect of the BDNF blocking antibody was
first manifest by a significant reduction in cleavage. However, compared to the serum
treatment group, the improvement or matching of blastocyst yields with exogenously
supplied BDNF was not paralleled by improved cleavage. Since BDNF did not increase
the quantity of cells in blastocysts, it is likely that its effect was on oocyte and embryo
survival as opposed to the promotion of growth.
BDNF signalling between cumulus and oocytes may be bi-directional with functionally
different consequences given that both cell types express BDNF and differentially
express p75 and TrkB isoforms, namely oocytes lack the latter. Trk and p75 receptors do
not bind directly to each other, but can be complexed together (Bibel et al., 1999; Lee et
al., 2001a). This allows the signalling pathways triggered by both receptors to interact.
The association of the two receptor types apparently results in higher affinity ligand
binding and a greater discrimination between neurotrophins. Thus, BDNF, NT3 and
NT4 can each bind to the TrkB receptor, but in the presence of p75 only BDNF provides
a functional response (Bibel et al., 1999). In neurons, Trk receptors and their substrates
can activate three main signalling cascades: 1) Differentiation, via a Ras/Raf/
MEK/MAP kinase pathway, 2) cell survival (anti-apoptosis), by association with insulin
receptor substrates leading to inactivation of proapoptotic proteins, and 3) calcium
release from internal stores via PLC-y mediated production of IP3 and production of
protein kinase C, which in neurons plays a role in neurotrophin mediated neurotrophin
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release (Bibel and Barde, 2000). All of these pathways may be relevant to follicular and
oocyte maturation, but most striking is the potential for neurotrophin mediated
stimulation of the MAP kinase pathway. Gonadotropin induced cumulus expansion and
resumption of meiosis in oocytes is dependent upon activation of MAP kinase in
granulosa cells. This activation is downstream of gonadotropin-induced elevation of
granulosa cell cAMP, and is dependent upon one or more paracrine factors from the
oocyte (Su et al., 2003). BDNF secretion by cumulus is another consequence of either
gonadotropin stimulation or artificial elevation of cAMP. Elevated cAMP in cumulus
could lead to the same in oocytes via gap junctions, culminating in BDNF secretion by
oocytes that could act in an autocrine or paracrine fashion to augment the effect of
cumulus-derived BDNF. It is unknown whether BDNF derived from oocytes or cumulus
would differ in their bioactivity. Neurotrophins in general are substrates for pro-protein
convertases that can alter the molecular bioactivity of their targets by proteolytic
cleavage during intracellular and extracellular processing. BDNF is an especially well
characterised example of convertase-dependent modulation of bioactivity (Mowla et al.,
1999). Thus, differences in BDNF bioactivity could be achieved by differential
expression of pro-protein convertases in cumulus and oocytes.
The functional consequences of ligand interaction with the p75 receptor are also
complex, and in neurons have been linked to cell survival, arrest, differentiation, and
programmed cell death. Recently the concept of p75 as a 'quality control' receptor has
been advanced based on evidence that it is capable of mediating programmed cell death
in response to either ligand binding or withdrawal. In essence the downstream
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consequence of ligand interactions are proposed to be dependent on the relative
proportions of p75 and Trk receptors and which neurotrophin is present (Rabizadeh and
Bredesen, 2003). According to this model, binding of neurotrophins to p75 in the
absence of Trk receptors, typically suppresses apoptosis. This could be the case for
bovine oocytes provided they do not express TrkA or C receptors. From mouse
knockout models, mice homozygous for a targeted mutation in p75, rendering it
functionally inactive, are viable and fertile, although they eventually develop deficits in
their peripheral sensory nerves characterised by heat sensitivity and susceptibility to
ulceration (Ernfors et al., 1994). This suggests that the most critical role for p75 may be
to ameliorate the effect of stress, which in the case of oocyte maturation and
developmental competence might be most affected by adverse in vitro culture
environments.
A number of other growth factors have been reported to improve oocyte competence
and to support embryo development, when applied during oocyte maturation in vitro.
EGF improves the yield of fertilised bovine blastocysts, but not cell number, relative to
serum-free culture conditions lacking hormones (Lonergan et al, 1996). However, this
effect is preceded by promotion of the proportion of cumulus enclosed or free oocytes
progressing to Mil, the latter supporting a direct effect on oocytes. EGF-receptor
tyrosine kinase mediated activation of meiosis was first described in Xenopus oocytes,
and later confirmed in the rat and mouse (Mailer, 1985; Ueno et al., 1988) (Downs,
1989). Studies in the latter also revealed a direct effect of EGF on cumulus leading to
the promotion of cumulus expansion. Like EGF, other groups have demonstrated that
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supplementation of bovine oocyte in vitro maturation culture with exogenous activin A
promotes meiotic maturation and subsequent yield of fertilised blastocysts (Stock et al.,
1997; Silva and Knight, 1998), an effect which is reduced by the activin binding protein
follistatin. These gene products are synthesised by granulosa cells and are prominent
components of follicular fluid (Braw-Tal et al., 1994). Activin A receptor mRNA can be
detected in both granulosa cells and oocytes (Cameron et al., 1994). In the former,
activin A appears to increase the number of FSH receptors in granulosa cells and as such
may promote gonadotropin action during maturation (Nakamura et al., 1993). A direct
effect of activin A on oocytes is supported by evidence of improved progression to Mil
of cumulus-free oocytes, although the mechanism by which this is achieved is unknown
(Stock et al., 1997). Activin A also promotes human germ cell survival and proliferation
prior to primordial follicle formation, as discussed earlier in Chapter 3 (Martins da Silva
et al., 2004). Only midkine, a heparin-binding growth/differentiation factor, which is
also a prominent feature of bovine follicular fluid, is similar to BDNF in promoting
oocyte competence to reach the blastocyst stage without also improving meiotic
progression to Mil (Ikeda et al., 2000). Midkine is also produced by granulosa cells
under the control of gonadotropins (Minegishi et al., 1996). Unlike BDNF however,
midkine does not appear to act directly on oocytes. Its actions can also be blocked by
heparin (Ikeda et al., 2000).
In conclusion, this study adds BDNF to the list of growth factors normally present in
follicular fluid, which can specifically promote oocyte developmental competence
during maturation in vitro. However, BDNF differs from most other factors identified in
195
that its effect is to promote cytoplasmic maturation without advancing nuclear
maturation. This effect is likely to be complex and mediated by direct effects on both
the oocyte and cumulus cells. This knowledge will be of value to the creation of
completely defined culture environments free of serum for oocyte maturation, which
will improve both their overall safety and the efficacy of assisted reproductive






This thesis provides support for the hypothesis that the growth factors studied, namely
activin, neurotrophin-4 and BDNF, play an essential role in the development and
organisation of the human fetal ovary during the second trimester. There is also support,
as evidenced by bovine in vitro maturation studies, that BDNF has a significant role in
later oocyte development, enhancing cytoplasmic maturation and embryo development
potential.
6.2 THE ROLE OF ACTIVIN IN HUMAN FETAL OVARIAN DEVELOPMENT
The studies described in Chapter 3 demonstrate the presence of activin subunits and
activin/inhibin type I and type II receptors in the mid-trimester human ovary. Neither the
inhibin subunit, nor its receptor, betaglycan, was identified by immunohistochemistry
techniques. The activin binding protein, follistatin, was also not identified in the fetal
ovary at this stage of development. These studies provide previously unpublished detail
concerning presence of activin / inhibin in the developing human fetal ovary focussed
around the time of follicular assembly.
Oogonia in the mid-trimester human fetal ovary were found to exclusively express the
pA subunit. Furthermore, quantitative PCR studies determined a significant increase in
PA expression over the mid-trimester. The effect of activin A on germ cell survival and
proliferation was therefore investigated using a tissue culture model. In vitro supplement
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with activin A resulted in a mean increase of 20% in the total number of germ cells, as
well as a significant increase in germ cell BrdU immunostaining, indicating increased
germ cell proliferation and/or entry into meiosis. Immunolocalisation of ActRIIA
receptors specifically to germ cells, the global presence of ActRIlB and ALK4 across
germ cell and non-germ cell compartments, and the stromal presence of ALK.2, suggests
that activin signalling can target germ cells both directly or indirectly, in an autocrine /
paracrine manner.
These data demonstrate the presence and localisation of activin receptors and subunits
within the developing human ovary, and support a role for activin A in the regulation of
germ cell proliferation during the developmental period leading up to primordial follicle
formation. This furthers our limited knowledge of the factors controlling germ cell
development in the human fetal ovary, and ultimately contributes to our understanding
of female fertility. Further work detecting and localising Smad downstream signalling
molecules has been undertaken in adult human ovary (Pangas et al., 2002), but not, as
yet, in the human fetal ovary. Future studies clarifying Smad localisation, and possibly
quantifying in vitro signalling responses, would generate further insight into the very
complex subject of TGF-J3 superfamily signalling, and potentially identify areas
amenable to therapeutic manipulation.
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6.3 THE ROLE OF NEUROTROPHINS IN HUMAN FETAL OVARIAN
DEVELOPMENT
The studies described in Chapter 4 have demonstrated the presence of the neurotrophins
NT4 and BDNF, and their signalling receptors TrkB and p75, in the developing human
ovary during the second trimester. This confirmed previous published data, with
preferential location of ligands (BDNF to oocyte, NT4 to pre-granulosa) supporting
autocrine / paracrine signalling. NT4 action was further studied by tissue culture
experiments where the ligand was supplemented, blocked or substituted with BDNF, and
the resulting effect on germ cell survival and proliferation examined.
Previous studies have shown decreased germ cell survival and proliferation when TrkB
signalling is blocked using K252a, a potent and specific inhibitor of all Trk receptors
(Spears et al., 2003). In the same series of tissue culture experiments, inhibition of both
NT4 and BDNF by use of blocking antibodies lowered murine oocyte survival, but
blocking either ligand alone had no detectable effect (Spears et al., 2003). In agreement,
inhibition of NT4 in mid-trimester human fetal ovary culture experiments (using the
same blocking antibody) showed no effect on germ cell survival. However, addition of
BDNF in the presence of NT4 blocking antibody resulted in decreased germ cell
survival, either by necrosis or apoptosis. It has long been recognised that massive germ
cell loss occurs during human embryological development (Baker, 1963) and that a key
feature in oocyte survival rests upon ovarian organisation and primordial follicle
formation (Hirshfield, 1991; McLaren, 1991; Fulton et al., 2005). It is possible that
NT4, derived from granulosal cells, is an important growth factor for oocyte survival at
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this time of primordial follicle assembly, and it is tempting to interpret these culture
findings to suggest oocyte-derived BDNF may trigger oocyte apoptotic pathways, or
render an oocyte vulnerable to necrosis, in the absence of NT4 signalling from
surrounding granulosal cells.
This data supports the importance of a functional NT4 / BDNF / TrkB signalling
complex in the developing human ovary, but leaves challenging questions concerning
ovarian development as yet unanswered. It is intriguing that, whilst NT4 and BDNF
presumably exist in some sort of balance, there is also a certain amount of plasticity in
this growth factor system: there is little effect seen on germ cell number when one
ligand is removed (blocked), supplemented, or removed and then replaced, possibly
because alternative neurotrophins ligands can substitute in this scenario. Yet absence of
both NT4 and BDNF, or their preferential receptor TrkB, results in significant oocyte
loss (Spears et al., 2003). Lack of NT4 in culture conditions supplemented with BDNF
similarly result in germ cell necrosis or apoptosis, however, the converse situation (lack
of BDNF replaced by NT4) would not appear to carry the same consequences (Fan et
al., 2000). The influence of stromal signalling via the p75 receptor, is also poorly
understood. Clearly, further studies are needed to unearth the complexities of ovarian
development.
A limiting factor in the acquisition of knowledge in this area of research is the relative
scarcity of tissue and difficulty in obtaining samples. As a result, information is often
gained by extrapolation from animal models. The unpredictable timing of sample
201
arrival, and potential delay in processing, is also a factor challenging efforts in this field.
In time, as a greater bank of frozen and optimally fixed tissue samples are accumulated,
it will be possible to continue and advance studies, thus gaining further knowledge
concerning the role of these factors in human ovary development.
6.4 THE ROLE OF BDNF IN BOVINE OOCYTE MATURATION
Significant legal and ethical issues restrict studies of human oocyte maturation. The
studies described in Chapter 5 therefore used a bovine model, selected on the basis of
relative similarity to the human; cows are mono-ovulatory and polyestrous (rather than
seasonal breeders). These studies have demonstrated the presence of the neurotrophin
BDNF, and its signalling receptors TrkB and p75, in the bovine ovary and cumulus-
oocyte complex. BDNF and p75 were also detected in immature and metaphase II
arrested oocytes. Neither full length nor truncated TrkB could be detected in oocytes.
Bovine oocyte maturation was studied to determine a possible role for BDNF. Oocyte
maturation entails nuclear maturation (progression to metaphase II, with extrusion of a
single polar body) as well as cytoplasmic maturation (re-distribution and organisation
of organelles in order to allow fertilisation, and molecular changes conferring
developmental competence and the ability to become an embryo). Studies have shown
that BDNF secretion is stimulated by the pre-ovulatory LH surge and suggest that it has
a role in promoting oocyte maturation (Seifer et al., 2002a; Kawamura et al., 2005).
BDNF supplementation of serum-free defined in vitro maturation media showed no
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increase in Mil (nuclear maturation) for either cumulus-enclosed oocytes or denuded
oocytes. However, BDNF supplement during in vitro maturation resulted in an
increased number of parthenogenetically activated oocytes forming blastocysts,
implying enhanced cytoplasmic maturation. Denuded oocytes also showed increased
cleavage rates and higher numbers of blastocysts when matured in the presence of
BDNF (or serum), although these results were lower than maturation of intact COCs.
Embryo cleavage was significantly lower in COC groups matured with BDNF blocking
antibody, an effect that was not seen in identical maturation conditions using denuded
oocytes. But no blastocysts were formed by denuded oocytes matured with BDNF
blocking antibody, suggesting that BDNF may exert an influence directly on oocytes, as
well as via cumulus.
These studies support a role for BDNF in oocyte cytoplasmic maturation, enhancing
oocyte competence to form parthenogenetic blastocysts. Further studies fertilising, rather
than activating, matured bovine oocytes would be useful to establish safety and optimal
BDNF supplement concentrations. Studies using human oocytes, should also be
undertaken, and, in time, it may be possible to create and refine defined serum-free in
vitro maturation media for agricultural use as well as human infertility treatment.
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In summary, this research has demonstrated that the various factors studied in the
preceding chapters are unequivocally present in the mid-trimester human fetal ovary,
and adult bovine ovary. These results alone imply essential roles in ovarian tissue
proliferation and development. The discovery that activin A increases germ cell
proliferation and/or entry into meiosis and the data supporting functional importance of
NT4 / BDNF / TrkB signalling furthers our understanding of processes affecting the
regulation of ovarian development at the time of follicular assembly. The discovery of
the beneficial effects of BDNF on oocyte cytoplasmic maturation and resultant enhanced
embryo developmental potential also contributes to our understanding of oocyte
development. Further research developing ways of manipulating these factors in vitro
will, hopefully, lead to therapeutic applications for this research.
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Sources of all reagents used for the experiments described in the preceding chapters are
detailed below.
HUMAN TISSUE CULTURE MATERIALS SOURCE
24-well culture plates Costar ltd, High Wycombe
Millicell CM filters Millipore UK, Watford
Minimal essential medium (MEMa) Gibco, Paisley
Bovine serum albumin (BSA), fraction V
Electrophoresis grade
Sigma, Poole, Dorset
Penicillin Sigma, Poole, Dorset
Streptomycin sulphate Sigma, Poole, Dorset
Amphotericin Sigma, Poole, Dorset
ITS Sigma, Poole, Dorset
Glutamine Sigma, Poole, Dorset
Pyruvate Sigma, Poole, Dorset
Recombinant human Activin A R&D Systems, Abingdon
Neurotrophin-4 (NT4) Peprotech EC Ltd
Anti-neurotrophin-4 (anti-NT4) Sigma, Poole, Dorset
Brain derived Neurotrophic Factor (BDNF) Peprotech EC Ltd
Bromodeoxyuridine (BrdU) Sigma, Poole, Dorset
Bouins fluid Triangle Biomedical Sciences,
Lancashire
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BOVINE MATURATION CULTURE SOURCE
PBS Oxoid, Basingstoke, Hampshire
Universal container Bibby Sterilin, Fisher Scientific
10ml syringe Becton Dickinson, Fisher
Scientific
18G needle Becton Dickinson, Fisher
Scientific
90mm petri dish Fisher Scientific
4 well nunc plates Nunc, Fisher Scientific
TCM199 Sigma, Poole, Dorset
FSH Ovagen
LH Sigma, Poole, Dorset
Estradiol Sigma, Poole, Dorset
Mycoplex fetal calf serum PAA labs, Yeovil, Somerset
Brain derived Neurotrophic Factor (BDNF) Peprotech EC Ltd
Anti- brain derived neurotrophic factor (Anti-BDNF) Sigma, Poole, Dorset
HEPES buffered TCM (HB TCM) See Appendix II for recipe
Bicarbonate buffered TCM (BB TCM) See Appendix II for recipe
Mineral Oil Sigma, Poole, Dorset
Hyaluronidase Sigma, Poole, Dorset
BOVINE PARTHENOGENESIS
Flepes buffered synthetic oviduct fluid (HSOF) See Appendix II for recipe
Ionomycin Sigma, Poole, Dorset
SOFaaBSA See Appendix II for recipe
6-DMAP Sigma, Poole, Dorset
Cycloheximide Sigma, Poole, Dorset
Hoescht 33342 Sigma, Poole, Dorset
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MOLECULAR BIOLOGY SOURCE
RNAlater Ambion, Huntingdon, Cambs
0.2ml eppendorf tubes Ambion, Huntingdon, Cambs
Deoxynucleotide triphosphate Roche Diagnostics, Lewes
2 x Thermostart PCR mastermix Abgene, Epsom
TBE buffer See Appendix 11 for recipe
Agarose Sigma, Poole, Dorset
Ethidium bromide Sigma, Poole, Dorset
Gel tank Biorad, CA, USA
Primer sequences MWG Biotech
LightCycler Fast start DNA MasterSYBR Green 1 Roche Molecular Biochemicals,
Master Mix Sussex
ISOLATION OF RNA, SYNTHESIS AND
AMPLIFICATION OF cDNA
RNeasy mini kit Qiagen, Crawley, Surrey
TRIReagent Sigma, Poole, Dorset
chloroform Sigma, Poole, Dorset
isopropanol BDH (VWR)
DNAase Gibco, Paisley
Deoxynucleotide triphosphate Roche Diagnostics, Lewes
QIAshredder cell lysate homogeniser Qiagen, Crawley, Surrey
Pellet paint Novagen
Bulk first strand cDNA synthesis kit Amersham Biosciences
dNTPs Boehringer Mannheim, Lewes
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IMMUNOHISTOCHEMISTRY SOURCE
Slides BDH Laboratory supplies
Histoclear National Diagnostics, Atlanta,
Georgia, USA
Hydrogen Peroxide (H2O2) Merck Ltd (BDH), Lutterworth,
UK
Methanol Merck Ltd (BDH), Lutterworth,
UK
Tris base Sigma, Poole, Dorset
Tris-buffered saline (TBS) See Appendix II for recipe
Blocking serum Diagnostics Scotland, Carluke, UK
Citrate buffer See Appendix II for recipe
Bovine serum albumin, fraction V, electrophoresis
grade
Sigma, Poole, Dorset
Avidin block Vector, Peterborough, UK
Biotin block Vector, Peterborough, UK
Biotinylated secondary antibodies Dako, Cambridge, UK
Biotinylated anti-chicken secondary antibody Jackson Laboratories, Bar
Harbour, Maine, USA
Avidin-Biotin complex-horseradish peroxidase Dako, Cambridge, UK
DAB liquid substrate-chromagen system Dako, Cambridge, UK
Haematoxylin See Appendix II for recipe
Eosin See Appendix II for recipe
Type I rat-tail collagen Sigma, Poole, Dorset
0.1M acetic acid BDH laboratory supplies
TCM199 Sigma, Poole, Dorset
IMMUNOCYTOCHEMISTRY
Microtubule stabilising buffer See Appendix II for recipe
Triton xlOO BDH Laboratory supplies
37% formaldehyde BDH Laboratory supplies
10% goat serum See Appendix II for recipe
5% goat serum See Appendix II for recipe
0.1% goat serum See Appendix II for recipe
Rhodamine phalloidin Sigma, Poole, Dorset
Alpha anti-tubulin FITC Sigma, Poole, Dorset
Vectashield and DAP1 Vector, Peterborough
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SPECIFIC IMMUNOHISTOCHEMISTRY SOURCE
Inhibin a subunit (179.3k)
Mouse monoclonal antibody Gift ofNP Groome
Inhibin / activin |3A subunit (E4)
Mouse monoclonal antibody Gift ofNP Groome
Inhibin / activin 0B subunit (13/14)
Mouse monoclonal antibody Gift of NP Groome
Inhibin / activin pB subunit
(PB (80-112)-NH2 PBL#197)
Rabbit polyclonal antibody Gift of W Vale
ActRIIA
Rabbit polyclonal antibody GiftofC-H Heldin
ActRIIB
Rabbit polyclonal antibody Gift of C-H Heldin
ALK2
Rabbit polyclonal antibody GiftofC-H Heldin
ALK4
Rabbit polyclonal antibody GiftofC-H Heldin
Betaglycan
Goat polyclonal antibody Santa Cruz, CA, USA
Follistatin (FS288)
Mouse monoclonal antibody Gift ofNP Groome
BrdU
Mouse monoclonal antibody Roche Diagnostics, Lewes
BDNF (N20)
Rabbit polyclonal antibody Santa Cruz, CA, USA
BDNF peptide block Santa Cruz, CA, USA
NT4
Rabbit polyclonal antibody Santa Cruz, CA, USA
TrkB
Chicken polyclonal antibody Promega, Southampton
Truncated TrkB
Rabbit polyclonal antibody Santa Cruz, CA, USA
p75




Recipes for solutions used in previously described experiments are detailed below. All
chemicals were from Sigma, Poole, UK unless otherwise stated.
MOLECULAR BIOLOGY SOLUTIONS
10X TBE
108 g tris base
55 g boric acid
3.77 g EDTA
Add milliQ water to a final volume of 1.0L




Mix in conical flask and heat for 2 minutes in microwave until agarose dissolved






CITRATE BUFFER (0.1M, pH 6.0)
42.02 g citric acid (monhydrate)
1900 ml distilled water
Add concentrated NaOH to pH 6.0
Make up to 2.0L with further distilled water
Use as 0.01M, diluting in distilled water
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TRIS BUFFERED SALINE (TBS) (0.5M, pH 7.5)
121.1 g tris (trizma base)
800 ml distilled water
Add concentrated HC1 to pH 7.5
Make up to 2.0L with further distilled water
IMMUNOCYTOCHEMISTRY SOLUTIONS
PHOSPHATE BUFFERED SALINE (PBS)
1 tablet per 100 ml milliQ water (Oxoid, Basingstoke, Hampshire)
5XSB
7.55 g Pipes (0.1M)
0.25 g MgCl2.6H20 (5mM)
0.235 g EGTA (2.5mM)
Add 10N NaOH to pH 6.9
Final volume 50 ml
Store at 4°C for 1 year
0.1% NGS WASH SOLUTION
50 ml goat serum
50 ml PBS
Store at 4°C for 1 month
5% NGS WASH SOLUTION
2.5 ml goat serum
47.5 ml PBS
0.01 g Na Azide
50 ml Triton XI00
Store at 4°C for 1 month
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10% NGS WASH SOLUTION
5 ml goat serum
72.5 ml PBS
0.015 gNa Azide
75 ml Triton XI00 (BDH)
Store at 4°C for 1 month
MICROTUBULE STABILISING BUFFER (MTSB)
1 ml 5XSB
5 ml DTT(IM)
2.5 ml D20 (Deuterium oxide)
1.5 ml MilliQ water
COMPLEX FIX
5 ml MTSB
5 ml Triton XI00
Warm to 37°C 30 minutes before use
Warm 270 ml formaldehyde (37% stock) and add just before
ANTIBODY SOLUTION
400 ml 5% NGS
5 ml rhodamine phalliodin
8 ml alpha a-tubulin FITC
Incubate in dark at 37°C for 1 hour
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BOVINE CULTURE MEDIA STOCKS
STOCK B (250 mM Sodium Bicarbonate)
1.05 gNaHC03
Add MilliQ water to 50 ml
Add 2-3 grains of phenol red
Osmolarity 430-440 mOsM
Filter and store at 4°C for up to 3 weeks
STOCK C (33 mM Sodium Pyruvate)
0.036 g Pyruvic Acid
Add MilliQ water to 10 ml
Osmolarity 55-60 mOsM
Filter and store at 4°C for up to 1 week
STOCK D (171 mM Calcium chloride)
1.26gCaCl2.2H20
Make to 50 ml with MilliQ dH20
Osmolarity 430-440 mOsM
Store filtered at 4°C for 3 months
STOCK G (60 mM Glucose)
0.54 g Glucose
Make to 50 ml with MilliQ dH20
Osmolarity 60-70 mOsM
Store filtered at 4°C for 3 months
STOCK GLN (10 mM Glutamine)
0.0438 g L-Glutamine
Make to 30 ml with MilliQ dH20
Osmolarity 8 mOsM
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Store filtered at 4°C for 1 week
STOCK H (250 mM Hepes)
3.0 g Hepes Free Acid
3.25 g Hepes Sodium Salt
Add MQ water to 100 ml
Add 2-3 grains of phenol red
Osmolarity 380-385 mOsM
Filter and store at 4°C for up to 1 month
STOCK L (330 mM Sodium Lactate)
11.75 ml Na Lactate (60%) Syrup
Make to 250 ml with MilliQ dH20.
Osmolarity 590-640 mOsM
Filter and store at 4°C for up to 3 months
STOCK M
0.5 g MgCl2.6H20
Make to 50 ml with MilliQ dH20
Osmolarity 120-130 mOsM






Make to 50 ml with MilliQ dH20
Osmolarity 2173 mOsM
Store filtered at 4°C for 3 months
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2X TCM 199 STOCK
20 ml TCM 199 (xlO)
0.01 g Kanamycin
0.04 g L-Glutamine
Add MilliQ water to 100 ml
Filter and store at 4°C for up to 1 week
BOVINE MATURATION MEDIA STOCKS
HEPES BUFFERED TCM199 (100 ml)
50 ml 2X TCM 199 Stock
6 ml Stock EI
2 ml Stock B
42 ml MilliQ water
Check osmolarity (280-300 mOsM)
Check pH (7.3-7.4)
Filter and aliquot into 9 ml, store at -20°C
HB TCM 199 9m 1
Add 1ml fetal calf serum
Filter sterilise
Use for COC / oocyte sorting and washes
BICARBONATE BUFFERED TCM 199 (50
25 ml 2X TCM 199 Stock
5 ml Stock B
0.3 ml Stock C
19.7 ml MilliQ water
Osmolarity 280-300 mOsM
Check pH (7.3-7.4)
Filter and aliquot into 5 ml, store at -20°C
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IN VITRO MATURATION BASE MEDIUM (serum free)
5 ml BBTCM199
50 ml FSH (final concentration 0.5 mg/ml)
20 ml LH (final concentration 5 mg/ml)
Filter sterilise
Add 2 ptl estradiol (final concentration 2pg/ml)
Use for COC / oocyte wash and wells in 1VM culture plates
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BOVINE PARTHENOGENIC ACTIVATION MEDIA
HEPES SOF (+ CALCIUM) (HSOF)
STOCK S2 2.0 ml
STOCK B 0.4 ml
STOCK H 1.6 ml
STOCK C 0.2 ml
STOCK D 0.2 ml
STOCK M 0.2 ml
STOCK L 0.2 ml
STOCK G 0.5 ml
MilliQ water 14.7 ml
Adjust pH to 7.40. Osmolarity 265-275 mOsM
Filter and store 1 - 2 weeks at 4°C
SOFaaBSA CULTURE MEDIUM
STOCK S2 1.5 ml
STOCK B 1.5 ml
STOCK C 0.15 ml
STOCK D 0.15 ml
STOCK M 0.15 ml
STOCK L 0.15 ml
STOCK G 0.375 ml
STOCK GLN 1.5 ml
Non Essential amino acids 0.15 ml
Essential amino acids 0.3 ml
MilliQ water 9.075 ml
Fatty acid free BSA 0.12 g
Adjust pH to 7.40. Osmolarity 265-275 mOsM
Filter and store 1 week at 4°C
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HYALURONIDASE
Add 1 ml MilliQ water to 30 mg vial
Divide into 10 [xl aliquots (=300U) and store at-20°C
Final concentration used is 300U/ml
Add 1 ml HSOF to 10 ptl aliquot
IONOMYCIN
Add 1338.5 ml DMSO to lmg to make ImM stock
Add 25.46 ml MilliQ water to make 0.05mM working stock
Divide into 100 jxl aliquots and store at -20°C
Final concentration used is 5mM
Add 50}xl to 450 ql HSOF
6-DIMETHYLAMINOPURINE (6-DMAP)
20mg 6-DMAP
Add 4.9 ml MilliQ water to make 25mM working stock
Divide into 100 q,l aliquots and store at -20°C
Final concentration used is 2.5mM
Add 50|xl to 450 jxl SOFaaBSA
CYCLOHEXIMIDE
Add DMSO to make lOOmg/ml stock solution
Add 1.99ml DMSO to 10|xl stock solution to make 500q.g/ml working stock
Divide into 20 |il aliquots and store at -20°C
Final concentration used is 1 Oug/ml
Used in combination with 6-DMAP








Expression of activin subunits and receptors in the developing
human ovary: activin A promotes germ cell survival
and proliferation before primordial follicle formation
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Abstract
The formation of the essential functional unit of the ovary, the primordial follicle, occurs during fetal life in humans. Factors regulating
oogonial proliferation and interaction with somatic cells before primordial follicle formation are largely unknown. We have investigated the
expression, localisation and functional effects of activin and its receptors in the human fetal ovary at 14-21 weeks gestation. Expression of
mRNA for the activin ftA and p>B subunits and the activin receptors ActRIIA and ActRIIB was demonstrated by RT-PCR. Expression of |iA
mRNA increased 2-fold across the gestational range examined. Activin subunits and receptors were localised by immunohistochemistry. The
(3A subunit was expressed by oogonia, and the (3B subunit and activin receptors were expressed by both oogonia and somatic cells. pA
expression was increased in larger oogonia at later gestations, but was low in oocytes within newly formed primordial follicles. Treatment of
ovary fragments with activin A in vitro increased both the number of oogonia present and oogonial proliferation, as detected by
bromodeoxyuridine (BrdU) incorporation. These data indicate that activin may be involved in the autocrine and paracrine regulation of germ
cell proliferation in the human ovary during the crucial period of development leading up to primordial follicle formation.
Crown Copyright © 2003 Published by Elsevier Inc. All rights reserved.
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Introduction
Germ cell survival is key to the reproductive life span of
the ovary and is determined by the continuing presence of
oocytes within primordial follicles. These are formed during
fetal life in the human. The number of follicles formed is
dependent upon the balance between early germ cell prolif¬
eration and loss, as well as the interaction between oocyte
and somatic cells (Hirshfield, 1991; McLaren, 1991). The
pathways regulating this crucial process are largely un¬
known, although several genes necessary for the formation
of a normal complement of primordial follicles have been
identified (Amleh and Dean, 2002; Matzuk, 2000). During
the period leading up to primordial follicle formation there is
* Corresponding author. MRC Human Reproductive Sciences Unit,
Centre for Reproductive Biology, University of Edinburgh Chancellors'
Building, 49 Little France Crescent, Old Dalkeith Road, Edinburgh,
Scotland, EH16 4SB, UK. Fax: +44-131-2426231.
E-mail address: r.a.anderson@hrsu.mrc.ac.uk (R.A. Anderson).
massive oogonial mitotic proliferation, both during and after
migration from the yolk sac to the nephrogonadoblastic
ridge. The oogonia associate with somatic cells resulting in
syncitial nests of germ cells intermingled with pre-granulosa
cells and surrounded by a meshwork of ovarian stroma
(Byskov, 1986; Pepling and Spradling, 2001; Sawyer et
al., 2002). The germ cells subsequently enter meiosis only
to arrest at diplotene of the first meiotic division. By mid-
gestation, the human fetal ovary contains its maximal num¬
ber of germ cells. This peak is followed by widespread germ
cell loss, by apoptosis, (De Pol et al., 1997; Vaskivuo et al.,
2001) so that less than 20% survive by the time of birth
(Baker, 1963). Primordial follicles are formed as oocytes
become individually surrounded by somatic cells (Hirsh¬
field, 1991) and it is this interaction that has been identified
as the event that determines oocyte survival, and presumably
protection against apoptosis. A number of locally derived
growth factors have been identified to be crucial to germ cell
survival at early developmental stages, such as BMP-4
(Fujiwara et al., 2001) and kit ligand (Godin et al., 1991;
0012-1606/$ - see front matter Crown Copyright © 2003 Published by Elsevier Inc. All rights reserved,
doi: 10.1016/j.ydbio.2003.10.030
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anova et al., 1990), and following primordial follicle
rmation, such as growth and differentiation factor 9
rDF-9) (Dong et al., 1996). However, little information is
ailable regarding factors regulating oogonial proliferation
id primordial follicle formation, particularly in human.
Activins and inhibins are members of the transforming
rowth factor p> (TGFfi) family. The component a and (5
ubunits can be combined into biologically active a[3 inhibin
" [ifi activin dimers with generally opposing functional
'fects, and are produced in both gonad and pituitary (Burger
id Igarashi, 1988; Chen, 1993; Mather et al., 1997).
Dllistatin is a structurally unrelated monomeric protein that
reversibly binds activin and neutralises its biological effects
lakamura et al., 1990; Schneyer et al., 1994). Members of
e TGF superfamily can influence many facets of cell
neage and activity including proliferation, differentiation,
Ihesion, motility and apoptosis. Many are involved in
nbryonic development as well as adult tissue homeostasis
vfishina et al., 1999; Padgett and Patterson, 2001). The
;tivins, together with other members of the TGF|3 super-
tmily, signal through membrane-bound serine-threonine
inase receptors. They bind to a type II receptor (ActRIIA
r ActRIIB), which recruits and phosphorylates a type I
;ceptor with subsequent modulation of gene expression via
mad protein activation (Massague, 1998). Several type I
;ceptors, termed activin receptor-like kinases (ALKs) have
een identified. ALK4 (ActRIB) is believed to be the
referential activin receptor, whereas ALK2 (ActRIA) pref-
rentially mediates BMP and anti-Miillerian hormone sig-
lalling. Whilst the Smad proteins are the central elements in
he activin receptor signalling pathway, other signalling
pathways may mediate at least some of the diverse biological
ssponses of the TGFfi superfamily, including mitogen-
ctivated protein kinase (MAPK) pathways (Massague,
000; Mulder, 2000). The initial steps coupling the activin
/pe II serine-threonine kinase receptor to MAPK are yet to
e defined, although signalling via TGF (^-activated kinase 1
TAK1) results in activation of stress-activated p38 and
•anscription factor ATF2, which can interact with Smad3
nd Smad4 to mediate transcription (Cocolakis et al., 2001;
Jerynck et al., 2001).
A substantial body of evidence has accrued that activins
nd inhibins are regulatory factors in the adult ovary in-
'olved in a wide range of functions, including folliculo-
;enesis, granulosa and theca cell proliferation, and
teroidogenesis (Findlay et al., 2002; Knight and Glister,
001; Mizunuma et al., 1999) as well as oocyte maturation
Alak et al., 1998; Izadyar et al., 1998). Activin is expressed
i the human gonad at very early stages of development
Harkness and Baird, 1997) and there are limited data
ndicating the expression of activin and inhibin in the
leveloping human ovary following primordial follicle for-
nation (Harkness and Baird, 1997; Rabinovici et al., 1991).
lowever, no data are available regarding the presence of
ictivin and its cognate receptors before primordial follicle
ormation in the human ovary. We have therefore explored
the expression and distribution of inhibin/activin subunits in
the human fetal ovary during the period of oogonial prolif¬
eration leading up to primordial follicle formation. The
localisation of activin receptors ALK4, ActRIIA and
ActRIIB, the inhibin receptor betaglycan (Lewis et al.,
2000) and the activin-binding protein follistatin has also
been investigated to identify potential sites of action of these
regulatory factors during this period of development. As
oogonia in the mid-trimester human fetal ovary were found
to express activin subunits and receptors, we have investi¬
gated the effect of activin A on oogonial survival and
proliferation using an in vitro tissue culture model.
Materials and methods
Tissues
Human fetal ovaries were obtained following medical
termination of pregnancy. Women gave consent according to
national guidelines (Polkinghome, 1989) and the study was
approved by the Lothian Paediatrics/Reproductive Medicine
Research Ethics Subcommittee. Termination of pregnancy
was induced by treatment with mifepristone (200 mg orally)
followed 48 h later by prostaglandin El analogue (Geme-
prost; Beacon Pharmaceuticals, Tunbridge Wells, UK) 1 mg
three hourly per vaginum. None of the terminations were for
reasons of fetal abnormality, and all fetuses appeared mor¬
phologically normal. Gestational age was determined by
ultrasound examination before termination and confirmed
by subsequent direct measurement of foot length.
Ovaries were dissected free and either fixed for immuno-
histochemical analysis, snap frozen and stored at —70°C,
placed in 500 pi RNAlater (Ambion (Europe) Ltd, Hunting¬
don, Cambs, UK) or further dissected and placed into
culture. Fixation was carried out in Bouin's fluid for 5 h,
followed by transfer to 70% ethanol before processing into
paraffin using standard methods.
Isolation ofRNA and synthesis and amplification of cDNA
Total RNA was extracted from fetal ovary (14-19 weeks)
using either the Rneasy Mini Kit (Qiagen, Crawley, UK) for
RT-PCR or TRIReagent (Sigma, Poole, Dorset, UK) for
quantitative PCR analysis according to the manufacturers'
instructions, and treated with DNase (Gibco, Paisley, UK).
Reverse transcription using a first-strand cDNA synthesis kit
(Roche Diagnostics, Lewes, UK) was followed by PCR
using 1 pi cDNA samples and Taq DNA polymerase (AGS
Gold; Hybaid, Ashford, UK) as previously described (Rob¬
inson et al., 2001). Primers were designed to span an intron
to ensure that genomic DNA was not amplified. Specific
primers for each subunit and receptor are given in Table 1.
Control tubes were run in parallel for each PCR, one in
which water replaced RNA and a second RT-sample in which
reverse transcriptase was omitted, to ensure there was no
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Table 1




Inhibin a TGAGGGCCCTGTTCTTGGATG CTGGCGGCTGCGTGTATGCTG
Inhibin/activin pA GAACTTATGGAGCAGACCTCGG TTGCCATCACACTCCAAGCC
Inhibin/activin pB GCCAGGAGCGCGTTTCCGAAATC CCGCTCGCCCCGCTCAAACAAi
GAPD GACATCAAGAAGGTGGTGAAGC GTCCACACCCTGTTGCTGTAG
genomic DNA contamination. The identity of all PCR
products were confirmed by direct sequencing using an
Applied Biosystems 373A automated sequencer.
Lightcycler quantitative PCR
Quantitative PCR was performed using the Lightcycler
system (Roche Molecular Biochemicals, Sussex, UK) as
previously described (Hartley et al., 2002) to investigate
changes in expression of the activin pA subunit over a range
of gestations. Reverse transcribed RNA samples (n = 29)
were diluted in water as indicated. One microliter of diluted
first-strand cDNA was added to a final volume of 10
pi containing 2 mM MgCl2 and 0.5 pM each of forward
and reverse primer in 1 x Lightcycler Fast Start DNA
MasterSYBR Green 1 Master Mix (Roche Molecular Bio¬
chemicals). Signal acquisition was performed for each of 45
amplification cycles followed by continuous melt curve
analysis to ensure product accuracy. Primers for GAPD
and activin pA subunit are given in Table 1.
Standard curves for GAPD and activin pA were derived
by making a series of first-strand cDNA dilutions from a 16-
week ovary. The number of cycles needed to yield a
fluorescent signal above background (the cross-over point,
Cp) was plotted against the log of relative concentration
using LightCycler Software (Molecular Dynamics Ltd.,
Buckinghamshire, UK) yielding a straight line for each
product. Quantification of ovarian pA mRNA expression
was subsequently performed. For each experiment, both
GAPD and activin pA amplification reactions were per¬
formed in duplicate for every cDNA sample used. Calcu¬
lations for activin pA mRNA concentration were made
relative to GAPD from the same sample to allow compar¬
isons between ovaries. Allowance for differences in ampli¬
fication rate for GAPD and activin pA was achieved by
determining the actual amount of amplification required to
yield a signal for each target. Data were analysed by
ANOVA.
Immunohistochemistry
Sections (5 pm) were mounted on BDH Superfrost Plus
slides (BDH Laboratory Supplies, Merck Ltd, Lutterworth,
Leics, UK) and dried overnight at 50°C before processing
for immunohistochemistry as previously described (Ander¬
son et al., 2002). Briefly, slides were incubated in 3%
H2C>2 in methanol for 30 min to inhibit endogenoi
peroxidase activity. After rinsing in distilled water, slide
were washed twice in Tris-buffered saline (TBS; 0.05 mo
1 Tris, 0.85% NaCl, pH 7.6) for 5 min and blocked for 3
min in appropriate serum (Diagnostics Scotland, Carluki
UK) diluted 1:5 in TBS containing 5% bovine serui
albumin. Sections were then blocked with avidin an
biotin (both from Vector, Peterborough, UK) with washc
in TBS in between. Various primary antibodies were usee
Rabbit antibodies to Activin receptor II (ActRlIA) an
Activin receptor IIB (ActRlIB) were kindly donated by D
C-H Heldin, Ludwig Institute for Cancer Researcl
Uppsala, Sweden, and used at a concentration of 1:60
and 1:400, respectively. Rabbit antibodies to ALK2 an
ALK4 were also kindly donated by Dr, C-H Heldir
Ludwig Institute for Cancer Research, Uppsala, Sweder
and both used at concentration 1:150. Goat antibody t
betaglycan (Santa Cruz Biotechnology, CA, USA) wa
used at a dilution of 1:25. Mouse monoclonal primary
antibodies to the inhibin/activin subunits included a sub-
unit (173.9k) used at a range of dilutions 1:1000 to 1:100,
pA subunit (E4) at 1:1000 and pB subunit (12/13) at
1:100, all the gift of NP Groome. Monoclonal antibod;
directed against recombinant follistatin FS288, which rec
ognises follistatin even when bound to activin, was used z
a range of dilutions 1:200 to 1:25, also gift of NP Groom
(Majdic et al., 1997). All were incubated at 4°C overnighl
Sections were then washed and incubated for 30 min witi
goat anti-rabbit (Santa Cruz Biotechnology), rabbit anti
goat (Dako, Cambridge, UK) or rabbit anti-mouse (Diag
nostics Scotland) biotinylated secondary antibody as ap
propriate, at a dilution of 1:500. Following washes in TBS
sections were incubated with avidin-biotin-horseradish per
oxidase linked complex (Dako) according to the manufac
hirer's instructions. Bound antibody was visualised using
3,3' -diaminobenzidine tetrahydrochloride (Dako). Nonim
mune serum was used in place of primary antibody fo
negative controls. Positive controls (human fetal testis fo
activin/inhibin subunits and receptors and adult rat testi
for follistatin) were also run in parallel.
Sections were counterstained with haematoxylin, dehy
drated, mounted and visualised by light microscopy
Images were captured using an Olympus Provis micro
scope (Olympus Optical Co., London) equipped witl
Kodak DC S330 camera (Eastman Kodak Co, Rochester-
NY).
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uclear diameter measurement
The size distribution of germ cells expressing activin pA
ibunit was determined in specimens of 18-19 weeks
estation. To avoid bias, sequential nonoverlapping frames
/ere captured using the Provis image analysis system, and
ie diameter of all germ cell nuclei within the frame
measured. Strongly immunostained germ cells were classi-
ed as pA positive, all other germ cells as negative. Data
rere analysed by the Mann-Whitney U test as the distri-
ution deviated from normal. For graphical representation,
umbers of immunopositive and immunonegative cells were
rouped in 1-gm increments of nuclear diameter. The
uclear diameter of a total of 527 germ cells was measured.
'rimary cell culture
Fetal ovaries were dissected and cultured in MEMa
ledium with phenol red (GibcoBRL, Life Technologies)
upplemented with 2 mM pyruvate, 2 mM glutamine, 1 x
TS supplement (Sigma) and 3 mg/ml BSA, and with
enicillin, streptomycin and amphotericin. A total of seven
varies were used for culture experiments. Fetal ovaries
-14-17 weeks) were dissected in prewarmed and gassed
ledium to yield tissue fragments approximately 1 mm3.
Ictween four and six fragments were transferred in 400-
1 medium to each of four designated wells containing
iserts (Millicell-CM; Millipore UK Ltd, Watford, UK) in
. 24-well tissue culture plate such that tissue fragments
vere supported at the meniscus of the medium. Tissue was
cultured for 17 h in a humidified incubator at 37°C and
5% CO2. Two treatment groups were cultured with 100 ng/
nl recombinant human activin A (R&D systems, Abing-
lon, UK). The other two groups acted as controls. Bro-
nodeoxyuridine (BrdU; Sigma) was supplemented at 10
,1/ml as a marker of cell proliferation. In each experiment,
IrdU was present in the media of one control and one
-reatment group for the duration of the experiment. BrdU
vas added to the other control and treatment group for the
inal 4 h of tissue culture only. Analysis of germ cell
lumber in these parallel cultures allowed confirmation that
:hanging the medium 4 h before the end of the culture
leriod did not influence the results. At the end of culture,
issues were washed in PBS and fixed in Bouin's fluid for
h, followed by processing to visualise BrdU incorpora-
ion by immunohistochemistry.
Serial sections (5 pm), four sections per slide, were
nounted on BDH Superfrost Plus slides (BDH Laboratory
supplies) and dried overnight at 50°C. Every fourth slide
vas processed for immunohistochemistry as described
ibove. The primary antibody used was formalin-grade
inti-BrdU mouse monoclonal antibody (Roche) at a dilution
)f 1:30, incubated at 4°C overnight. On completion of the
mmunohistochemistry protocol, sections were counter-
itained with haematoxylin, dehydrated and mounted before
inalysis.
Sections of uncultured control and cultured tissue were
analysed to quantify the effects of culture and activin A on
the number and proliferation of germ cells. Analysis was
carried out blind using the Area Fraction Probe in the
Stereologer software programme (Systems Planning and
Analysis Inc, Alexandria, VA, USA) as previously described
(Robinson et al., 2003; Sharpe et al., 2002). Tissue was
serially sectioned and sections greater than 20 pm apart
were counted, ensuring the same cells were not counted
more than once. The counting was performed using a 121
point grid in the eyepiece of the microscope. Each tissue
fragment was outlined and frames randomly selected there¬
after by the programme. The number of points lying outside
the tissue in any grid was also recorded and the total cell
numbers were corrected for this. Average number of germ
cells per grid was calculated for each experimental condi¬
tion, and data were analysed using paired / tests.
Results
Expression of mRNAs for activin/inhibin submits and
receptors
mRNA expression was detected by RT-PCR using RNA
extracted from human fetal ovaries (Fig. 1). Amplicons of
expected sizes corresponding to the inhibin a (278 bp),
inhibin/activin pA (274 bp) and pB (325 bp) subunits and
the activin receptors ActRllA (435 bp) and ActRlIB (283
bp) were amplified from cDNA derived from ovaries across
14-19 weeks gestation. Product identity was confirmed by
direct sequencing.
Quantitative PCR
Changes in the expression of the activin pA subunit
mRNA between 14 and 19 weeks gestation were investi¬
gated by quantitative RT-PCR. There was an approximately
2-fold increase in the relative expression of the pA subunit
mRNA expression between 14 and 19 weeks gestation (P <
0.001, Fig. 2). The increase in expression was not contin¬
uous across the gestational range examined, but mostly
occurred between 17 and 19 weeks.
Immunohistochemistry
Inhibin/Activin subunits
Expression of the pA inhibin/activin subunit protein was
detected in the fetal ovary at all gestations investigated. It
was specifically localised to the germ cell cytoplasm at all
gestations studied, but a marked change in the pattern of
immunostaining was seen across the gestational range (Figs.
3D-F). At 14 weeks gestation, a gradient of distribution
was observed. Oogonial immunostaining was detected
throughout the ovary, but was most marked at the periphery,
particularly in germ cells in the outermost few layers of the
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Fig. 1. Expression of mRNA for inhibin/activin subunits and type II activin
receptors in the human fetal ovary. RT-PCR analysis of samples extracted
from human fetal ovaries at 14, 16 and 19 weeks gestation. mRNA
expression for inhibin/activin subunits and receptors ActRIIA and ActRIIB
as indicated. Lanes marked 14—, 16— and 19— contained samples in which
reverse transcriptase was omitted. W refers to water instead of cDNA in the
PCR reaction. The size of each amplicon is indicated on the right.
gonad. At 17—19 weeks gestation, a different distribution of
immunostaining had emerged with a discrete subpopulation
of germ cells showing intense staining. These germ cells
tended to be larger oocytes, and were distributed in small
clusters of less than 10 largely located in the medullary
region of the ovary. However, oocytes within newly formed
primordial follicles showed only weak or no immunostain¬
ing for activin pA.
Differential expression of pA subunit by larger germ
cells was confirmed by direct measurement of nuclear
diameter. A total of 527 germ cells were measured, of
which 79 (15%) were intensely immunopositive for the
pA subunit. These pA-expressing germ cells were signifi¬
cantly larger than those only weakly immunopositive or
immunonegative (11.3 ± 0.2 vs. 9.8 ± 0.1 pm, P= 0.0001,
Fig. 4) although the very largest germ cells with nuclear
diameter >16 pm, that is, those within primordial follicle
were immunonegative.
Expression of pB inhibin/activin subunit protein w;
also detected throughout the ovary across the range (
gestations examined. Immunostaining was widespread, wit
both germ cells and stromal cells expressing the pB subun
(Figs. 3G-I). Howevei, at the periphery of the ovary, som
genu and somatic cells did not express the pB subunit
There was no difference in distribution of immunostainin
of either stiomal ut genu cells between 14 and 18 week
gestation. Two antibodies directed against the pB subun
(CI2/13 monoclonal antibody, gift of NP Groome, and o
cyclic inhibin pB (80-112)-NH2 PBL#197 rabbit polyclor
al, gift of W Vale) were used, with similar results.
Immunostaining for the inhibin a subunii was m
detected in any cell type in the human fetal ovary acros
a range of gestations and despite using a wide range c
antibody titres. Fetal testes were used as a positive contrc
and showed immunostaining in both Leydig cells in th
interstitium and Sertoli cells in the seminiferous tubules a
previously described (Figs. 3A—C) (Anderson et al
2002).
Activin and inhibin receptors
Expression of the type II receptor ActRIIA was detecte'
at all gestations from 14 to 21 weeks and was localise
specifically to germ cell cytoplasm (Figs. 5C, D). There wu
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Fig. 2. Real-time PCR quantification of pA expression in the fetal ovary
Expression of pA subunit mRNA was quantified in human fetal ovar
specimens over the gestational range 14-19 weeks. Data calculated as p/
mRNA expression relative to GAPD for ovaries of 14, 15, 16, 17, 18and ll
weeks gestation (« = 6, 5, 5, 5, 3 and 5, respectively, mean ± SEM). SEN
for 15 weeks = 0.00. *P < 0.001 by ANOVA.




"^'TvP ' \ ' «>
•»: ■. -TV •> ■'$ ■■■ '*•" :* i' i ■ ,— ~jf -.f
•.a
"
. .' • j • •- i: « -
o- - '• ■
•
* , , ;
> :T-.'






-•ViT* T>V"• VV' ?*■




Fig. 3. Immunohistochemical localisation of inhibin/activin subunits in human fetal ovary. (A) Inhibin a subunit, 14-week ovary. (B) Inhibin a subunit, 19-
week ovary. (C) Inhibin a subunit positive control, 19-week testis. (D) (3A subunit, 14-week ovary. (E) (3A subunit, 17-week ovary (inset shows negative
control). (F) pA subunit, 17-week ovary at higher magnification. (G) pB subunit, 14-week ovary. (H) pB subunit, 18-week ovary (inset shows negative
control). (1) pB subunit, 18-week ovary at higher magnification. Positive staining in all panels is brown and sections are counterstained with haematoxylin. o,
oogonia; s, stroma; t, tubule; i, interstitium. Scale bars in A-H, 50 |im. F and I, 20 jim.
cells of primordial follicles, nor cells at the ovarian surface.
There was no significant difference in distribution across the
gestational range studied.
ActRIIB immunoexpression was distributed widely with¬
in the fetal ovary at all gestations from 14 to 21 weeks (Figs.
5E, F). Immunostaining was detected in both stromal and
germ cells but not in the cells at the ovarian surface. Intense
immunostaining was noted in larger germ cells at later
gestations and expression persisted in cytoplasm of oocytes
organising into primordial follicles.
Expression of ALK4 protein, the preferential activin
type I receptor, was detected throughout the ovary
predominantly in stromal and pre-granulosa cells but also
with weak expression in germ cells (Fig. 5A). At 14
weeks gestation, ALK4 immunostaining clearly demarcat¬
ed a meshwork of ovarian stromal cells with weaker
immunostaining of the oogonia intermingled with more
strongly immunopositive pre-granulosa cells. At later
gestations (18 weeks), the ovarian stroma was less
strongly immunopositive, and the predominant site of
ALK.4 expression was the pre-granulosa cells surrounding
individual and grouped oogonia, although oogonia
remained weakly immunopositive.
In contrast to ALK4, expression of ALK2 protein was
exclusively localised to the stromal cells at 14-18 weeks
gestation, with no immunostaining identified in germ cells at
any gestation (Fig. 5B). Intense immunostaining was partic¬
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Fig. 4. Size distribution of pA-immunopositive germ cells in the human
fetal ovary. Histogram shows the frequency of distribution of nuclear
diameter of cells strongly immunopositive for pA subunit (filled columns)
and those either weakly immunopositive or immunonegative for pA subunit
(open columns) in human fetal ovary at 18-19 weeks gestation, n = 79 and
n = 448, respectively.
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Fig. 5. Immunohistochemical localisation of inhibin/activin receptors in human fetal ovary. (A) ALK2, 14-week ovary. (B) ALK4, 18-week ovary. (C)
ActRIIA, 14-week ovary. (D) ActRIIA, 21-week ovary (inset shows negative control). (E) ActRIIB, 14-week ovary. (F) ActRIIB, 21-week ovary (inset shows
negative control). (G) Betaglycan, 14-week ovary. (H) Betaglycan-positive control, 15-week testis. Positive staining in all panels is brown and sections are
counterstained with haematoxylin. s, stroma; g, pre-granulosa cells; o, oogonia; pf, primordial follicle; t, tubule; p, peritubular cells. Scale bars, 50 pm in all
panels.
outlining genn cells. This pattern of stromal cells immunos-
taining appeared to increase with increasing gestation and the
formation of primordial follicles.
No expression of (3-glycan protein was detected in any
mid-trimester gestation ovary studied. Intense immunos-
taining was detected in the peritubular cells of fetal testes
used as a positive control (Figs. 5G, H).
In all cases, negative controls showed no immunostain-
ing. Fetal testis sections were used as a positive control,
and showed distinct immunostaining as previously de¬
scribed (Anderson et al., 2002).
Follistatin
No expression of follistatin was detected in any mid-
trimester ovary studied (14-20 weeks gestation). Adult rat
testis was used as a positive control and showed positive
immunostaining in Leydig cells as previously described
(Majdic et al., 1997).
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Tissue Culture
A total of seven separate experiments were carried out to
investigate the effect of activin on germ cell survival and
proliferation in vitro, using ovaries between 14 and 17
weeks gestation. Comparison of germ cell number in control
cultures showed good oogonial survival (46 ± 2 oocytes per
grid after 17 h culture vs. 68 ± 2 in uncultured tissue) and
there was no effect of changing the medium 4 h before the
end of culture period in those experiments where BrdU was
added at that time point (45 ± 4 germ cells per grid in
controls vs. 46 ± 3 in those in which the medium was
changed). Treatment with 100 ng/ml activin A resulted in a
significant increase in total number of germ cells. Activin
A-treated groups showed a mean increase of 20% in the
total number of germ cells from 45 ± 4 to 56 ± 4 per grid,
P = 0.001. Very similar results were obtained in the cultures
in which BrdU was present for 4 h (Fig. 6A). When BrdU
was present in the culture medium for the duration of culture
(17 h), more genn cells were immunopositive than when
BrdU was present for only the final 4 h of culture, as
expected (6.4 ± 1 vs. 2.8 ± 0.4 stained germ cells per grid
when exposed to BrdU for only 4 h). Activin A treatment
also resulted in a significant increase in number of BrdU-
immunopositive genn cells. There was a 44% increase in
number of immunostained germ cells (9.2 ± 1.3 vs. 6.4 ±
0.8 per grid, P = 0.01) when cultured with activin A and
BrdU for 17 h. Immunostained germ cells were increased by
89% (5.3 ± 0.9 vs. 2.8 ± 0.4 per grid, P < 0.05) when
cultured with activin A for 17 h and exposed to BrdU for
only the final 4 h of culture (Figs. 6B, C).
Discussion
FTigh interspecies conservation of activins, inhibins and
activin receptors and the universal presence of activins in
mammals, birds, amphibians and fish suggest an evolution-
Fig. 6. Analysis of the effect of activin A on the number of germ cells in human fetal ovary. (A) Graph shows the number of germ cells per grid for time 0 tissue
(shaded column), control groups (open columns) and groups cultured for 17 h with 100 ng/ml recombinant activin A (filled columns) in human fetal ovary at
14-17 weeks gestation (mean ± SEM). Treatment and control groups were either exposed to BrdU for 4 h or for the duration of culture (17 h) as indicated. *P
< 0.05; **P = 0.001 vs. control. (B) Graph shows the number of BrdU-immunopositive germ cells per grid for control groups (open columns) and those
cultured for 17 h with 100 ng/ml recombinant activin A (filled columns) in human fetal ovary at 14-17 weeks gestation (mean ± SEM). Treatment and control
groups were either exposed to BrdU for 4 h or for the duration of culture (17 h). *P < 0.05; **P= 0.01 vs. control. Example of immunohistochemical staining
of BrdU in cultured human fetal ovary. (C) Control 17-week ovary cultured for 17 h with BrdU. (D) Seventeen-week ovary cultured with 100 ng/ml
recombinant activin A and BrdU for 17 h. Positive staining in all panels is brown and sections are counterstained with haematoxylin. o, oogonia; b, BrdU-
immunopositive oogonia. Scale bar, 50 pm.
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arily conserved role of these proteins in animal develop¬
ment. Activins have potent effects on early amphibian
embryonic events during mesoderm-forming (Nieuwkoop)
induction both in vitro and in vivo (Dyson and Gurdon,
1997). In mammals, activins have also been demonstrated to
have morphogenetic effects, notably in renal tubule devel¬
opment (Ritvos et al., 1995). However, there are few
published data available concerning the presence, expres¬
sion and potential roles of activins, inhibins and their
receptors during mammalian gonadal development. Whilst
activin is thought to act primarily in an autocrine and/or
paracrine manner, inhibin acts primarily as an endocrine
feedback regulator of pituitary FSH release (Welt et al.,
2002). Our data demonstrate the presence and localisation of
activin receptors and subunits within the developing human
ovary, and suggest a role for activin A in the regulation of
germ cell proliferation during the developmental period
leading up to primordial follicle formation. In contrast,
follistatin was not expressed. Follistatin binds and neutral¬
ises activin activity. It also binds several other TGFp
superfamily members, including BMP4 (Fainsod et al.,
1997; Lin et al., 2003). Follistatin expression has been
detected in the fetal sheep ovary at late gestation, but not
before primordial follicle formation (Braw-Tal et al., 1994).
Similarly, follistatin is not expressed in the developing
human or rat testis (Majdic et al., 1997) despite the presence
of activin subunits and receptors (Anderson et al., 2002). It
would therefore appear that activin activity in the develop¬
ing human gonad is not regulated by follistatin.
Transgenic mice have been generated to study physio¬
logical models deficient in inhibins, activins and their
receptors (Bums and Matzuk, 2002). Gene knockout experi¬
ments have been inconclusive in determining activin func¬
tion in vivo, but functional analysis would suggest that
activins are not essential for mammalian mesodenn forma¬
tion. A number of reasons are cited to explain the lack of
definitive conclusions from this body of work; firstly, some
mutations are lethal, secondly, deficient activin ligand or
receptor signalling results in a phenotype with suppressed
FSH which results in reproductive and developmental
defects and thirdly, there may be some functional overlap
between TGFp superfamily ligand and receptor signalling.
Mutations in the gene encoding the pA subunit are lethal.
Mutant mice develop to tenn but have secondary palate
defects and lack whiskers and lower incisors (Matzuk et al.,
1995b). The mutant mice die within 24 h of birth due to
feeding difficulties and there are thus no conclusions re¬
garding ovarian follicular development. Mice lacking the
pB subunit suffer eye lesions as a result of failed eyelid
fusion. Mutant females do not show a disruption in follic¬
ular development but manifest impaired reproduction char¬
acterised by perinatal lethality of their offspring (Vassalli et
al., 1994). Highly increased pA expression was noted in the
ovaries of these pB-deficient female mice, suggesting the
possibility of functional compensation within the TGFp
superfamily. Using a gene knockin approach, it has been
found that activin pB can rescue the craniofacial defects and
neonatal lethal phenotype of pA-deficient mice. However,
activin pB is unable to substitute for all the functions of pA.
The pB knockin mouse is subfertile and phenotypic abnor¬
malities in the gonads and external genitalia, as well as
delayed lethality remain in these mice. Ovaries in the
hemizygous knockin female mouse are much smaller than
those of controls (Brown et al., 2000). This may suggest
activin pA expression is necessary for development of the
correct complement of germ cells in the mouse ovary,
consistent with the present data in the human. It is interest¬
ing that mice carrying a null mutation in the ActRII gene do
not, as one might expect, phenocopy activin-deficient mice.
Despite lacking a crucial component of the activin signal¬
ling pathway, only 25% of these mice die at or shortly after
birth with mandible defects. Surviving adults have defective
reproductive performance and small gonads although this
may be in part due to abnormal FSH secretion in addition to
deficient germ cell proliferation (Matzuk et al., 1995a).
There is also some evidence that it is the second messenger
(Smad) signalling which is more crucial to specific embry¬
onic and extra-embryonic development pathways than par¬
ticular ligand and receptor interactions (Chang et al., 2001).
Activin subunits and receptors showed a differential
distribution within the developing ovary. Activins bind to
a type II receptor (ActRIIA or ActRIIB), which recruits and
phosphorylates a type I receptor with subsequent modula¬
tion of gene expression via Smad protein activation (Mas-
sague, 1998) Several type I receptors (ALKs) have been
identified. ALK4 (ActRIB) is believed to be the preferential
activin receptor. The activin (JA subunit was specifically
expressed by germ cells, whereas both somatic and germ
cells expressed the (AB subunit. ActRIIA was specifically
localised to germ cells, whereas ActRIIB and the type 1
receptor ALK4 were expressed by both stromal and germ
cells. The distinct distribution of both activin subunits and
receptor subtypes between germ cells and somatic cells
suggest that activin may have several distinct roles in
ovarian development and organisation, and more specifical¬
ly in germ cell regulation. This is supported by observations
of an increase in (iA mRNA expression as well as changes
in the pattern of pA protein expression across the mid-
trimester. With increasing gestation, intense pA expression
was found in small clusters of larger, more mature germ
cells. However, the largest oocytes, within primordial fol¬
licles, show little or no pA expression. This pattern suggests
that the increase in pA subunit expression may be transient
as the germ cells mature, with reduction of gene expression
following primordial follicle formation. Increased expres¬
sion however may be associated with differences in subse¬
quent survival, consistent with the effects of activin on
oogonial survival as demonstrated in the tissue culture
experiments here described.
Despite detecting inhibin a subunit mRNA by RT-PCR,
we were unable to demonstrate the protein by immunohis-
tochemistry. Previous studies suggest that activin but not
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inhibin is present in the human fetal ovary at mid-gestation
(16-23 weeks) (Rabinovici et al., 1991). Rabinovici et al.
localised the pA subunit to primordial follicles by immu-
nohistochemistry, but did not observe immunostaining for
pB or a subunits. In contrast, immunostaining for all three
subunits was detected in late gestation fetal rhesus monkey
ovary, which contained primordial and early growing fol¬
licles. Furthermore, culture medium from mid-gestation
human fetal ovaries was found to contain undetectable
levels of inhibin-a by radioimmunoassay. Recent immuno-
localisation studies performed in baboons revealed minimal
to nondetectable levels of ot subunit in mid- and late-
gestation ovaries (Billiar et al., 2003) and there is also
indirect evidence from in situ hybridisation studies on
primate ovaries that follicles preferentially synthesise acti-
vin rather than inhibin in the early stages of development
(Schwall et al., 1990; Yamoto et al., 1993). The putative
inhibin receptor betaglycan (Lewis et al., 2000) was also not
detected in the mid-trimester human fetal ovary. The fact
that neither the a subunit nor betaglycan receptor were
identified by immunohistochemistry in mid-trimester human
fetal ovaries indicates that inhibin is not a regulatory factor
at this stage of development, but becomes of importance
later during follicular growth (Welt et al., 2002).
An in vitro tissue culture model was used to investigate
the effect of activin on oogonial survival and proliferation.
Activin A treatment resulted in an increase in germ cell
proliferation and survival in fetal ovary tissue fragments.
This concurs with the earlier demonstration that activin A
stimulated [3H] thymidine incorporation in vitro in the
differentiating rat ovary (Kaipia et al., 1994). BrdU was
used as a marker for cell proliferation. It is interesting to
note that immunostaining was observed predominantly
towards the edge of cultured ovarian fragments. This may
represent a diffusion effect, but may also partly reflect the
organisation of the tissue. Mitotically dividing germ cells
tend to be placed peripherally in the mid-trimester fetal
ovary with a gradient of maturity across the developing
ovary such that relatively more mature cells are found in the
medulla compared to the cortex (Byskov, 1986). A recent
study of follicle formation during fetal development in
sheep also noted a cortical pattern of distribution of BrdU
staining following in vivo administration (Sawyer et al.,
2002), which became more pronounced up to primordial
follicle formation.
In the adult ovary, activin A induces expression of genes
signalling cellular differentiation and maturation. In the
developing fetal ovary, key events involve germ cell prolif¬
eration, organisation and survival by somatic cell interaction
and primordial follicle formation (Hirshfield, 1991; McLa¬
ren, 1991). The present data support a role of activin A in
germ cell survival and proliferation. The Bcl-2 family of
proteins are key regulators of apoptosis in many cell types.
This family comprises pro-apoptotic (Bax, Bad and Bak)
and anti-apoptotic (Bcl-2, BcI-Xl and Mcl-1) subfamilies.
Mcl-1 is a rapidly inducible short-term effector of cell
viability and is expressed in a subset of oocytes at the time
of primordial follicle formation (Hartley et al., 2002). The
distribution of Mcl-1 in the fetal ovary is similar to that of
activin pA subunit and it is possible that activin A promotes
cell survival by signalling via Mcl-1, as has been demon¬
strated in a leukaemia cell line (Fukuchi et al., 2001). Whilst
both activin A and Mcl-1 expression are most marked in
larger oogonia preceding primordial follicle expression,
oocytes within primordial follicles continue to express
Mcl-1, whereas activin pA expression is low once that
developmental stage is reached. It is possible that activin
and Mcl-1 constitute part of the signalling pathway that
determines survival for a small proportion of the oogonia in
the mid-trimester ovary.
In conclusion, we have found the human fetal ovary to
be a site of expression of activin subunits and receptors
before the formation of primordial follicles. Protein ex¬
pression of the inhibin a subunit and the betaglycan
receptor was not detected. The distribution of activin
subunits and receptors suggests that whilst somatic cells
may produce any of the activin forms, oogonia only
produce activin A, and is consistent with an autocrine
and/or paracrine mode of action for activins within the
developing ovary. Increased expression of pA by larger/
more mature oogonia may reflect selection for follicle
formation and data from tissue culture experiments support
activin A as a regulatory factor in fetal germ cell prolif¬
eration and survival. These data suggest that activin may
be of particular importance during the period of develop¬
ment immediately preceding primordial follicle formation.
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Abstract
The ability of an oocyte to support early embryonic development requires both nuclear and cytoplasmic maturation. We have
investigated the effects of brain-derived neurotrophic factor (BDNF) on maturation of the bovine oocyte and embryo develop¬
ment after parthenogenetic activation. By RT-PCR and immunohistochemistry, cumulus and oocytes were shown to express
mRNA and protein for BDNF and the p75 common neurotrophin receptor. However, mRNA for the BDNF-specific full length
and truncated isoforms of the TrkB receptor are only detected in cumulus, suggesting that oocytes and cumulus differ in their
capacity to respond to neurotrophin signalling. In in vitro maturation experiments, the proportion of cumulus oocyte com¬
plexes maturing to metaphase II was not altered by BDNF in groups lacking fetal calf serum (FCS), but was significantly lower
than the positive control containing 10% FCS (P< 0.01). However, after maturation, the proportion of parthenogenetically
activated oocytes forming blastocysts was highest for 10ng/ml BDNF (24%, n = 95) followed by 100ng/ml BDNF (18%,
n = 91) and 10% FCS (15%, n = 103), which in turn were greater than no serum (10%, n = 83; P< 0.01). Maturation in the
presence of a BDNF blocking antibody resulted in a blastocyst yield that was comparable to the absence of serum, and lower
than in the presence of BDNF (P< 0.01). Similar effects on progression to metaphase II and blastocyst formation were
observed using oocytes matured without cumulus. Together, these results provide the first evidence for a role for neurotro-
phins in promoting oocyte cytoplasmic competence to support embryonic development, despite being insufficient in the
absence of serum to enhance nuclear maturation.
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Introduction
Oocyte competence to support development after fertilisa¬
tion or parthenogenetic activation is acquired gradually
over the course of oogenesis and folliculogenesis and is
completed during meiotic maturation (Eppig 2001, Liu &
Aoki 2002, Liu et al. 2003). At this time the meiotic segre¬
gation of chromatin is accompanied by critical changes in
oocyte cytoplasm that remain poorly defined. The signifi¬
cance of these changes is illustrated by the wide differ¬
ences observed in embryo developmental competence
following variations in oocyte in vitro maturation culture
conditions (Keskintepe & Brackett 1996, Krisher & Bavister
1999, Watson et al. 2000). A broad range of factors has
been found to improve meiotic maturation in vitro and
subsequent embryo developmental potential. These
include supplementation of culture media with follicular
fluid or serum, or specific gonadotroph ins, steroid and
thyroid hormones, retinoids, and different energy sub¬
strates and nutrients. These can benefit oocytes directly or
© 2005 Society for Reproduction and Fertility
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via cumulus cells (see reviews by Sutton et al. (2003),
Chian et al. (2004)). Specific growth factors identified as
intra-ovarian regulators of oocyte maturation that have
been shown to be beneficial to bovine oocyte develop¬
mental competence in in vitro studies include epidermal
growth factor (ECF), insulin-like growth factor I (IGF-I),
activin A, inhibin A, and midkine, a heparin-binding
growth factor (Lonergan et al. 1996, Stock et al. 1997,
Rieger et al. 1998, Silva & Knight 1998, Ikeda et al.
2000).
There is increasing evidence of a role for neurotrophins
in ovarian development and function, including oocyte
maturation. Neurotrophins are a family of related growth
factors initially identified to be important for regulation of
neuronal survival and differentiation, but which have also
been described in a variety of non-neuronal tissues includ¬
ing the cardiovascular, immune, endocrine and reproduc¬
tive systems (Matsuda et al. 1988, Polak et al. 1993). They
include nerve growth factor (NGF), brain-derived neuro¬
trophic factor (BDNF), and neurotrophins 3 and 4 (NT3
DOI: 10.1530/rep.l.00471
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and NT4). Neurotrophins are unique in that they utilise
two different receptors to mediate their biological actions:
tyrosine kinase (Trk) receptors encoded by the trk proto-
oncogene family (Trk A-C and truncated isoforms), and
the p75 receptor, a member of the tumour necrosis factor
(TNF) receptor superfamily (Bibel & Barde 2000, Rabiza-
deh & Bredesen 2003). The p75 receptor is widely
expressed and binds all neurotrophins. By contrast, the
Trk receptors show selective affinity for different neurotro¬
phins (i.e. TrkA for NCF, TrkB for BDNF and NT4 and
TrkC for NT3). Splice variants and truncated isoforms of
Trk receptors lacking intracellular tyrosine kinase domains
have also been identified (Bibel & Barde 2000)
BDNF and TrkB have been identified in the adult avian
ovary (Jensen & Johnson 2001) and NT4 expression has
also been localised to the oocyte in both rodent (Dissen
et al. 1995) and Xenopus (Ibanez et al. 1992). TrkB
expression appears to be central to the normal formation
of primordial follicles that occur in the ovary in the few
days following birth in the rodent (Spears et al. 2003), and
for oocyte survival during early follicular growth (Raredes
et al. 2004), an effect that may be predominantly
mediated by truncated TrkB receptors. Mice carrying a
null mutation of the NGF gene show deficient develop¬
ment of primordial follicles (Dissen et al. 2001). A direct
effect of BDNF on murine oocyte maturation in vitro has
also been reported, with increased first polar body extru¬
sion rate in oocytes stripped of cumulus prior to matu¬
ration (Seifer et al. 2002a). BDNF is present in human
follicular fluid (Seifer et al. 2003), and there is evidence
for increased secretion of BDNF by cumulus cells, but not
mural granulosa cells, in response to cAMP (Seifer et al.
2002a). These data suggest that cumulus-derived BDNF
may be involved in oocyte maturation, and it is possible
that its production is stimulated by gonadotrophins.
In the present study we have investigated the effects of
BDNF on maturation of the bovine oocyte as well as
implications for embryo development after parthenoge-
netic activation. Parthenogenesis provides a means of
assessing oocyte cytoplasmic competence to elicit devel¬
opment independently of sperm mediated factors, and is
an accepted standard to assess oocyte viability for cloning
and nuclear reprogramming (De Sousa et al. 2002, Liu &
Aoki 2002). We provide evidence that cumulus cells and
oocytes may have different capacities to respond to neuro-
trophin signalling, and that neurotrophin signalling during




Bovine ovaries were collected from a local abattoir and
kept warm during transportation. In the laboratory, ovaries
were washed in Dulbecco's phosphate-buffered saline
(PBS; Oxoid Ltd, Basingstoke, Hampshire, UK) at 38°C,
after which follicles measuring 4-8 mm were aspirated.
For immunohistochemistry, all tissue was fixed in Bouin's
fluid overnight, and transferred to 70% ethanol before par¬
affin embedding and sectioning. To facilitate their hand¬
ling prior to fixation, cumulus oocyte complexes (COCs)
were first embedded in 50 jxl droplets of collagen solution
prepared by dissolving 4.2 mg type I rat-tail collagen
(Sigma, Poole, UK) in 1 ml 0.1 M acetic acid (BDH) and
mixing with an equal volume of 2 x TCM199 (Sigma),
pH 7.2, immediately before use. Droplets containing
COCs were then incubated at 37 °C for 10min to set (Iza-
dyar et al. 1998). For RNA isolation, ovaries were diced to
5 mm3 cubes and COCs, denuded oocytes and cumulus
were snap frozen and stored at — 70 °C.
Extraction of RNA and synthesis and amplification of
cONA
Total RNA was extracted using a RNAeasy mini kit (Qiagen,
Crawley, UK) as previously described (Young et al. 1998).
Reverse transcription using a bulk first strand cDNA syn¬
thesis kit(Amersham Biosciences, Bucks, UK) was followed
by PCR on 2 p,l cDNA samples using 2 x thermostart PCR
mastermix as per manufacturers instructions (Abgene,
Epson, UK). Specific primers for each gene are given in
Table 1. For each gene, negative controls to confirm the
absence of genomic DNA consisted of PCR on RNA with¬
out performing first-strand cDNA synthesis (RT—), and
water. A further control tube was included and run in para¬
llel as a blank for Qiagen reagents (non-embryo control).
The identity of all PCR products was confirmed by direct
sequencing using an Applied Biosystems 373A automated
sequencer (Applied Biosystems, Foster City, CA, USA).
Immunohistochemistry
Immunohistochemistry was performed on sections of
whole ovary and COCs. Sections (5 pun) were mounted on
BDH Superfrost Plus slides (BDH Laboratory Supplies,
Merck Ltd, Lutterworth, UK) and dried overnight at 50°C
before processing for immunohistochemistry as previously
described (Anderson et al. 2002). Briefly, slides were incu¬
bated in 3% H202 in methanol for 30min to inhibit
Table 1 PCR primer sequences.
Product
Gene3 Primer Sequence size (bp)
BDNF Forward 5'-CATGGGACTCTGGAGAGCAT-3' 198
Reverse 5'-CAAAGGCACTTGACTGCTGA-3'
Trk B Forward 5'GGCCCAGATGCTGTCATTAT-3' 206
Reverse 5'-TCCTGCTCAGGACAGAGGTT-3'
Truncated Forward 5'CATGTTACCAATCACACGGAGTA-3' 430
Trk B
Reverse 5'CCATCCAGTGGGATCTTATGAAA-3'
p75 Forward 5'TGGACAGCGTGACCTTCTC-3' 153
Reverse 5'-TCGTCTCGTCCTGGTAATAGC-3'
3 Gene specific primers were designed based on homology to Gen-
bank sequences specified by the following accession numbers: BDNF
X97914; Trk B, NM_006180; Truncated Trk B, AF508964; p75,
(AF228020).
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endogenous peroxidase activity. After rinsing in distilled
water, slides were washed twice in Tris-buffered saline
(TBS; 0.05 M Tris, 0.85% NaCI, pH 7.6) for 5 min and
blocked for 30 min in serum (Diagnostics Scotland, Car¬
luke, UK) diluted 1:5 in TBS containing 5% bovine serum
albumin. Sections were then blocked with avidin and bio-
tin (both from Vector, Peterborough, UK) with washes in
TBS in between. The following primary antibodies were
used: BDNF (N20) (rabbit polyclonal; Santa-Cruz Biotech¬
nology, CA, USA) which was used at 1:100 as previously
described (Schneider et at. 2001); TrkB (chicken polyclo¬
nal; Promega, Southampton, UK) used at 1:25; p75
(mouse monoclonal; Neomarkers, Soham, Cambridge¬
shire, UK) used at 1:25. All were incubated at 4°C over¬
night. Sections were then washed and incubated for
30min with swine anti-rabbit (Dako, Cambridge, UK),
donkey anti-chicken (The Jackson Laboratory, Bar Harbor,
ME, USA) or rabbit anti-mouse (Dako) biotinylated sec¬
ondary antibody as appropriate, at a dilution of 1:500. Fol¬
lowing washes in TBS, sections were incubated with
avidin-biotin-horseradish peroxidase linked complex
(Dako) according to the manufacturer's instructions.
Bound antibody was visualised using 3,3'-diaminobenzi-
dine tetrahydrochloride (Dako). Non-immune serum was
used in place of primary antibody for negative controls as
well as BDNF blocking peptide (sc-546 P, Santa Cruz Bio¬
technology), whilst rat brain was used as a positive control
tissue. Sections were counterstained with haematoxylin,
dehydrated, mounted and visualised by light microscopy.
Images were captured using an Olympus Provis micro¬
scope (Olympus Optical Co., London, UK) equipped with
Kodak, DCS330 camera (Eastman Kodak Rochester, NY,
USA).
Oocyte maturation in vitro
Follicular aspirate was maintained at 38°C and allowed to
settle. The cellular debris was then transferred to a petri-
dish containing HEPES-buffered TCM199 (Sigma) with
10% (heat inactivated) FCS to allow sorting and selection
of COCs. All procedures were carried out in a laminar flow
hood using a Leica microscope (Leica, Wetzlar, Germany)
with heated stage at 38 °C. COCs were transferred through
3 X 1.5 ml volumes of HEPES-buffered TCM199 with 10%
FCS before transfer in a minimal volume to 1.5 ml of base
maturation medium for random allocation into maturation
treatment groups. The base medium for cumulus enclosed
and denuded (see below) oocyte maturation consisted
of bicarbonate-buffered TCM199 supplemented with
0.01 lU/ml follicle stimulating hormone (FSH)(Ovagen:
ICPbio, Auckland, New Zealand), 0.125 lU/ml LH (Sigma)
and 2 (xg/ml oestradiol (Sigma). In vitro maturation treat¬
ments were comprised of culturing 15-25 oocytes in
500 |xl volume of base medium with no additional sup¬
plements (i.e. serum-free negative control), 10% FCS (posi¬
tive control), 10-100ng/ml of recombinant human BDNF
(PeproTech EC Ltd, London, UK), 5p.g/ml monoclonal
anti-human BDNF (Sigma) or both 10ng/ml recombinant
human BDNF and 5 M-g/ml monoclonal anti-human BDNF.
COCs were cultured at 38.5 °C in a humidified incuba¬
tor with 5% C02. After 26 h maturation culture COCs
were stripped and either processed for immunocytochem-
istry to assess meiotic progression or activated to produce
parthenogenetic embryos. Cumulus was stripped from
oocytes by a combination of mechanical vortex and incu¬
bation in 300IU/ml hyaluronidase (Sigma) for 60-90
seconds in serum-free HEPES buffered Synthetic Oviduct
Fluid (HEPES SOF) consisting of 108mM NaCI, 7.2 mM
KCI, 1.2 mM KH2P04, 5 mM NaHC03, 20mM HEPES,
0.33 mM Na-Pyruvate, 1.7mM CaCI2, 0.5 mM MgCI2,
3.3 mM Na-Lactate, 1.5mM glucose, 3mg/ml BSA (fatty
acid free), pH 7.4, osmolarity 265-275 (Thompson et at.
1995). Enzymatic action was neutralised by transferring
oocytes through subsequent washes of HEPES SOF+ sup¬
plemented with 10% FCS.
In a second group of experiments oocytes were stripped
of cumulus prior to maturation, and only completely
denuded oocytes were selected, and washed in serum-free
base maturation medium (see above). Five cumulus-free
maturation treatments were evaluated consisting of base
medium with no additional supplements (i.e. serum-free),
10% FCS, lOng/ml of recombinant human BDNF, 5 (o,g/ml
monoclonal anti-human BDNF or both 10ng/ml recombi¬
nant human BDNF and 5|xg/ml anti-human BDNF. In
each experimental replicate, a sixth group of cumulus
enclosed oocytes were matured in base maturation media
supplemented with 10% FCS (positive control). As pre¬
viously, oocytes were cultured at 38.5 °C in a humidified
incubator with 5% C02 for 26 h and subsequently either
processed for immunocytochemistry to assess meiotic pro¬
gression or activated to produce parthenogenetic embryos.
Immunocytochemical analysis of meiotic progression
Maturation to metaphase II (Mil) was assessed by immuno¬
cytochemical staining of microtubules to visualise spindle
morphology, of microfilaments to visualise cortical mem¬
branes and segregation of the first polar body, and DAPI to
visualise condensed chromatin. Stripped oocytes were fixed
and immunostained for microtubules and microfilaments
using a modification of the method described by Messinger
& Albertini (1991). Microtubule stabilising buffer compris¬
ing 5 X SB (0.1 M Pipes (Sigma), 5 mM MgCI2, 2.5 mM
EGTA pH 6.9 in NaOH), 1 M DTT, deuterium oxide
(Aldrich, Gillingham, UK) and distilled water was incubated
with Triton X100 (BDH) and 37% formaldehyde to make
complex fix. Stripped oocytes were incubated in complex
fix for 30 min at 37 °C and then washed 3 times in 0.1% goat
serum before blocking in 10% goat serum for 1 h at room
temperature. Oocyte groups were then incubated in the
dark at 37 °C for 1 h in 50 p.l droplets of 5% goat serum with
rhodamine phalloidin and anti-tubulin FITC, washed 3
times in 10% goat serum and then mounted in Vectashield
and DAPI (Vector). Oocytes were partially squashed with a
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coverslip that was then sealed using clear nail varnish.
Slides were visualised using fluorescent microscopy and
each oocyte scored for meiotic progression. Oocytes were
scored as Mil arrested if they exhibited an alignment of
chromatin along the centre of the spindle and extrusion of a
single polar body containing chromatin.
Parthenogenetic activation and embryo culture
Cumulus-free oocytes were activated for 5min at room
temperature with 5 |j,M ionomycin (Sigma) in HEPES SOF
and 10% FCS. They were subsequently washed twice in
HEPES SOF with 10% FCS and then washed in SOFaaBSA
culture medium (i.e. HEPES-free SOF supplemented with
1 mM-L-Glutamine, 8mg/ml BSA (fatty acid free), 1 X
essential amino acids (Sigma B6766), 1 X non-essential
amino acids (Sigma M7145), pH 7.4, osmolarity 265-275)
(Thompson eta/. 1995, Walker eta/. 1996). Oocytes were
then incubated for 4h in SOFaaBSA containing 2.5 mM
6-dimethylaminopurine (6-DMAP; Sigma) and 35.5 n-M
cycloheximide (Sigma) at 38.5 °C in humidified 5% 02,
5% C02 and 90% N2 atmosphere. Following activation,
oocytes were washed three times in SOFaaBSA and trans¬
ferred into 4-well Nunc plates for final culture in 500 pJ
SOFaaBSA under mineral oil. Embryos were examined for
cleavage at 24 h post activation (day 1), and for blastocyst
development on day 7. Embryo culture media was sup¬
plemented with FCS to a final concentration of 9% on day
5 of culture. Blastocyst cell nuclei were stained by addition
of Hoescht 33342 (Sigma) to the culture medium at 5 ug/ml
and incubated for 15min. Subsequently, embryos were
mounted on glass slides and visualised by fluorescence
microscopy to determine their nuclear number.
Statistical analysis
The developmental data (proportion of oocytes reaching
Mil and blastocysts) were analysed by logistic regression.
Effects of replicate and treatment, and their interaction
were incorporated into the analysis. Also, the treatment
effect was split into contrasts between one or two treat¬
ments and the rest in order to examine the differences
between them. The interaction between treatment and
replicate was found to be not significant. Results from all
replicates were pooled for presentation. The data on blas¬
tocyst nuclei count were analysed by ANOVA to look for
treatment and replicate effects.
Results
Evaluation of BDNF and receptor mRNA expression
We first considered whether mRNA for BDNF and associ¬
ated receptors could be detected in RNA isolated from
bovine ovary COCs, and cumulus and oocytes separately.
Amplification products of the expected size corresponding
to BDNF (198bp), TrkB (206bp), truncated TrkB (430bp)
and p75 (153 bp) receptors were first detected in RNA
extracted from bovine ovarian tissue and confirmed by
DNA sequencing (data not shown). All gene transcripts
were also detected in RNA isolated from COCs, and
cumulus cells alone (Fig. 1). Neither full length or trun¬
cated TrkB was ever detected in oocytes in six indepen¬
dent trials which simultaneously confirmed their presence
in COCs and cumulus mRNA. It is therefore likely that
expression in the former was reflective of transcripts in the
cumulus cell component. In contrast, both BDNF and p75
could be detected in maturing and Mil arrested oocytes
sampled 26 h post in vitro maturation (IVM) in five inde¬
pendent trials.
Immunohistochemistry for BDNF and associated
receptors
We next evaluated whether BDNF and its receptors could
be localised in the bovine ovary and COCs by immuno¬
histochemistry. BDNF specific staining was evident in
both oocytes and granulosa cells of preantral and antral
follicles, and in expanded cumulus and oocytes following
IVM (Fig. 2). While BDNF expression in oocyte cytoplasm
was only faint in ovarian tissue sections, it was more
marked in isolated COCs (Fig. 2C). Cumulus cells also
exhibited strong immunostaining. Some immunostaining
of the theca cell layer surrounding antral follicles was also
evident, as was prominent staining of vascular endothelial
cells (Fig. 2B). No staining was detected in negative con¬
trols, following preabsorption of the primary antibody
with BDNF peptide (Fig. 2D-F).
A similar pattern of distribution as for BDNF was also
evident for p75. Thus p75 was expressed by granulosa
cells of preantral and antral follicles (Fig. 2G and 2H),
with faint staining of theca cells surrounding antral fol¬
licles (Fig. 2H). Oocytes of isolated COCs were positive
for p75-specific immunohistochemical staining (Fig. 21).
We were unable to obtain clear specific immunostaining
for TrkB, although staining was detected in rat brain as a
positive control (not shown).
Effect of BDNF on maturation of cumulus-enclosed
oocytes to Mil
To evaluate the effect of BDNF on bovine oocyte matu¬
ration, cumulus-enclosed oocytes were matured in the pre¬
sence (positive control) or absence (negative control) of
10% FCS, or in serum-free media supplemented with 10 or
100ng/ml BDNF, 5|ig/ml anti-BDNF blocking antibody
alone, or the latter with 10ng/ml BDNF. All oocytes in
each treatment group had undergone germinal vesicle
breakdown (CVBD) by the time they were analysed. In
total 77% of COCs in maturation medium containing FCS
were scored as Mil arrested after 26 h of culture. This was
2-3-fold greater (P< 0.01) than that observed in all other
treatment groups, between which there was no significant
difference in outcome (Fig. 3). Thus, supplementation of
serum-free maturation medium with BDNF was insuffi¬
cient to substitute for the known benefit of serum to
Reproduction (2005) 129 423-434 www.reproduction-online.org









"206 bp «430 bp
o
Z
Figure 1 Expression of BDNF, p75 and
TrkB mRNA isoforms in bovine cumulus
and oocyte complexes. By RT-PCR, cDNA
amplification products representative of
BDNF (198 bp), p75 (153 bp), TrkB
(206 bp) and truncated TrkB (Trunc TrkB,
430 bp) mRNA are detectable in RNA
prepared from whole bovine cumulus-
oocyte complexes (COC), cumulus alone,
or ovary. In mature (Mil) and maturing
(non-Mil) oocytes collected 26 h post in
vitro maturation, only BDNF and p75
mRNA transcripts could be detected. As
negative controls, PCR was performed on
water, tissue/cell extract with omission of
bulk first-strand cDNA synthesis (RT -)
and reagent blank non-embryo control
(NEC).
support nuclear maturation, when assessed at a single
point in time when oocytes should have reached Mil. Fur¬
thermore, a blocking antibody to BDNF did not have any
additive detrimental effect on nuclear maturation above
that observed for serum-free maturation in general.
Effect of BDNF during maturation of cumulus-enclosed
oocytes on parthenogenetic embryo development
Parthenogenetic embryo development to cleavage and
blastocyst stages were evaluated following activation of
oocytes matured as COCs in the previously defined treat¬
ment groups. In these trials, no attempt was made to score
maturation status of oocytes following IVM, thus most
oocytes, except those damaged during removal of cumu¬
lus, subsequently underwent parthenogenetic activation,
irrespective of maturation status. In a first series consisting
of three replicate trials, COCs matured without serum and
activated (total n = 83) were compared with those
matured with FCS (n=103) or either 10 (n=95) or
100ng/ml BDNF (n = 91; Fig. 4A-C). Evaluating the pro¬
portion of activated oocytes undergoing first cleavage after
24 h, there were no significant differences across treat¬
ment groups (serum-free, 63%; FCS, 65%; 10ng/ml
BDNF, 65%; 100ng/ml BDNF, 74%; Fig. 4A). By contrast,
the proportion of activated oocytes forming blastocysts fol¬
lowing maturation with 10ng/ml BDNF was over 1.5-fold
higher (P< 0.01) than with FCS, which was equivalent to
the higher concentration of BDNF. Blastocyst yields in all
treatment groups were also significantly higher than
oocytes matured without serum (serum-free, 10%; FCS,
15%; 10 ng/ml BDNF, 24%; 100ng/ml BDNF, 18%;
P<0.01). Improved blastocyst development following
maturation with the lower concentration of BDNF was
also apparent if calculated relative to the number of
cleaved embryos (serum-free, 15%; FCS, 22%; 10 ng/ml
BDNF, 37%; 100 ng/ml BDNF, 24%; P< 0.01).
In a second series of three replicate trials, the develop¬
ment of COCs matured without serum was compared
against those matured with 10 ng/ml BDNF (the best treat¬
ment in the previous series), 10ng/ml BDNF + 5 (jug/ml
blocking antibody, or 5 p.g/ml blocking antibody alone.
The proportion of activated oocytes undergoing first clea¬
vage after 24 h was significantly lower following matu¬
ration with the blocking antibody alone (30%, n= 81) vs
all of the other treatment groups (i.e. serum-free, 64%,
n = 83; 10ng/ml BDNF, 60%, n = 85; 10ng/ml BDNF +
blocking antibody, 63%, n = 76; P<0.01). Blastocyst
yields in this experimental series were generally poorer
than that observed in the first series, possibly due to seaso¬
nal variations in oocyte quality commonly encountered
with abattoir derived ovaries. Despite this, treatment with
10 ng/ml BDNF yielded significantly more blastocysts per
activated oocytes vs any of the other treatment groups
(10ng/ml BDNF, 9%; serum-free, 2%; BDNF + blocking
antibody, 4%; blocking antibody alone, 4%; P<0.01).
Evaluating blastocyst nuclear counts for each treatment
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Figure 2 Immunohistochemical staining for BDNF and p75 in bovine ovarian follicles and cumulus oocyte complexes (COCs). BDNF specific
immunostaining was evident in both oocytes (o) and granulosa (g) cells of preantral (A) and antral (B) follicles and in cumulus (c) and oocytes
following in vitro maturation of isolated COCs (C). Some immunostaining of the theca (t) cell layer surrounding antral follicles was also evident,
as was prominent staining of vascular (v) endothelial cells. In matched serial sections, this staining was blocked (D-F) if the primary antibody
was first pre-incubated with the BDNF blocking peptide. Immunostaining for p75 (G-l) which was above that observed following omission of
the primary antibody (J, H), was also detected in the granulosa and thecal cell layer of preantral (G) and antral follicles (H), and in oocytes and
cumulus cells of in vitro matured COCs (I, J), Polar bodies (pb) and a metaphase plate (mp) are labelled.
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Figure 3 Effect of BDNF on maturation of cumulus-enclosed oocytes
to Mil. COCs were matured in the presence (positive control) or
absence (negative control) of 10% FCS, or in serum-free media sup¬
plemented with 10 or 100ng/ml BDNF, 5 p.g/ml anti-BDNF blocking
antibody alone, or the latter with 10 ng/ml BDNF. The experiment
was repeated four times to arrive at the average proportion of oocytes
at Mil after 26 h of culture. Different letters denote significant differ¬
ences (P < 0.01). Number of COCs per group: serum-free n = 49;
10% FCS n = 43; 10ng/ml BDNF, n = 49; 100 ng/ml BDNF, n = 47;
5p,g/ml anti-BDNF, n = 48; 10 ng/ml BDNF + 5p.g/ml anti-BDNF,
n = 47.
within and between experiment trials revealed no signifi¬
cant differences (i.e. for each treatment group, means±
S.E.M., serum-free, 68 ± 8, n= 12; FCS, 68 ± 5, n— 15;
10ng/ml BDNF, 65 ± 6, n = 31; 100ng/ml BDNF,
77 ± 6, n=16; 10ng/ml BDNF + blocking antibody,
54 ± 6, n = 3; blocking antibody alone, 63 ± 10, n = 3).
Effect of BDNF on maturation of cumulus-free oocytes
to Mil
To evaluate the effect of BDNF on bovine oocyte matu¬
ration without cumulus, germinal vesicle oocytes were
denuded at the time of collection and matured in medium
with or without 10% FCS, or in serum-free media sup¬
plemented with 10ng/ml BDNF, 10ng/ml BDNF + 5
p,g/ml anti-BDNF blocking antibody, or 5 |xg/ml anti-
BDNF blocking antibody alone. These were compared
against cumulus enclosed oocytes matured with 10% FCS
(positive control). At the time of analysis all oocytes had
undergone GVBD. Similar to the first maturation exper¬
iment evaluating BDNF on cumulus enclosed oocytes,
71% (n = 73) of COCs matured with FCS were scored as
Mil arrested after 26h of culture. This was significantly
higher than cumulus-free oocytes matured with FCS (39%,
n= 69; P<0.01), which in turn was approximately
double (P<0.01) that observed in all of the other
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Figure 4 Development of parthenogenetic embryos following in vitro
maturation of cumulus-enclosed oocytes with BDNF. COCs were
matured in the presence (positive control) or absence (negative
control) of 10% FCS, or in serum-free media supplemented with
10 ng/ml or 100 ng/ml BDNF, then activated. Data from three repli¬
cate trials were pooled to arrive at the average proportion of activated
eggs undergoing cleavage (A) or forming blastocysts (B), or the pro¬
portion of cleaved embryos forming blastocysts (C). Different letters
(a-b) denote significant differences (P< 0.01). Number of activated
oocytes per group: + FCS, n = 103; serum-free, n = 83; 10 ng/ml
BDNF, n = 95; 100 ng/ml BDNF, n = 91.
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BDNF, 25%, n=71; BDNF + blocking antibody, 19%,
n = 36; and blocking antibody alone, 18%, n = 49). Thus,
although progression to Mil is generally poorer in the
absence of cumulus cells, exogenous BDNF cannot
substitute for serum to support nuclear maturation in the
presence or absence of cumulus cells. Furthermore, a
blocking antibody to BDNF did not have any additive det¬
rimental effect on nuclear maturation beyond that
observed for serum-free maturation in general.
Effect of BDNF during maturation of cumulus-free
oocytes on parthenogenetic embryo development
In a final series of experiments, parthenogenetic embryo
development to cleavage and blastocyst stages was eval¬
uated following activation of oocytes matured in the
absence of cumulus cells as described above. As with
the activation experiments involving cumulus-enclosed
maturation, the maturation status of oocytes was not
scored and all morphologically intact oocytes were acti¬
vated. This design was repeated in 5 replicate trials,
each of which also included a positive control of COCs
matured with 10% FCS (Fig. 5A-C). The proportion of
activated oocytes that had cleaved by 24 h was signifi¬
cantly higher for COCs and stripped oocytes matured
with FCS and stripped oocytes matured with BDNF, vs
all of the other treatment groups (i.e. COCs + FCS,
61%, n=114; stripped + FCS, 53%, n=119; stripped
serum-free, 32%, n=115; 10ng/ml BDNF, 43%,
n=116; 10ng/ml BDNF + blocking antibody, 29%,
n=118; blocking antibody alone, 28%, n=120;
P<0.05). Similarly, the proportion of activated oocytes
forming blastocysts was significantly highest for COCs
matured with FCS (33%). Cumulus-free oocytes matured
with serum (13%) or 10ng/ml BDNF (7%) were in turn
significantly different from BDNF with blocking antibody
(4%), and serum-free (2%), with no blastocysts formed
by treatment with blocking antibody alone (P< 0.01). A
similar relationship between treatment groups was
observed if blastocyst yields were expressed relative to
numbers of cleaved embryos (P< 0.01), with the excep¬
tion that there no longer was a significant difference
between BDNF and BDNF with blocking antibody. Irre¬
spective of differences in the proportion of embryos
forming blastocysts there were no differences in blasto¬
cyst nuclear counts between cumulus-free treatment
groups (means±s.E.M: stripped 4-FCS, 61 ± 4, n=15;
stripped serum-free, 53 ± 13, n = 2; 10ng/ml BDNF,
57 ± 6, n= 8; 10ng/ml BDNF + blocking antibody,
59 ± 5, n = 5). However, blastocyst nuclear counts for
COCs matured in medium containing serum were sig¬
nificantly higher than cumulus-free groups (85 ± 8,
n = 38; P<0.01)
These findings suggest that BDNF can substitute for
serum but not cumulus cells during IVM in order to
support oocyte competence to form parthenogenetic
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Figure 5 Development of parthenogenetic embryos following in vitro
maturation of cumulus-free oocytes with BDNF or blocking antibody.
Germinal vesicle oocytes were denuded at the time of collection and
matured in medium with or without 10% FCS (serum), or in serum-
free media supplemented with lOng/ml BDNF, 10ng/ml BDNF +
BDNF blocking antibody, or blocking antibody alone prior to acti¬
vation. Data from five replicate trials were pooled to arrive at the
average proportion of activated eggs undergoing cleavage (A) or
forming blastocysts (B), or the proportion of cleaved embryos forming
blastocysts (C). Significant differences denoted by different letters
(a-c; P < 0.01). Number of activated oocytes per group: COCs +
FCS, n = 114; stripped oocytes + FCS, n = 119; stripped oocytes -
FCS, n= 115; 10ng/ml BDNF, n = 116; 10ng/ml BDNF with block¬
ing antibody, n = 118; blocking antibody alone, n = 120.
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antibody to completely block blastocyst formation
suggests that BDNF may also exert an influence on
oocytes directly.
Discussion
Using a bovine oocyte IVM and parthenogenesis model
system we have investigated the role of BDNF in confer¬
ring oocyte developmental competence. Both oocytes and
cumulus express mRNA transcripts and protein for BDNF
and the p75 receptor that has affinity for all neurotrophins,
but transcripts for the full length and truncated forms of
the specific TrkB receptor are confined to cumulus. BDNF
cannot substitute for serum in supporting meiotic pro¬
gression to Mil during IVM of cumulus-enclosed or -free
oocytes. Despite this it can increase or approach the yield
of parthenogenetic blastocysts relative to serum mediated
maturation of cumulus-enclosed or -free oocytes, respect¬
ively, via signalling pathways which are sensitive to a
BDNF specific blocking antibody. These results suggest
that BDNF plays a role in conferring oocyte cytoplasmic
competence to support early embryo development, inde¬
pendently of nuclear maturation, and that this may involve
both autocrine and paracrine signalling within COCs.
Our study relied on parthenogenesis rather than fertili¬
sation to assess oocyte competence for embryonic devel¬
opment. In mammals parthenogenesis can yield viable
offspring provided that parent-specific imprints regulating
gene expression are overcome to permit the formation of
a functional placenta (Kono et al. 2004). Without such
manipulations, parthenogenesis still provides a valuable
measure of oocyte competence to initiate a developmental
program since development to the blastocyst stage is inde¬
pendent of epigenetic imprinting (Latham et al. 1994).
Accordingly, it is commonly used to assess oocyte compe¬
tence to support early development following somatic or
pronuclear transfer (Liu et al. 2001, De Sousa et al. 2002).
The method of parthenogenetic activation used in our
study has previously been characterised to yield equival¬
ent rates of development to the blastocyst stage in a direct
comparison with fertilised oocyte cohorts, although with a
significant reduction in resulting cell number, similar to
the present results (De La Fuente & King 1998).
Important roles for Trk B receptors in oocyte survival in
both the perinatal period of primordial follicle formation
and during the early stages of follicle growth have been
demonstrated using mouse knockout models (Spears et al.
2003, Raredes et al. 2004). Unfortunately however, these
models have failed to illuminate the roles for these recep¬
tors or BDNF in the later stages of ovarian follicle devel¬
opment and for oocyte competence, due to the neonatal
lethalities that they invoke (Klein et al. 1993, Ernfors et al.
1994). BDNF, NT-4 and NT-3 have all been detected in
adult human follicular fluid (Seifer et al. 2002b, Seifer
et al. 2003). In vitro studies on human cumulus cells have
also found that BDNF secretion can be stimulated by
treatment with cAMP and human chorionic gonadotropin
(hCG), but not recombinant FSH (Feng et al. 2003). Both
BDNF and NT-4, but not NT-3 also promoted first polar
body extrusion in cumulus-free mouse oocytes matured in
vitro, compared with those matured in the absence of
serum or hormones (Seifer et al. 2002a,b). Accordingly, by
immunohistochemistry these studies have reported that
most mouse oocytes are positive for TrkB, the BDNF and
NT-4 receptor tyrosine kinase, with no immunoreactivity
for TrkC, the respective receptor for NT-3. By RT-PCR the
present data show p75 but not TrkB isoform mRNAs in
bovine oocytes. Furthermore, we found no difference
between BDNF and serum-free treatment groups in the
proportion of oocytes reaching Mil, both of which were
inferior to supplementation with serum. This may reflect a
species difference.
Our current study provides the first evidence that BDNF
may benefit oocyte competence for embryonic develop¬
ment without necessarily benefiting maturation. Whereas
approximately 80% of oocytes matured with FCS (positive
control) reached Mil, this was reduced to 30% in all FCS-
free experimental treatments, including those with BDNF.
In succeeding trials there was no difference between
BDNF and FCS treatment groups in the proportion of
parthenogenetic embryos which cleaved (~60%), with
blastocyst yields improved or matched by BDNF treat¬
ment. Serum-free IVM has previously been shown to yield
significantly fewer oocytes reaching Mil, 50-60% vs 80-
90% with serum (Lonergan et al. 1994, Ali & Sirard
2002). Our serum-free Mil yields were generally lower. If
in the absence of serum BDNF is inhibitory to meiotic
maturation, this would not have been apparent in our
experiments. Flowever there was no evidence of an
inhibitory effect of BDNF on subsequent parthenogenetic
development.
Cumulatively, our results indicate a role for BDNF in
oocyte maturation enabling both early embryo cleavage
and blastocyst formation. For both cumulus-enclosed and
-free maturation, the effect of the BDNF blocking antibody
was first manifested by a significant reduction in cleavage.
Compared with the serum treatment group, the improve¬
ment or matching of blastocyst yields with exogenously
supplied BDNF was not paralleled by improved cleavage.
Since BDNF did not increase the quantity of cells in blas¬
tocysts, it is likely that its effect was on oocyte and
embryo survival as opposed to the promotion of growth.
Further work is necessary to determine if BDNF has a
physiological role during oocyte maturation.
BDNF signalling between cumulus and oocytes may be
bi-directional with functionally different consequences
given that both cell types express BDNF and differentially
express p75 and TrkB isoforms, namely oocytes lack the
latter. Trk and p75 receptors do not bind directly to each
other, but can be complexed together (Bibel et al. 1999,
Lee et al. 2001). This allows the signalling pathways trig¬
gered by both receptors to interact. The association of the
two receptor types results in higher affinity ligand binding
and a greater discrimination between neurotrophins. Thus,
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BDNF, NT3 and NT4 can each bind to the TrkB receptor,
but in the presence of p75, only BDNF provides a func¬
tional response (Bibel et al. 1999). In neurons, Trk recep¬
tors and their substrates can activate three main signalling
cascades: 1) differentiation, via a Ras/Raf/ MEK/MAP
kinase pathway; 2) cell survival (anti-apoptosis) by associ¬
ation with insulin receptor substrates leading to inacti-
vation of proapoptotic proteins; and 3) calcium release
from internal stores via PLOy mediated production of IP3
and production of protein kinase C, which in neurons
plays a role in neurotrophin mediated neurotrophin
release (for review see Bibel & Barde 2000). All of these
pathways may be relevant to follicular and oocyte matu¬
ration, but most striking is the potential for neurotrophin
mediated stimulation of the MAP kinase pathway. Gon¬
adotropin induced cumulus expansion and resumption of
meiosis in oocytes is dependent upon activation of MAP
kinase in granulosa cells. This activation is downstream of
gonadotropin-induced elevation of granulosa cell cAMP,
and is dependent upon one or more paracrine factors
from the oocyte (Su et al. 2003). BDNF secretion by
cumulus is another consequence of either gonadotropin
stimulation or artificial elevation of cAMP. Elevated cAMP
in cumulus could lead to the same in oocytes via gap
junctions, culminating in BDNF secretion by oocytes that
could act in an autocrine or paracrine fashion to augment
the effect of cumulus-derived BDNF. It is unknown
whether BDNF derived from oocytes or cumulus would
differ in their bioactivity. Neurotrophins in general are
substrates for pro-protein convertases that can alter the
molecular bioactivity of their targets by proteolytic clea¬
vage during intracellular and extracellular processing.
BDNF is an especially well characterised example of con-
vertase-dependent modulation of bioactivity (reviewed in
Seidah & Chretien 1999). Thus, differences in BDNF
bioactivity could be achieved by differential expression of
pro-protein convertases in cumulus and oocytes.
The functional consequences of ligand interaction with
the p75 receptor are also complex, and in neurons have
been linked to cell survival, arrest, differentiation, and
programmed cell death. Recently the concept of p75 as a
'quality control' receptor has been advanced based on evi¬
dence that it is capable of mediating programmed cell
death in response to either ligand binding or withdrawal.
In essence the downstream consequence of ligand inter¬
actions are proposed to be dependent on the relative pro¬
portions of p75 and Trk receptors and which neurotrophin
is present (Rabizadeh & Bredesen 2003). According to this
model, binding of neurotrophins to p75 in the absence of
Trk receptors, typically suppresses apoptosis. This could
be the case for bovine oocytes provided they do not
express TrkA or TrkC receptors. From mouse knockout
models, mice homozygous for a targeted mutation in p75,
rendering it functionally inactive, are viable and fertile,
although they eventually develop deficits in their periph¬
eral sensory nerves characterised by heat sensitivity and
susceptibility to ulceration (Lee et al. 1994). This suggests
that the most critical role for p75 may be to ameliorate
the effect of stress, which in the case of oocyte maturation
and developmental competence, might be most affected
by adverse in vitro culture environments.
A number of other growth factors have been reported to
improve oocyte competence to support embryo develop¬
ment, when applied during oocyte maturation in vitro.
Epidermal growth factor (EGF) improves the yield of ferti¬
lised bovine blastocysts, but not cell number, relative to
serum-free culture conditions lacking hormones (Lonergan
et al. 1996). However, this effect is preceded by pro¬
motion of the proportion of cumulus-enclosed or -free
oocytes progressing to Mil, the latter supporting a direct
effect on oocytes. EGF-receptor tyrosine kinase mediated
activation of meiosis was first described in Xenopus
oocytes, and later confirmed in the rat and mouse (Mailer
1985, Ueno et al. 1988, Downs 1989). Studies in the lat¬
ter also revealed a direct effect of EGF on cumulus, lead¬
ing to the promotion of cumulus expansion. Like EGF,
other groups have demonstrated that supplementation of
bovine oocyte IVM culture with exogenous activin A, pro¬
motes meiotic maturation and subsequent yield of ferti¬
lised blastocysts (Stock et al. 1997, Silva & Knight 1998),
an effect which is reduced by the activin binding protein
follistatin. These gene products are synthesised by granu¬
losa cells and are prominent components of follicular
fluid (Braw-Tal 1994). Activin A receptor mRNA can be
detected in both granulosa cells and oocytes (Cameron
et al. 1994). In the former, activin A appears to increase
the number of FSH receptors in granulosa cells and as
such may promote gonadotropin action during maturation
(Nakamura et al. 1993). A direct effect of activin A on
oocytes is supported by evidence of improved progression
to Mil of cumulus-free oocytes, although the mechanism
by which this is achieved is unknown (Stock et al. 1997).
Activin A also promotes human germ cell survival and
proliferation prior to primordial follicle formation (Martins
da Silva et al. 2004). Only midkine, a heparin-binding
growth/differentiation factor, which is also a prominent
feature of bovine follicular fluid, is similar to BDNF in
promoting oocyte competence to reach the blastocyst
stage without also improving meiotic progression to Mil
(Ikeda et al. 2000). Midkine is also produced by granulosa
cells under the control of gonadotropins (Minegishi et al.
1996). Unlike BDNF however, midkine does not appear
to act directly on oocytes. Its actions can also be blocked
by heparin (Ikeda et al. 2000).
In conclusion, our study adds BDNF to the list of
growth factors, normally present in follicular fluid, which
can specifically promote oocyte developmental compe¬
tence during IVM. BDNF differs from most other factors
identified however in that its effect is to promote cyto¬
plasmic maturation without advancing nuclear maturation.
This effect is likely to be complex and mediated by direct
effects on both the oocyte and cumulus cells. This knowl¬
edge will be of value to the creation of completely defined
culture environments free of serum for oocyte maturation,
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which will improve both their overall safety and the effi¬
cacy of assisted reproductive technologies applied to both
animals and humans.
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Neurotrophin Signaling in Oocyte Survival
and Developmental Competence:
A Paradigm for Cellular Toti-Potency
P.A. DE SOUSA,1 S.J. MARTINS DA SILVA,2 and R.A. ANDERSON2
ABSTRACT
While not fulfilling the criterion of a "stem cell" in being capable of self-renewal, mature and
fertilized oocytes are the original "toti-potent" cells, whose capacity for expansion and dif¬
ferentiation can only be approximated by stem cells of embryonic or adult origin in vitro. As
such, the mechanisms by which oocytes acquire and manifest competence to support embryo
development is of fundamental interest to efforts to control and re-specify somatic cell fate
and toti-potency. This is underscored by the unparalleled capacity of oocyte cytoplasm to suc¬
cessfully re-specify the genetic program of animal development following cell nuclear re¬
placement (i.e., cloning). Thus, the knowledge gained by understanding the acquisition of
oocyte developmental competence could ultimately facilitate the creation of adult stem cells
in vitro from terminally differentiated cells, ex ovo. In this paper, we review the concept of
oocyte developmental competence, and focus on our own research and that of others impli¬
cating a role for neurotrophins in this process, and that of oocyte cell survival. Lastly we pro¬
pose a role for neurotrophin signalling in embryo stem cell survival.
INTRODUCTION
Oocyte competence to support embryo de¬velopment is acquired gradually over a pro¬
longed period of oocyte growth (i.e., oogenesis)
and follicular development (i.e., folliculogenesis),
and is reliant on complex bi-directional interac¬
tions between germ and follicular somatic cells
beginning in the fetus and extending into adult
life (Buccione et al., 1990; Eppig, 2001). While ini¬
tial follicular formation and growth is regulated
by intraovarian factors (Matzuk et al., 2002), later
development and final maturation are under the
overall control of pituitary gonadotropins. In
fetal ovaries, mitotically dividing female germs
cells (i.e., oogonia) become oocytes as they initi¬
ate meiosis and arrest at the diplotene stage of
prophase I. This occurs as they become sur¬
rounded by a flattened layer of somatic pregran-
ulosa to form primordial follicles. Also concur¬
rent with this process is a massive wave of oocyte
cell death that results in the loss of up to 90% of
oocytes in mice and humans (Hirshfield, 1991).
This event determines female reproductive life¬
span by limiting the supply of primordial follicles
from which developmentally competent oocytes
can be derived in the future. Its timing in mam¬
mals can vary from mid-gestation (5 months) in
humans to around the time of birth in mice.
Oocytes within primordial follicles are re¬
garded as being in a resting state, and compe¬
tence to support embryo development is only ac¬
quired after the completion of oocyte growth and
maturation. Oocyte growth commences with the
1Division of Gene Function and Development, Roslin Institute, Roslin, Midlothian, United Kingdom.
2MRC Human Reproductive Sciences Unit, Centre for Reproductive Biology, Edinburgh, United Kingdom.
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formation of primary follicles, distinguished from
primordial follicles by the rounding of the single
layer of granulosa cells adhering to oocytes.
Granulosa cells continue to proliferate into sev¬
eral layers and subsequent antrum formation is
correlated with oocyte competence to undergo
meiotic maturation. Oocyte growth is typified by
a prolonged phase of intensive RNA and protein
synthesis and storage which is accompanied
late in oogenesis by epigenetic modifications of
oocyte chromatin that are necessary for regulat¬
ing gene expression and development post-
implantation (Kono et al., 1996). Transcription
ceases once oocytes undergo maturation and re¬
sume meiosis, which in vivo is triggered by an
ovulation-inducing surge of lutenizing hormone
(LH). In the mouse, oocyte transcriptional silenc¬
ing in antral follicles has been shown to correlate
with chromatin remodeling and is modulated by
granulosa cell interactions that precede resump¬
tion of meiosis (De La Fuente et al., 2001).
Oocyte maturation is characterized by both nu¬
clear and cytoplasmic changes. The former in¬
volves nuclear envelope breakdown and the mei¬
otic segregation of chromatin to yield a haploid
set of replicated chromosomes, whose final seg¬
regation awaits fertilization or an activation stim¬
ulus. In contrast to this fairly defined process, the
latter more broadly entails the acquisition of com¬
petence to initiate a cascade of developmental
events. This includes the capacity to (1) respond
to signal transduction triggered by autocrine,
paracrine, or endocrine stimulation, and sperm
or artificial activation; (2) structurally remodel
sperm and oocyte chromatin and nuclei to form
a new functionally integrated genome that will
divide mitotically; and (3) transcriptionally acti¬
vate and regulate the expression of the newly
formed genome to specify a developmental pro¬
gram. The complexity and interrelation of these
capacities has made cytoplasmic maturation com¬
paratively poorly understood.
During oocyte maturation, gene expression is
regulated by selective mRNA recruitment. This
involves mRNA sub-localization, translation,
adenylation, and degradation, as well as post-
translation modification of newly synthesised
and existing proteins (Eichenlaub-Ritter et al.,
2002). Competence to resume and complete meio¬
sis during maturation and in response to an acti¬
vation stimulus is associated with an accumula¬
tion of cell cycle regulatory molecules, such as for
example an increase in the nuclear concentration
of both cyclin B and p34cdc2 (Albertini et al., 1998;
Mitra et al., 1996). Other factors that undergo dy¬
namic shifts between cytoplasmic and nuclear
compartments during oocyte growth and matu¬
ration include those involved in the regulation of
genomic imprinting, calcium signalling, and mi¬
crotubules spindle organization (Avazeri et al.,
2000; Combelles et al., 2001; Howell et al., 2001).
While meiotic and cytoplasmic maturation are
both necessary, the former does not ensure or
guarantee the latter. Thus, in mice, in vitro oocyte
maturation in the absence of cumulus cells yields
oocytes that can complete meiotic segregation of
chromatin and even pronuclear formation after
fertilization or activation; however, the chromatin
assembled in pronuclei by the cytoplasm of such
oocytes has almost no competence to support de¬
velopment of resulting offspring (Liu et al., 2001).
Errors in meiotic recombination that can be in¬
duced by mutations in gene products required for
this process do not block oocyte nuclear matura¬
tion, although they do block spermatogenesis
(Hunt et al., 2002). Although these errors can re¬
sult in aneuploid eggs, they do not necessarily re¬
sult in embryonic lethality, as evidenced in hu¬
mans by non-dysjunction of chromosome 21
resulting in Down's syndrome,
Oocyte cytoplasmic competence is likely to be
dependent on genes encoding factors involved in
chromatin remodeling, such as those associated
with the SWI/SNF remodelling complex. Em¬
bryos lacking components encoded by SNF5 or
BRG1 genes develop normally to the blastocyst
stage, but die in the perimplantaton period
(LeGouy et al., 1998; Klochendler-Yeivin et al.,
2000). In amphibian oocytes, nucleoplasmin is
known to remodel sperm chromatin or trans¬
planted somatic nuclei in the absence of DNA
replication (Brown et al., 1987; Gurdon et al.,
1976). However, the role of mammalian ho-
mologs is not as well understood. Female mice
with a null mutation for one homolog, mNPM2
are infertile, despite the fact that decondensation
of sperm nuclei occurs, with severe abnormalities
apparent in the nucleolar organization of oocytes
and embryos (Burns et al., 2003). Other proteins
that are able to assemble nucleosomes in the ab¬
sence of DNA replication include nucleosome as¬
sembly protein 1 (NAP-1) (Ishimi et al., 1991),
which is known to be expressed in mouse oocytes
(McLay et al., 2002).




Culture systems supporting oocyte and follicu¬
lar growth and oocyte maturation remain the sub¬
ject of intensive research across a diverse range of
species. However, the generation of developmen-
tally competent oocytes from primordial follicles
in vitro is an achievement that to date has only
been possible in the mouse (O'Brien et al., 2003;
Thomas et al., 2003). By contrast in vitro systems
for the maturation of full-grown oocytes from
antral follicles exist in numerous species, with the
most notable success observed in the bovine.
While variations exist across species, the devel¬
opmental potential of oocytes in these systems has
generally benefited by the supplementation of cul¬
ture media with follicular fluid or serum, specific
gonadotrophins, steroid hormones, retinoids, and
different energy substrates and nutrients. These
have been found to benefit oocytes both directly
or via cumulus cells (Chian et al., 2004; Sutton
et al., 2003). Specific growth factors identified as
intra-ovarian regulators of oocyte maturation,
shown to be beneficial in one or more animal mod¬
els of oocyte maturation include epidermal
growth factor (EGF), insulin-like growth factor I
(IGF-I), activin A, inhibin A, and Midkine, a hep-
arin-binding growth factor (Downs, 1989; Eppig
et al., 1998; Ikeda et al., 2000; Lonergan et al., 1996;
Rieger et al., 1998; Sadatsuki et al., 1993; Silva et
al., 1998; Stock et al., 1997; Wang et al., 1995).
The targets and effects of growth factors during
oocyte maturation in vitro can be distinct as evi¬
denced by studies in the bovine (Table 1). For ex¬
ample, when applied during oocyte maturation
culture, EGF improves the subsequent yield of fer¬
tilized bovine blastocysts, but not cell number,
when compared with serum-free culture condi¬
tions lacking hormones (Lonergan et al., 1996). This
effect is preceded by promotion of the proportion
of cumulus enclosed or free oocytes progressing to
Mil, the latter supporting a direct effect on oocytes.
EGF-receptor tyrosine kinase mediated activation
of meiosis was first described in Xenopus oocytes,
and later confirmed in the rat and mouse (Downs,
1989; Mailer, 1985; Ueno et al., 1988). Studies in the
latter also revealed a direct effect of EGF on cu¬
mulus leading to the promotion of cumulus ex¬
pansion. Like EGF, the supplementation of oocyte
in vitro maturation culture with exogenous activin
A promotes meiotic maturation and subsequent
yield of fertilized blastocysts (Silva et al., 1998;
Stock et al., 1997), an effect that is reduced by the
activin binding protein follistatin (Silva et al., 1998).
These gene products are synthesised by granulosa
cells and are prominent components of follicular
fluid (Braw-Tal, 1994). Activin A receptor mRNA
can be detected in both granulosa cells and oocytes
(Cameron et al., 1994). In the former, activin A ap¬
pears to increase the number of follicle stimulating
hormone (FSH) receptors in granulosa cells and as
such may promote gonadotropin action during
maturation (Nakamura et al., 1993). A direct effect
of activin A on oocytes is supported by evidence
of improved progression to Mil of cumulus-free
oocytes, although the mechanism by which this is
achieved is unknown (Stock et al., 1997). In con¬
trast to EGF and activin, midkine, a heparin-bind-
ing growth/differentiation factor that is also a
prominent feature of bovine follicular fluid, pro¬
motes oocyte competence to reach the blastocyst
stage without also improving meiotic progression
to MB (Ikeda et al., 2000). Midkine is normally pro¬
duced by granulosa cells under the control of go¬
nadotropins and does not appear to act directly on
oocytes (Minegishi et al., 1996).
Table 1. Effect of Exogenous Growth Factors on in Vitro Maturation of
Bovine Oocytes Relative to Defined Serum-Free Culture
Growth Cumulus Blastocyst
factor Mil expansion Blastocyst cell number Target Reference
EGF +/- IGF T T T (F) - Oo & Cum
Activin /(Inhibin) T T 1(F) ? Oo & Cum b<c
Midkine - ? T (F) ? Cum d
BDNF - - T (P) - Oo & Cum
Fertilised (F). Parthenogenetic (P). Not described (?). No effect (-). Improvement (T). Oocyte (Oo). Cumulus (Cum).
References: aLonergan et al., 1996; bSilva et al., 1998; cStock et al., 1997; dIkeda et al., 2000; eMartins da Silva et al.,
submitted.




Neurotrophins are a family of related growth
factors initially identified to be important for
regulation of neuronal survival and differentia¬
tion, but which have also been described in a va¬
riety of non-neuronal tissues including the cardio¬
vascular, immune, endocrine and reproductive
systems (Matsuda et al., 1988; Polak et al., 1993).
They include nerve growth factor (NGF), brain-
derived neurotrophic factor (BDNF), and neu¬
rotrophins 3 and 4 (NT3 and NT4). Neurotrophins
are unique in that they utilize 2 different recep¬
tors to mediate their biological actions: tyrosine
kinase (Trk) receptors encoded by the trk proto-
oncogene family (Trk A-C and truncated iso-
forms), and the p75 receptor, a member of the tu¬
mour necrosis factor (TNF) receptor superfamily
(Bibel et al., 2000; Rabizadeh et al., 2003). The p75
receptor is widely expressed and binds all neuro¬
trophins. By contrast, the Trk receptors show se¬
lective affinity for different neurotrophins (i.e.,
TrkA for NGF, TrkB for BDNF, and NT4 and TrkC
for NT3). Splice variants and truncated isoforms
of Trk receptors lacking intracellular tyrosine ki¬
nase domains have also been identified, which re¬
tain the capacity to initiate intracellular signalling
(Baxter et al., 1997; Bibel et al., 2000).
Intra-ovarian factors contributing to follicular
development include oocyte derived growth dif¬
ferentiation factor 9 (GDF-9) and basic fibroblast
growth factor (bFGF) and granulosa cell derived
Kit-Ligand (Dong et al., 1996; Huang et al., 1993;
Nilsson et al., 2001; Matzuk et al., 2002). How¬
ever, a role for neurotrophins in ovarian devel¬
opment and function, has been suspected since
the detection of virtually all ligands and recep¬
tors in fetal and adult rodent ovaries (Dissen et
al., 1995; Klein et al., 1989; Lamballe et al., 1991).
Subsequently, mouse knockout models have sug¬
gested roles in early follicular formation and
oocyte survival. Mice carrying a null mutation of
the NGF gene are deficient in primordial to
primary follicle differentiation and subsequent
growth (Dissen et al., 2001). Different phenotypes
have been described for mice lacking either just
full-length or both full-length and truncated TrkB
isoforms, the former showing near complete loss
of oocytes at the time of primordial follicle for¬
mation (Spears et al., 2003), whereas mice lacking
all Trk B isoforms are deficient in the growth of
primary follicles, specifically granulosa cell pro¬
liferation and differentiation (Paredes et al., 2004).
In the mouse, both full length and truncated iso¬
forms of the Trk B (i.e., receptors for BDNF and
NT4) are expressed in oocytes in primordial and
primary follicles in neonatal ovaries. However,
whereas the full length isoform is continually ex¬
pressed at low levels in oocytes and granulosa
cells, the truncated isoform becomes abundantly
expressed in oocytes and targeted to the mem¬
brane when primary follicles initiate growth
(Paredes et al., 2004). Co-incident with this NT4
expression in humans and rodents shifts from
germ cells to granulosa cells as mitotically divid¬
ing oogonia become oocytes with the formation
of primordial follicles (Anderson et al., 2002; Dis¬
sen et al., 1995; Paredes et al., 2004). The same has
been shown for BDNF in the mouse, and mice
carrying null mutations for both BDNF and NT4,
but not NT-4 alone, have a similar deficiency in
the number of growing secondary follicles as the
Trk B isoform null mutants (Paredes et al., 2004).
Without Trk B, oocytes in primary follicles
eventually undergo apoptosis, as observed fol¬
lowing transplantation of Trk B — / — ovaries into
wild type mice (Paredes et al., 2004). Similarly
culture of mouse neonatal and human fetal
ovaries with a potent inhibitor of all Trk recep¬
tors, or alternatively NT-4 and BDNF blocking
antibodies, shows that oocyte survival is depen¬
dent on Trk B ligands (Spears et al., 2003). Other
growth factor signalling is also likely to be im¬
portant in oocyte survival around the time of fol¬
licle assembly, as evidenced by recent studies
from some of the authors (S.M. da Silva and R.A.
Anderson, 2004, unpublished data) implicating
Activin A in the promotion of human oocyte sur¬
vival and proliferation (Martins da Silva et al.,
2004).
NEUROTROPHINS IN OVULATION AND
OOCYTE MATURATION AND
DEVELOPMENTAL COMPETENCE
Multiple neurotrophins ligands and receptors
have also been implicated in the control of ovu¬
lation in the adult and more recently, oocyte mat¬
uration and acquisition of developmental com¬
petence. Increased expression of NGF/TrkA by
granulosa cells is induced by the surge in luteiniz¬
ing hormone (LH) during first ovulation (Dissen
et al., 1996), and this is believed to be involved in
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the regulation of intercellular gap junction in¬
tegrity between theca cells (Mayerhofen et al.,
1996). Increased NGF production within the
ovary also results in disruption of estrus cyclic-
ity (Dissen et al., 2000).
BDNF, NT-4, and NT-3 have all been detected
in adult human follicular fluid (Seifer et al., 2003,
2002b). In vitro studies on human cumulus gran¬
ulosa cells have also found that BDNF secretion
can be stimulated by treatment with cAMP,
forskolin (an activator of cAMP), human chorionic
gonadotropin (hCG), menopausal urinary gonad¬
otropin (a mixture of approximately equal FSH
and LH bioactivities), but not recombinant FSH
alone (Feng et al., 2003). Both BDNF and NT-4,
but not NT-3 promote first polar body extrusion
in cumulus-free mouse oocytes matured in vitro,
compared with those matured in the absence of
serum or hormones (Seifer et al., 2002a,b). Ac¬
cordingly, by immunohistochemistry these stud¬
ies have reported that most mouse oocytes are
positive for TrkB, with no immunoreactivity for
TrkC, the normal receptor for NT-3.
Recently, we have investigated the effects of
BDNF on maturation of bovine oocytes, with the
implications for embryo development assessed
by parthenogenetic activation (Martins da Silva
et al., 2004b). Parthenogenesis provides a means
of assessing oocyte cytoplasmic competence to
elicit development independently of sperm me¬
diated factors, and is an accepted standard to as¬
sess oocyte viability for cloning and nuclear re-
programming. We have found that BDNF and the
p75 receptor protein are expressed in preantral
and antral follicles by granulosa cells and oocytes.
Similarly, protein and mRNA for this ligand and
receptor are expressed by cumulus cells and
oocytes before and after maturation. In contrast
to the mouse, mRNA for the full-length and trun¬
cated isoforms of the TrkB receptor are only pres¬
ent in cumulus, suggesting that oocytes and cu¬
mulus may differ in their capacity to respond to
neurotrophin signalling. We have also confirmed
a similar expression of BDNF ligand and recep¬
tors in both ovine (Fig. 1) and human cumu-
lus-oocyte complexes (De Sousa et al., 2004, un¬
published data). These similarities suggest that
cow or sheep might provide better models with
which to predict the consequences of neu¬
rotrophin signalling in human oocytes.
In bovine oocyte in vitro maturation experi¬
ments using hormone supplemented media (i.e.,
FSH, LH, and estradiol) as a base, supplementa¬
tion with BDNF is inferior to supplementation
with serum and equivalent to serum-free condi¬
tions, in the yield of cumulus enclosed oocytes
which reach metaphase II by 27 h of maturation
(i.e., a time by which they are ready to be artifi¬
cially activated or fertilized). However, after mat¬
uration and activation, the proportion of oocytes
which can form parthenogenetic blastocysts is
improved with BDNF (relative to serum). This
effect can be blocked by in vitro maturation in
the presence of a BDNF blocking antibody (Mar¬
tins da Silva et al., 2004b). Interestingly, BDNF
alone with hormones does not support cumulus
expansion to the extent observed with serum.
Similar effects on Mil yield and blastocyst for¬
mation are observed using oocytes matured
without cumulus, indicating that BDNF may act
directly on oocytes as well as cumulus. Partheno¬
genetic blastocyst cell numbers are unaffected by
in vitro maturation culture supplemented with
BDNF, serum, blocking antibody, or nothing.
Thus, the effect of BDNF during in vitro matur¬
ation of oocytes appears to be in promoting
oocyte competence to yield embryos, rather than
the promotion of better embryos as such. Fur¬
thermore, it appears to do so without equally sup¬
porting nuclear maturation or cumulus expan¬
sion (Fig. 1).
Although we have yet to characterize whether
other neurotrophin ligands (i.e., NGF, NT3 and
4) and receptors (Trk A and C) are expressed in
bovine cumulus-oocyte complexes, our studies
suggest that BDNF signaling between cumulus
and oocytes may be bi-directional with different
signaling pathways elicited in each cell owing to
differentially expression of receptors (i.e., p75
and TrkB isoforms in cumulus, with the latter ab¬
sent in oocytes). Trk and p75 receptors do not
bind directly to each other, but can be complexed
together (Bibel et al., 1999; Lee et al., 2001). This
association results in higher affinity ligand bind¬
ing and a greater discrimination between neu-
rotrophins. Thus, BDNF, NT4, and even NT3 can
bind to the TrkB receptor, but in the presence of
p75 only BDNF provides a functional response
(Bibel et al., 1999).
In neurons, Trk receptors and their substrates
can activate three main signalling cascades: (1)
differentiation, via a Ras/Raf/ MEK/MAP ki¬
nase pathway, (2) cell survival (anti-apoptosis),
by association with insulin receptor substrates
leading to inactivation of proapoptotic proteins,
and (3) calcium release from internal stores via
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FIG. 1. Expression of BDNF, the p75 low-affinity neurotrophin receptor, and isoforms of the high-affinity TrK B re¬
ceptor in ovine cumulus-oocyte complexes. Neurotrophin ligand and receptors were amplified by RT-PCR as de¬
scribed in da Silva et al. (submitted). Amplification products representative of BDNF (198 bp), p75 (153 bp), TrkB (206
bp) and truncated TrkB (Trunc TrkB, 430 bp) mRNA are detectable in RNA prepared from in vitro matured ovine cu¬
mulus oocyte complexes (COC) or isolated cumulus (C) cells. By contrast, only BDNF and p75 mRNA products can
be detected in mature oocytes (O). As negative controls, PCR was performed on water (W), COC RNA that was not
reverse transcribed (RT—) and a blank reverse transcription reaction lacking COC RNA (i.e., NEC, non-egg/embryo
control).
PLC--y mediated production of IP3 and produc¬
tion of protein kinase C, which in neurons plays
a role in neurotrophin mediated neurotrophin re¬
lease (Bibel et al., 2000). All of these pathways
may be relevant to follicular growth and differ¬
entiation and final oocyte ovulation and matura¬
tion. Gonadotropin induced cumulus expansion
and resumption of meiosis in oocytes is depen¬
dent upon activation of MAP kinase in granulosa
cells. This activation is downstream of gonado-
tropin-induced elevation of granulosa cell cAMP,
and is dependent upon one or more paracrine
factors from the oocyte (Su et al., 2003). BDNF se¬
cretion by cumulus is another consequence of ei¬
ther gonadotropin stimulation or artificial eleva¬
tion of cAMP (Feng et al., 2003). Since oocytes and
cumulus cells communicate via gap junctions and
elevation of cAMP in cumulus leads to the same
in oocytes, BDNF secretion by oocytes may also
be a downstream consequence of gonadotropin
stimulation. This could then act in an autocrine
or paracrine fashion to augment the effect of cu¬
mulus-derived BDNF (Fig. 2). If in fact BDNF
plays a role in cumulus expansion our data sug¬
gests that there is still a requirement for factor(s)
provided by serum. It is unknown whether BDNF
derived from oocytes or cumulus would differ in
their bioactivity. Neurotrophins in general are
substrates for pro-protein convertases that can al¬
ter the molecular bioactivity of their targets by
NEUROTROPHIN SIGNALING IN OOCYTE SURVIVAL 381
FIG. 2. Schematic of BDNF ligand and receptor expres¬
sion in cumulus-oocyte complexes and potential signal¬
ing consequences. In bovine, ovine and human cumu¬
lus-oocyte complexes BDNF and p75 expression is
observed in both cumulus and oocytes, whereas Trk B
isoforms (full and truncated) are in cumulus cells only
(Martins da Silva et aL, 2004b; De Sousa et al., 2004, un¬
published data). BDNF secretion by cumulus cells is
downstream of elevated cAMP and stimulation by LH
and FSH (Feng et al., 2003). InterceUular communication
between cumulus cells and the oocyte via gap junctions
is known to result in elevated oocyte cAMP. Theoretically,
this could stimulate secretion of oocyte BDNF. As such,
cumulus and oocyte derived BDNF could function in au¬
tocrine or paracrine signaling.
proteolytic cleavage during intracellular and ex¬
tracellular processing. BDNF is an especially well
characterized example of convertase-dependent
modulation of bioactivity (Seidah et al., 1999).
Thus, differences in BDNF bioactivity could be
achieved by differential expression of pro-protein
convertases in cumulus and oocyte. At present,
however, there is no information about the ex¬
pression of these molecules in this context.
As with Trk receptors, the functional conse¬
quences of ligand interaction with the p75 recep¬
tor are also complex, and in neurons have been
linked to cell survival, arrest, differentiation, and
programmed cell death. Recently, the concept of
p75 as a "quality control" receptor has been ad¬
vanced based on evidence that it is capable of me¬
diating programmed cell death in response to ei¬
ther ligand binding or withdrawal. It suggests
that the downstream consequence of ligand in¬
teraction is dependent on the relative proportions
of p75 and Trk receptors and which neurotrophin
is present (Rabizadeh et al., 2003). According to
this model, p75 is proposed to suppress apopto-
sis (i.e., pro-cell survival) in the absence of Trk re¬
ceptors. As a member of the tumor necrosis fac¬
tor receptor superfamily, the stimulation of pro-
or anti-apoptotic mechanisms via p75 is also de¬
pendent on the availability of different cytoplas¬
mic factors (Chung et al., 2002). Recruitment of
TNF-receptor associated factor 6 (i.e., TRAF6) to
p75, leading to activation of NF-kB, has been
shown to result in cell survival in numerous cell
types (Denchant, 2002). From mouse knockout
models, mice homozygous for a targeted muta¬
tion in p75, rendering it functionally inactive, are
viable and fertile, although they eventually de¬
velop deficits in their peripheral sensory nerves
characterized by heat sensitivity and susceptibil¬
ity to ulceration (Lee et al., 1994). However, since
the expression of p75 in mouse fully grown antral
follicles or oocytes has never been properly char¬
acterised, the significance of the null phenotype
is unclear. Further experiments are therefore nec¬
essary to elucidate the role of p75 in both cumu¬
lus and oocytes. We hypothesize that expression
in the latter in the absence of Trk receptors may
promote oocyte survival, which would be espe¬
cially critical to overcoming the stress of in vitro
culture.
NEUROTROPHIN SIGNALING IN STEM
CELL SURVIVAL
Neurotrophins are of course well established
regulators of neuronal cell survival as well as
differentiation (Bibel et al., 2000). In vivo this has
been illustrated by targeted mutation of both
ligands and receptors generally resulting in de¬
ficiencies in nervous system innervation or le¬
sions (Ernfors et al., 1994; Lee et al., 1992; Schim-
mang et al., 1995). In vitro this is evident in neural
progenitor cells isolated from the cortical ven¬
tricular zone of the hippocampus of mouse fetal
and neonatal brain. These cells secrete BDNF
and NT3 and express their corresponding re¬
ceptors, Trk B and C, as well as p75 (Barnabe-
Heider et al., 2003; Hosomi et al., 2003). Inhibi¬
tion of these neurotrophins using function-block¬
ing antibodies results in a decreased survival of
cortical progenitors, accompanied by decreased
proliferation and inhibition of neurogenesis. This
is achieved by the suppression of separate path¬
ways mediating survival (i.e., phosphatidyl in-
ositol-3-kinase) and differentiation (MAP kinase)
(Barnabe-Heider et al., 2003).
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A role for neurotrophin signaling in the sur¬
vival of other types of stem cells has yet to be
demonstrated although some supporting evi¬
dence is provided by the detection of p75 and as¬
sociated factors. Human esophageal keratinocyte
stem cells are characterized by and can be iso¬
lated from differentiating derivatives by the ex¬
pression of p75 together with the cell adhesion
molecules, f31 and /34 integrins (Okumura et al.,
2003). More significant is the outcome of a re¬
cent microarray comparison of differences be¬
tween human and mouse embryonic stem (ES)
cells. In contrast to the mouse, human ES cells
highly express p75, and associated factors capa¬
ble of mediating cell survival (i.e., anti-apopto-
sis), namely TRAF6, and BLK, the latter a Src fam¬
ily protein tyrosine kinase that participates in
NF-kB activation (Ginis et ah, 2004). Recently, a
functional interrelationship between the control
of apoptosis and differentiation has been sug¬
gested in both mouse and embryo stem cells
(Zwaka et ah, 2004). In these cells, caspase activ¬
ity mediating protein cleavage during cell death
transiently increases upon induction of differen¬
tiation. Application of specific caspase blockers
also causes differentiation. Since p75 can mediate
both cell death and survival, signaling via this re¬
ceptor may prove as relevant to stem cell sur¬
vival, as it may be in the oocyte to preserve de¬
velopmental competence.
CONCLUSION
In conclusion, oocyte developmental compe¬
tence is gradually acquired over the course of
oocyte growth and completed with maturation.
It is dependent on bi-directional signaling with
follicular granulosa cells. Neurotrophin signaling
plays a key role in oocyte survival and follicular
formation and growth initiated in fetal ovaries.
In the adult ovary, this signaling is responsive
to gonadotropins and may be involved in the
control of ovulation. Our research adds neu-
rotrophins, specifically BDNF, to the list of
growth factors normally present in follicular
fluid, which can specifically promote oocyte
developmental competence during maturation.
However, BDNF differs from most other growth
factors, in that improved competence to support
embryo development is not preceded by im¬
proved nuclear maturation or support of cumu¬
lus expansion. Thus, BDNF plays a key role in the
acquisition of oocyte cytoplasmic competence to
support development. This effect is likely to be
mediated by autocrine and paracrine signaling
between cumulus cells and oocytes, which we
hypothesize in the latter may stimulate cell sur¬
vival mechanisms. This knowledge is of direct
relevance to assisted reproductive technologies.
However, as the original toti-potent cell, insight
gained from an improved understanding of
oocyte developmental competence may contrib¬
ute generally to understanding the control of
stem cell toti-potency and survival.
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